Europium(ii)-Containing Complexes For Responsive Magnetic Resonance Imaging by Ekanger, Levi Alexander
Wayne State University
Wayne State University Dissertations
1-1-2016
Europium(ii)-Containing Complexes For
Responsive Magnetic Resonance Imaging
Levi Alexander Ekanger
Wayne State University,
Follow this and additional works at: http://digitalcommons.wayne.edu/oa_dissertations
Part of the Bioimaging and Biomedical Optics Commons, and the Inorganic Chemistry
Commons
This Open Access Dissertation is brought to you for free and open access by DigitalCommons@WayneState. It has been accepted for inclusion in
Wayne State University Dissertations by an authorized administrator of DigitalCommons@WayneState.
Recommended Citation
Ekanger, Levi Alexander, "Europium(ii)-Containing Complexes For Responsive Magnetic Resonance Imaging" (2016). Wayne State
University Dissertations. Paper 1529.
EUROPIUM(II)-CONTAINING COMPLEXES FOR  
RESPONSIVE MAGNETIC RESONANCE IMAGING 
 
by 
LEVI ALEXANDER EKANGER 
DISSERTATION 
Submitted to the Graduate School 
of Wayne State University, 
Detroit, Michigan 
in partial fulfillment of the requirements 
for the degree of 
DOCTOR OF PHILOSOPHY 
2016 
         MAJOR: INORGANIC CHEMISTRY 
         Approved By: 
 
         ____________________________________________ 
         Advisor            Date 
 
         ____________________________________________ 
 
                 ____________________________________________ 
 
             ____________________________________________ 
 
 
 
ii 
 
DEDICATION 
 
 
 
 
 
 
 
 
 
 
To my wife and our little dog 
 
 
 
 
 
 
 
 
 
 
 
 
iii 
 
ACKNOWLEDGEMENTS 
 To say that I am fortunate for my doctoral advisor, Professor Matt Allen, would be an 
understatement. Matt is an excellent role model and I could not have asked for a better mentor. 
From the beginning of my time in his lab, the time and effort he put into the group was a 
constant source of motivation. Importantly, joining his group gave me the opportunity to study 
fascinating chemistry, to make a contribution to science, and to secure a fantastic postdoctoral 
position. 
 I thank Professor Stephanie Brock, Professor Jeremy Kodanko, and Professor Juri 
Gelovani for serving on my committee. Their suggestions and helpfulness served me well. I 
would like to thank Kathryn White and Professor Lisa Polin for their help and advice regarding 
mouse studies, Dr. Yimin Shen and Professor Mark Haacke for assistance with imaging at the 
School of Medicine, Dr. Meser Ali for help with imaging at Henry Ford Hospital, Dr. Judy 
Westrick for the opportunity to manage the electron paramagnetic resonance spectrometer in the 
Lumigen Instrument Center, Dr. Bashar Ksebati for assistance with NMR spectroscopy, Dr. Phil 
Martin for assistance with X-ray diffraction, Corey Lambert for assistance with inductively 
coupled plasma optical emission spectroscopy and mass spectrometry, and the front office and 
science stores staff including Jackie Baldyga and Jason Parizon. From the day I interviewed to 
these final days before my defense, Melissa Barton has been one of the nicest and most 
knowledgeable people in the department. The doctoral requirements seemed much less daunting 
with her help. I would also like to thank those that provided letters of recommendation for my 
proposals including Dr. Judy Westrick, Professor Lisa Polin, Dr. Meser Ali, Professor Tom 
Getman, Professor Jeremy Kodanko, Professor Matt Allen, and Professor Christine Chow. I am 
also grateful for the generosity of A. Paul and Carol Schaap and Wayne State University for 
iv 
 
providing support in the form a Schaap-Rumble Graduate Research Fellowship. This fellowship 
allowed me to focus on research and make significant progress in my third year of the program. 
Much of this research was supported by the National Institutes of Health through R01EB013663 
(Professor Matt Allen), K25CA129173 (Dr. Meser Ali), and P30CA022453 (Barbara Ann 
Karmanos Cancer Institute).  
My high school and undergraduate chemistry mentors, Jeff Shull and Professor Tom 
Getman, initiated and confirmed my passion for chemistry, respectively. One day in my 
undergraduate career, I was staring at a bulletin board with flyers from graduate programs in 
chemistry. Tom thought I was looking at the flyer from Wayne State, and highly recommended 
that I apply. This chance encounter lead me to graduate school in Detroit. 
Transitioning to graduate school was made easier with the help of my friend Dr. Derek 
Averill. He was one of the graduate students that took me out to lunch during my visit, and he 
offered me a room to rent in his house in Ferndale within an hour after meeting for the first time. 
I am glad that I accepted that offer because it helped me feel at home in a new environment. 
I thank Dr. Joel Garcia for helping me get started in the Allen laboratory, Dr. Akhila 
Kuda-Wedagedara for saving one of my first relatively large scale reactions in which I forgot to 
add triethylamine, Chamika Lenora for navigating requirements with me as my batchmate, and 
to Lina Basal, Matt Bailey, and Mike Cross for lively and down-to-earth discussions. I am 
thankful to all of the Allen lab members, both past and present, for being both supportive and 
critical of one another. The group, as a whole, improved my ability to be critical of my first 
interpretation of data and to always be willing to change my mind. 
My parents, Holger and Lisa, are responsible for creating and fostering an interest in 
math and science. In early elementary school, I struggled with understanding mathematical 
v 
 
concepts. I remember my father sitting with me for hours at the dinner table practicing problems 
night after night. One night, everything clicked. It was as if my logic capabilities instantly came 
out of dormancy, and mathematics and science have been my strongest subjects ever since. My 
mother saw my passion for math and science, and put significant time and effort into finding a 
high school with a curriculum designed around math, science, and the scientific method. 
Fortunately for me, she found the Macomb Academy of Arts and Sciences and, despite my 
protests, convinced me to attend. The Academy gave students freedom in the classroom and in 
independent research. Every Wednesday, faculty let students disperse throughout the school to 
collect data on their year-long research projects instead of holding traditional classes. This 
experience was an incredible taste of real science that cemented my desire to pursue research. I 
owe a lot to my mother and father for initiating my pursuit of the sciences.  
My most ardent supporter during my graduate studies has been my best friend and 
beautiful wife, Kelly. She believed in my abilities when I did not, and made life outside of the 
lab full of laughter. She is the most thoughtful and compassionate person I have ever met, and I 
admire her work ethic and contagious passion for primates and genetics. Kelly, along with our 
little dog, Ruckus, make me hopeful for our future together. 
 
 
 
 
 
 
 
 
vi 
 
TABLE OF CONTENTS 
 
Dedication ....................................................................................................................................... ii 
 
Acknowledgements ........................................................................................................................ iii 
 
List of Tables ................................................................................................................................ vii 
 
List of Figures .............................................................................................................................. viii 
 
List of Abbreviations ................................................................................................................... xvi 
 
Chapter 1: Overcoming the Concentration Dependence of Responsive Contrast Agents for 
Magnetic Resonance Imaging ......................................................................................1 
 
Chapter 2: Evaluation of Europium(II)-Based Positive Contrast Enhancement After 
Intravenous, Intraperitoneal, and Subcutaneous Injections ........................................44 
 
Chapter 3: A Europium(II)-Containing Cryptate as a Redox Sensor in MRI of Living Tissue ..54 
 
Chapter 4: Oxidation-Responsive Europium(II/III)–Liposomal Contrast Agent for Dual-Mode 
MRI.............................................................................................................................73 
 
Chapter 5: Spectroscopic Characterization of the 3+ and 2+ Oxidation States of Europium in a 
Macrocyclic Tetraglycinate Complex ........................................................................94 
 
Chapter 6: Conclusions and Future Directions ..........................................................................115 
 
Appendix A: 1H- and 13C-NMR Spectra .....................................................................................120 
 
Appendix B: Crystallography Data for Complex 3.6 .................................................................128 
 
Appendix C:  Permission/License Agreements for Copyrighted Materials .................................135 
 
References ....................................................................................................................................152 
 
Abstract ........................................................................................................................................167 
 
Autobiographical Statement.........................................................................................................169 
 
 
 
 
 
 
 
vii 
 
LIST OF TABLES 
 
Table 1.1. Amide and bound water proton chemical shifts relative to bulk water of LnDOTA-
tetra(amide) complexes at pH 7. Both values are required for single-molecule 
ratiometric CEST .........................................................................................................12 
 
Table 3.1. 17O linewidths for 3.6 and phosphate buffer as a function of temperature ..................63 
 
Table 3.2. Crystallographic properties of 3.6 ................................................................................64 
 
Table B1. Data collection and structure refinement for 3.6 ........................................................128 
 
Table B2. Atomic coordinates and equivalent isotropic atomic displacement parameters (Å2) for 
3.6...............................................................................................................................128 
 
Table B3. Bond lengths (Å) for 3.6 .............................................................................................129 
 
Table B4. Bond angles (°) for 3.6 ...............................................................................................130 
 
Table B5. Anisotropic atomic displacement parameters (Å2) for 3.6 .........................................132 
 
Table B6. Hydrogen atomic coordinates and isotropic atomic displacement parameters (Å2) for 
3.6...............................................................................................................................133 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
viii 
 
LIST OF FIGURES 
 
Figure 1.1.  The first responsive contrast agent. In the presence of β-galactosidase, a galactose 
unit is removed from the contrast agent to facilitate the coordination of a water 
molecule and, consequently, a change in contrast enhancement;33,34 B. A contrast 
agent (1.3 to 1.4) that responds to changes in the concentration of calcium ions ......3 
 
Figure 1.2.  The relaxivities of 1.3 and 1.4 are the slopes of the lines of the paramagnetic 
contribution to relaxation rate (1/T1P) as a function of the concentration of contrast 
agent. The plots illustrate the relaxivity in the presence (1.4, 5.76 mM–1 s–1) and 
absence (1.3, 3.26 mM–1 s–1) of calcium ions.35,36 Relaxivity (slope of a linear 
function) can be expressed as an equation in the form of 1/T1P = r1x + b (in this 
example b = 0 because only the paramagnetic contribution is being plotted), where 
r1 is the relaxivity or slope of the line and x is the concentration of the contrast 
agent. When calcium is present, the concentrations of 1.3 and 1.4 can be expressed 
as x1.3 and x1.4, and the linear equation becomes 1/T1P = (r11.3)x1.3 + (r11.4)x1.4. The 
vertical dashed line is a visual guide to demonstrate that a known concentration of 
contrast agent (in this example 0.60 mM was arbitrarily selected) permits 1/T1P 
measurements (horizontal dashed lines) to indicate the absence (2.0 s–1) or presence 
(3.5 s–1) of calcium. When the initial concentration of contrast agent is known (0.60 
mM), the total concentration will remain 0.60 mM because the volume of a sample 
(in vitro) is constant. Accordingly, the total concentration of contrast agent bound to 
calcium can be expressed as x1.4 = 0.60 mM – x1.3. Substituting for x1.4 in 1/T1P = 
(r11.3)x1.3 + (r11.4)x1.4 yields 1/T1P = (r11.3)x1.3 + (r11.4)(0.60 mM – x1.3), which is 
solvable because there is one equation and one variable. In this example, the 1/T1P 
values for 1.3 and 1.4 are boundaries, and the actual value can fall anywhere 
between the two boundaries. However, the 1/T1P equation is solvable even for 
incomplete conversions between 1.3 and 1.4 .............................................................4 
 
Figure 1.3.  The relaxivities of 1.3 and 1.4 plotted as in Figure 1.2, where 1/T1P = (r11.3)x1.3 + 
(r11.4)x1.4. The horizontal dashed line is a visual guide to demonstrate that a 
measured 1/T1P value (in this example 2.0 s
–1 was arbitrarily selected) can be 
produced by a 0.6 mM solution of 1.3, a lower concentration of 1.4, or a mixture of 
1.3 and 1.4. Without knowing the concentration of at least one of the contrast 
agents or the total amount of the two agents, the equation for 1/T1P contains two 
unknown variables (x1.3 and x1.4) and, consequently, cannot be solved......................5 
 
Figure 1.4.  A simplified representation of chemical exchange saturation transfer (CEST) 
viewed as a 1H-NMR spectrum. The signal from an exchangeable proton that is 
different from bulk water is reduced via a selective radiofrequency pulse while the 
proton is exchanging with protons in the bulk water. The combination of these two 
events results in a reduction of the signal intensity from bulk water, which can be 
measured and expressed as a percent decrease ...........................................................6 
 
 
ix 
 
Figure 1.5.  Structures of 5,6-dihydrouracil (1.5), 5-hydroxytryptophan (1.6), and 2-
imidazolidinethione (1.7) used to demonstrate the first ratiometric CEST response 
to pH.74 ........................................................................................................................7 
 
Figure 1.6.  Structures of LnDOTA-tetra(amide) complexes.45–47,84 .............................................9 
 
Figure 1.7.  Percent saturation transfer as a function of radiofrequency irradiation time at the 
same saturation power (B1 = 25 µT) for 1.10 (30 mM,▼), 1.11 (30 mM, ▲), 1.12 
(40 mM, ♦), 1.13 (40 mM, ), and 1.14 (30 mM, ■) at 7 T, 312 K, and pH 8.1. 
Figure adapted with permission from Paramagnetic Lanthanide(III) Complexes as 
pH-Sensitive Chemical Exchange Saturation Transfer (CEST) Contrast Agents for 
MRI Applications/S. Aime, A. Barge, D. D. Castelli, F. Fedeli, A. Mortillaro, F. U. 
Nielsen and E. Terreno/Magn. Reson. Med., 47/4. Copyright © 2002 Wiley-Liss, 
Inc .............................................................................................................................10 
 
Figure 1.8.  Saturation transfer (ST) as a function of pH for protons of amides (filled symbols) 
and coordinated water molecules (open symbols) for 1.9 (circles), 1.15 (triangles), 
and 1.16 (squares) at 7 T and 312 K after a 4 s irradiation. Figure adapted with 
permission from Novel pH-Reporter MRI Contrast Agents, S. Aime, D. D. Castelli 
and E. Terreno/Angew. Chem., 114/22. Copyright © 2002 WILEY-VCH Verlag 
GmbH & Co. KGaA, Weinheim ...............................................................................12 
 
Figure 1.9.  Structure of 1.17 for pH and nitric oxide detection. The YbIII-containing product of 
the nitric oxide and oxygen reaction is 1.18.48,72 ......................................................13 
 
Figure 1.10. Structure of 1.19 investigated for concentration-independent temperature 
response.59 .................................................................................................................14 
 
Figure 1.11. In vitro temperature maps (1 cm tube diameter) of a solution containing 1.9 (10 
mM) at pH 7.0 with a calibrated color bar on the far right. Tair is the temperature of 
air flowing over the sample. Reprinted with permission from S. Zhang, C. R. 
Malloy and A. D. Sherry, J. Am. Chem. Soc., 2005, 127, 17572. Copyright 2005 
American Chemical Society 14 
 
Figure 1.12. Structure of YbHPDO3A (1.20) used for concentration-independent detection of pH 
and temperature.58 .....................................................................................................16 
 
Figure 1.13. Twisted-square antiprism (TSAP) and square antiprism (SAP) isomeric forms of 
LnHPDO3A related to one another either through arm rotation or ring inversion. 
The bottom chart demonstrates eight possible isomers. Figure adapted with 
permission from YbIII-HPDO3A: A Dual pH- and Temperature-Responsive CEST 
Agent/D. D. Castelli, E. Terreno and S. Aime/Angew. Chem. Int. Ed., 50/8. 
Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim .............16 
 
Figure 1.14. Ratiometric CEST values (calculated using the ratio of the CEST effect of each 
isomer) as a function of pH at 20 (■) and 37 °C (). Error bars represent the 
x 
 
standard deviation from the mean. Figure adapted with permission from YbIII-
HPDO3A: A Dual pH- and Temperature-Responsive CEST Agent/D. D. Castelli, E. 
Terreno and S. Aime/Angew. Chem. Int. Ed., 50/8. Copyright © 2011 WILEY-VCH 
Verlag GmbH & Co. KGaA, Weinheim ...................................................................17 
 
Figure 1.15. Structure of 1.21 used for dual pH and temperature response that was independent 
of the concentration of contrast agent.57 ...................................................................18 
 
Figure 1.16. (a) CEST spectra of a mouse leg muscle generated pre- (solid line) and post-
injection (dashed line) with MTRasym (bottom left) post-injection at 45 ppm upfield 
from bulk water. Solid and dashed lines were generated using a tenth-order 
polynomial; (b) pH map superimposed onto a pre-injection image of the mouse leg 
muscle; and (c) temperature map superimposed onto a pre-injection image.  Colored 
pixels represent regions exhibiting CEST contrast at ≥95% probability. Figure 
adapted with permission from Simultaneous In vivo pH and Temperature Mapping 
Using a PARACEST-MRI Contrast Agent/N. McVicar, A. X. Li, M. Suchý, R. H. 
E. Hudson, R. S. Menon and R. Bartha/Magn. Reson. Med., 70/4. Copyright © 
2012 Wiley Periodicals, Inc ......................................................................................19 
 
Figure 1.17. Structure of ligand 1.22 used for ratiometric pH detection with CoII.49 ...................20 
 
Figure 1.18. CEST ratio as a function of pH using the CoII-containing complex of 1.22 (4 mM) 
in 2-(N-morpholino)ethanesulfonic acid or 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid buffer (20 mM) with NaCl (100 mM). Measurements 
were recorded at 4.7 T and 37 °C. Error bars represent standard deviations of three 
measurements. Adapted from Ref. 49 with permission from The Royal Society of 
Chemistry ..................................................................................................................20 
 
Figure 1.19. Structures of 1.23 and the product of its reaction with singlet oxygen (1.24).70 ......21 
 
Figure 1.20. (A) Ms/M0 as a function of saturation offset for increasing concentrations of singlet 
oxygen at 9.4 T and 298 K. Inset: Enlarged view. (B) CEST ratio as a function of 
concentration of singlet oxygen. Adapted from Ref. 70 with permission from The 
Royal Society of Chemistry ......................................................................................22 
 
Figure 1.21. Structure of 1.25 used for concentration-independent pH measurements using 
ratiometric relaxation rates.50 ....................................................................................24 
 
Figure 1.22. Left: Relaxation rate ratio as a function of GdIII concentration at pH 7 (■), 8.5 (), 
10 (▲), and 12 (♦). Right: Relaxation rate ratio as a function of pH. All 
measurements were recorded at 14 T and 25 °C. Adapted with permission from S. 
Aime, F. Fedeli, A. Sanino and E. Terreno, J. Am. Chem. Soc., 2006, 128, 11326. 
Copyright 2006 American Chemical Society ...........................................................25 
 
xi 
 
Figure 1.23. Structure of a contrast agent that is responsive to the activity of matrix 
metalloproteinase-2 before (1.26) and after (1.27) peptide cleavage by the 
enzyme.88 ..................................................................................................................26 
 
Figure 1.24. R2p/R1p as a function of contrast agent concentration (CT) demonstrating 
concentration-independence and that R2p/R1p responds to decreasing mole fraction 
of 1.26 (χGdL). Figure adapted with permission from A R2p/R1p Ratiometric 
Procedure to Assess Matrix Metalloproteinase-2 Activity by Magnetic Resonance 
Imaging/V. Catanzaro, C. V. Gringeri, V. Menchise, S. Padovan, C. Boffa, W. 
Dastrù, L. Chaabane, G. Digilio and S. Aime/Angew. Chem. Int. Ed., 52/14. 
Copyright © 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim .............26 
 
Figure 1.25. Structure of 1.28 and 1.29 used for ratiometric relaxation rate measurements at 
different magnetic field strengths for concentration-independent measurements of 
pH.51,53.......................................................................................................................28 
 
Figure 1.26. pH measured using liposome-encapsulated 1.28 and the ratiometric R1P approach vs 
pH measured by an electrode. Adapted with permission from E. Gianolio, S. Porto, 
R. Napolitano, S. Baroni, G. B. Giovenzana and S. Aime, Inorg. Chem., 2012, 51, 
7210. Copyright 2012 American Chemical Society .................................................28 
 
Figure 1.27. Structure of adamantane-functionalized contrast agents used for 1H- (1.30) and 19F-
MRI (1.31, stereochemistry of hydroxyl group not specified).55..............................31 
 
Figure 1.28. Structure of 1.32 used for dual-mode PET and 1H-MRI for quantitative pH 
measurements.52 Phosphonates are drawn singly protonated because of the expected 
pKa values of the first (pKa ≈ 2–3) and second (pKa ≈ 7–8) phosphonate oxygen 
atoms .........................................................................................................................32 
 
Figure 1.29. pH determined with the MR/PET technique vs pH determined using a glass 
electrode. The solid line represents a linear fit of the data and the dashed line 
represents a hypothetical 1:1 correspondence between the x- and y-axes. Figure 
adapted with permission from Bimodal MR–PET Agent for Quantitative pH 
Imaging/L. Frullano, C. Catana, T. Benner, A. D. Sherry and P. Caravan/Angew. 
Chem., 122/13. Copyright © 2010 WILEY-VCH Verlag GmbH & Co. KGaA, 
Weinheim ..................................................................................................................32 
 
Figure 1.30. Structure of 1.33 used for liposome encapsulation to demonstrate a response to 
oxidation using CEST and T1-weighted 
1H-MRI.73 ..................................................34 
 
Figure 1.31. Structure of 1.34, 1.35, 1.36 used to generate in vivo pH maps using a dual-
injection strategy.56,104,105 ..........................................................................................35 
 
Figure 1.32. Calculated pH maps of mouse kidneys generated using the dual-injection strategy 
of a mouse without (left) and with (right) acetazolamide treatment demonstrating 
alkalinization of kidneys. A pH scale bar is on the far right. Figure adapted with 
xii 
 
permission from Renal and Systemic pH Imaging by Contrast-Enhanced MRI/N. 
Raghunand, C. Howison, A. D. Sherry, S. Zhang and R. J. Gillies/Magn. Reson. 
Med., 49/2. Copyright © 2003 Wiley-Liss, Inc ........................................................35 
 
Figure 1.33. Structure of 1.37 and its protonated form 1.38 that alter the chemical shift of tert-
butyl protons through changes in ligand field. The ratiometric pH response was 
measured using 1.39 as a secondary compound with a different pH dependence ....39 
 
Figure 1.34. Ratio of tert-butyl proton chemical shift intensities of 1.37 and 1.39 as a function of 
pH. Reproduced from Ref. 54 with permission from The Royal Society of 
Chemistry ..................................................................................................................39 
 
Figure 2.1.  pO2 ranges in necrotic and non-necrotic tumor (converted from percent hemoglobin 
saturation using a hemoglobin saturation curve),134,135 subcutaneous space,136 
venous blood,136 the peritoneal cavity,137 and arterial blood.136 ...............................45 
 
Figure 2.2. Representative T1-weighted images demonstrating the response of 1.33 after 
different injection types. The images are (A) pre-intravenous injection; (B) 3 min 
post-intravenous injection; (C) 8 min post-intravenous injection; (D) pre-
intraperitoneal injection; (E) 3 min post-intraperitoneal injection; (F) 8 min post-
intraperitoneal injection; (G) pre-subcutaneous injection; (H) 3 min post-
subcutaneous injection; and (I) 8 min post-subcutaneous injection. Red arrows 
denote areas of positive contrast enhancement. The area represented by each image 
is 31 mm × 90 mm ....................................................................................................50 
 
Figure 2.3. Structure of GdIII-diethylenetriaminepentaacetate (2.1) used as a non-redox-active 
control .......................................................................................................................51 
 
Figure 2.4. Percent of injected dose of europium retained per organ 1 h post-injection for 
intravenous (white bars) and intraperitoneal (black bars) injections. Error bars 
represent the standard error of the mean of 3 independent experiments ..................52 
 
Figure 3.1. Longitudinal relaxation rate vs 3.6 concentration in phosphate-buffered saline ......62 
 
Figure 3.2. (a) Proposed solution-phase structure of 3.6 with non-coordinated chloride 
counteranions and one or two coordinated water molecules (n = 1 or 2). (b) X-ray 
crystal structure of 3.6 with a coordinated chloride ion (hydrogen atoms and the 
outer sphere chloride counteranion are not shown for clarity). R-factor = 0.0248. 
Resolution = 0.59 Å. Thermal ellipsoids are drawn at the 50% probability level ....65 
 
Figure 3.3. (a) X-ray crystal structure (viewed along the N–Eu–N axis) of 3.6 (hydrogen atoms 
are not shown for clarity) alongside a cartoon representation of the solid-phase 
geometry in the same orientation as the crystal structure. Outer sphere chloride, 
Cl00, related by symmetry is included in the image. (b) Cartoon representation of 
the proposed solution-phase geometry of 3.6 with one or two coordinated water 
molecules viewed along the N–Eu–N axis. The blue and teal spheres in the cartoons 
xiii 
 
represent nitrogen and europium, respectively, and the bold lines represent the 
cryptands. R-factor = 0.0248. Resolution = 0.59 Å. Thermal ellipsoids are drawn at 
the 50% probability level ..........................................................................................67 
 
Figure 3.4. T1-weighted in vivo sagittal plane images of a 4T1 tumor injected with 3.6 (a) pre-
injection; (b) 3 min, (c) 20 min, and (d) 120 min post-intratumoral injection; (e) 
difference between the 120 min and pre-injection images (image d minus image a) 
colored using the ImageJ green lookup table; (f) hematoxylin- and eosin-stained 
slice of tumor imaged in a–e; and (g) sum of images e and f. All images are on the 
same scale. Imaging parameters included an echo time of 1.5 ms, repetition time of 
11 ms, flip angle of 40°, field of view of 30 mm × 90 mm, and an in-plane 
resolution of 0.352 mm × 0.352 mm ........................................................................69 
 
Figure 3.5. Structure of GdIII-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate (3.7) ........71 
 
Figure 4.1. Representation of the oxidation of liposome-encapsulated 1.33 (T1 enhancement 
and CEST effect) to form liposomes containing 4.1 (T1 silent with CEST effect). On 
the far right is a depiction of the liposomal phospholipid bilayer with ovals as 
cholesterol molecules. For clarity, only one complex is shown in each liposome and 
coordinated water molecules are not drawn .............................................................74 
 
Figure 4.2. Structure of the diamagnetic control 4.2 ...................................................................78 
 
Figure 4.3. Structures of 4.3 and 4.4 ...........................................................................................79 
 
Figure 4.4. CEST spectra (7 T, ambient temperature) of raw image intensity data before 
(hollow circles) and after (solid circles) air exposure of (a) blank liposomes, (b) 
liposomes containing 28 mM 4.2, (c) liposomes containing 13 mM 1.33, (d) 
liposomes containing 24 mM 1.33, (e) liposomes containing 40 mM 1.33, and (f) 
liposomes containing 45 mM 1.33 ............................................................................82 
 
Figure 4.5. Mathematica commands or Lorentzian curve fitting CEST imaging data and relative 
error per data point for blank liposomes ...................................................................83 
 
Figure 4.6. Mathematica output for blank liposomes of (a) fitted variables, (b) Lorentzian 
function plotted with raw CEST data, and (c) relative error calculated for each data 
point ..........................................................................................................................84 
 
Figure 4.7. Intensity percent vs size of liposomes containing 45 mM 1.33 used for in vitro 
CEST imaging prior to air exposure .........................................................................85 
 
Figure 4.8. Intensity percent vs size of liposomes that contained 45 mM 1.33 used for in vitro 
CEST imaging after 24 h of air exposure .................................................................85 
 
Figure 4.9. Intensity percent vs size of liposomes containing 45 mM 1.33 used for in vitro T1-
weighted imaging prior to air exposure ....................................................................85 
xiv 
 
 
Figure 4.10. Intensity percent vs size of liposomes that contained 45 mM 1.33 used for in vitro 
T1-weighted imaging after 24 h of air exposure .......................................................86 
 
Figure 4.11. CEST spectra (7 T, ambient temperature) of 1.33-containing liposomes before () 
and after () 24 h air exposure. Data points represent the mean of six 
independently prepared samples [liposomes containing only phosphate-buffered 
saline; 4.2 (28 mM Sr); and 1.33 (13, 24, 40, and 45 mM Eu)], and error bars 
represent the standard error of the mean. The upfield signal was referenced to 0 
ppm using the Lorentzian-fitted spectra and signal intensities were calculated from 
in vitro images after a 2 s presaturation with a 17 µT radiofrequency pulse from 5 to 
–5 ppm in 0.2 ppm increments..................................................................................89 
 
Figure 4.12. Lorentzian-fitted CEST spectrum (7 T, ambient temperature) of liposomes filled 
with phosphate-buffered saline. The upfield signal was referenced to 0 ppm, and 
signal intensities were calculated from in vitro images after a 2 s presaturation with 
a 17 µT radiofrequency pulse from 5 to –5 ppm in 0.2 ppm increments .................90 
 
Figure 4.13. MR phantom images (5 mm tube diameter) at 7 T and ambient temperature of 
water, non-oxidized liposomes containing EuII, and oxidized liposomes containing 
EuIII. In the top row are T1-weighted images and on the bottom is a CEST map 
generated by subtracting presaturation at 1.2 ppm from presaturation at –1.2 ppm 
and the difference was divided by presaturation at –1.2 ppm. %CEST represents the 
decrease in bulk water signal intensity as a result of presaturation exchangeable 
water protons associated with liposomes ..................................................................92 
 
Figure 5.1. Reduction of a commercially available CEST contrast agent (5.1) to the T1-
shortening EuII-containing analogue (5.2) using Zn0 under an atmosphere of N2. 
Oxidation to the 3+ oxidation state yields the original complex. The table compares 
magnetic and spectroscopic properties between EuIII- and EuII-containing 
complexes in the ground state ...................................................................................97 
 
Figure 5.2. Absolute intensity vs concentration of 5.1. The lowest point was measured 7 times 
using independently prepared samples to determine the minimum detectable 
concentration as described in the experimental section of this chapter ..................100 
 
Figure 5.3. Longitudinal relaxation rate (1/T1) vs concentration of independently prepared 
solutions of 5.2 (top row) or 5.1 (bottom row) .......................................................103 
 
Figure 5.4. Cyclic voltammograms of (A) EuII/III-DOTA-4AmC (3 mM) with 
tetraethylammonium perchlorate (50 mM) as the supporting electrolyte (pH = 4) 
and (B) EuII/III-DOTA-4AmC (10 mM) with potassium chloride (100 mM) as the 
supporting electrolyte (pH = 7) ...............................................................................105 
 
Figure 5.5. (A) Emission spectra (395 nm excitation) of 5.1 (– –), 5.2 (—), and 5.1 after 
oxidation of 5.2 by exposure to air (··). The dashed and dotted lines overlap exactly. 
xv 
 
All solutions were 2 mM in degassed water under an atmosphere of N2 for Eu
II or 
air for the oxidized sample. (B) EPR spectra of 5.1 (– –) and 5.2 (—) in H2O at 110 
K under an atmosphere of N2 ..................................................................................108 
 
Figure 5.6. 1H-NMR spectra of 5.1 (top), 5.2 (middle), and 5.1 after oxidation of 5.2 by 
exposure to air (bottom). All solutions contained 23 mM of complex in degassed 
D2O under an atmosphere of N2 for Eu
II or air for the oxidized sample ................109 
 
Figure 5.7. (A) UV–visible absorption spectra of 5.1 (– –), 5.2 at t = 0 s (—) and t = 5400 s (— 
· —), and EuCl2 (— · · —). All samples were measured in 0.1 M HCl. (B) 5.2 
absorption at 425 nm as a function of time in 0.1 M HCl. Error bars represent the 
standard error of the mean of three independent measurements ............................111 
 
Figure 5.8. CEST spectra (pH 7.4) and MTRasym plots (inset) of 5.1 (– –), 5.2 (—), and 5.1 after 
oxidation of 5.2 by exposure to air (· ·) ..................................................................112 
 
Figure 5.9. (A) T1-weighted image and (B) CEST difference image (55 ppm image subtracted 
from the –55 ppm image) of 5 mm diameter NMR tubes containing (1) 5.1, (2) 5.2, 
(3) 5.1 after oxidation of 5.2, and (4) water ............................................................113 
 
Figure A1. 1H-NMR spectrum of 3.2 ........................................................................................120 
 
Figure A2. 13C-NMR spectrum of 3.2 .......................................................................................121 
 
Figure A3. 1H-NMR spectrum of 3.3 ........................................................................................122 
 
Figure A4. 13C-NMR spectrum of 3.3 .......................................................................................123 
 
Figure A5. 1H-NMR spectrum of 3.4 ........................................................................................124 
 
Figure A6. 13C-NMR spectrum of 3.4 .......................................................................................125 
 
Figure A7. 1H-NMR spectrum of 3.5 ........................................................................................126 
 
Figure A8. 13C-NMR spectrum of 3.5 .......................................................................................127 
 
 
 
 
 
 
 
 
 
 
 
xvi 
 
LIST OF ABBREVIATIONS 
 
Abbreviation Term 
brs broad singlet 
calcd calculated 
CEST chemical exchange saturation transfer 
d doublet 
dd doublet of doublets 
ddd doublet of doublet of doublets 
EDXF energy dispersive X-ray fluorescence 
EPR electron paramagnetic resonance 
FLASH fast low angle shot 
GI gastrointestinal 
HRESIMS high-resolution electrospray ionization mass spectrometry 
ICP–MS inductively coupled plasma mass spectrometry 
ICP–OES inductively coupled plasma optical emission spectroscopy 
Ln lanthanide 
m multiplet 
MRI magnetic resonance imaging 
MTRasym magnetization transfer ratio asymmetry 
PBS phosphate-buffered saline 
PET positron emission tomography 
Rf retention factor 
s singlet 
SAP square antiprism 
SPECT single-photon emission computed tomography 
t triplet 
td triplet of doublets 
TLC thin-layer chromatography 
TSAP twisted-square antiprism 
 
 
 
 
 
 
 
 
 
 
xvii 
 
Abbreviation Term Structure 
2.2.2 
4,7,13,16,21,24-hexaoxa-1,10-
diazabicyclo[8.8.8]hexacosane 
 
cyclen 1,4,7,10-tetraazacyclododecane 
 
DOTA-tetra(amide) tetrakis(N-amide)-containing cyclen derivative 
 
DOTA-4AmC 
1,4,7,10-tetraazacyclododecane-1,4,7,10-
tetrakis(N-acetamidoacetate) 
 
HPDO3A 
10-(2-hydroxylpropyl)-1,4,7,10-
tetraazacyclododecane-1,4,7-triacetate 
 
 
1 
 
CHAPTER 1: OVERCOMING THE CONCENTRATION DEPENDENCE OF 
RESPONSIVE CONTRAST AGENTS FOR MAGNETIC RESONANCE IMAGING 
 
Parts of this chapter were adapted with permission from Ekanger, L. A.; Allen, M. J. 
Metallomics, 2015, 7, 405. Reproduced by permission of The Royal Society of Chemistry. 
 
Introduction 
This chapter describes strategies used to design responsive contrast agents that are 
concentration-independent. Strategies to overcome concentration-dependent responsive contrast 
agents are relevant to this thesis because EuII-containing complexes offer a platform for 
concentration-independent responsive imaging. Responsive contrast agents have been discussed 
elsewhere,1–20 but this chapter focuses on overcoming concentration-dependence in responsive 
contrast agents for magnetic resonance imaging (MRI). Specifically, this chapter discusses 
strategies that complement the depth penetration of MRI, including ratiometric chemical 
exchange saturation transfer, ratiometric relaxation rates, dual-mode imaging, dual-injection, and 
ligand field induced chemical shift strategies from the year 2000 to present.  
The responsive contrast agents discussed in this chapter have been designed for MRI. 
MRI is a staple of modern diagnostic medicine and preclinical research because of its non-
invasive nature and exquisite spatial resolution (0.025 mm isotropic resolution in preclinical 
scans).21 The contrast-to-noise ratio of MRI scans can be enhanced with the use of exogenous 
molecules called contrast agents, often paramagnetic compounds, that interact with nearby nuclei 
(1H is the most commonly detected), resulting in darker or brighter pixels in an image. The 
intensity of pixels in a conventional MRI image correlates to the amount of time—longitudinal 
(T1), transverse (T2), or both—needed for the nuclear dipoles of protons to realign with the 
external magnetic field (generated by the scanner) after the nuclear dipoles have been misaligned 
by a radiofrequency pulse (also generated by the scanner). Paramagnetic contrast agents, 
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endowed with their own local magnetic field, can catalytically expedite the realignment, or 
relaxation, by interacting with numerous water protons through the exchange of water molecules 
or protons. Every contrast agent, even if structurally similar, produces contrast to different 
extents in MRI, and the behavior of paramagnetic contrast agents has been modeled and 
understood through the modified Solomon–Bloembergen–Morgan theory.22–24 With the 
predictive power of this theory, chemists have performed a great deal of research with the goal of 
optimizing contrast agent efficiency [longitudinal (r1) or transverse (r2) relaxivity],
25–32 which is 
a measure of the ability to relax protons as a function of the concentration of a contrast agent. 
Accordingly, the enhanced relaxation time brought about by a contrast agent is inherently 
dependent upon the concentration of a contrast agent. This dependence is one of the major 
limitations of contrast agents that change in response to specific stimuli.  
 Some of the earliest efforts toward developing responsive MRI contrast agents revolved 
around protein binding, which often caused relatively large increases in relaxivity.23 The first 
reported enzyme-responsive contrast agent, the galactopyranose-functionalized gadolinium(III)-
containing complex 1.1 (Figure 1.1), was introduced by Meade and co-workers and responded to 
the presence of β-galactosidase to form 1.2 with a 20% increase in r1.33,34 In a separate report 
using 1.3 (Figure 1.1), the same group observed a 77% change (3.26 to 5.76 mM–1 s–1) in r1 in 
response to changes in the concentration of calcium ions resulting in the formation of 1.4.35,36 
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Figure 1.1. A. The first responsive contrast agent. In the presence of β-galactosidase, a galactose 
unit is removed from the contrast agent to facilitate the coordination of a water molecule and, 
consequently, a change in contrast enhancement;33,34 B. A contrast agent (1.3 to 1.4) that 
responds to changes in the concentration of calcium ions.35,36 
 
 Since these seminal reports, many other responsive contrast agents for MRI have been 
developed that respond to a wide range of stimuli including changes in pH,37–58 temperature,57–62 
metal ion concentration,35,36,63–65 and redox-active species.66–73 Many responsive contrast agents 
are designed with the goal of improving diagnostic capabilities in vivo. When performing in vivo 
imaging, however, the response of a contrast agent is meaningful only when the concentration of 
the contrast agent is known. To illustrate this point, the relaxivities of 1.3 and 1.4 have been 
plotted to exemplify the differences between in vitro (Figure 1.2) and in vivo (Figure 1.3) 
experiments. For in vitro experiments, the concentration of the contrast agent can easily be 
determined; therefore, the readout of 1/T1 can be used to determine if a contrast agent has 
responded. With in vivo studies, the concentration of contrast agents cannot be easily 
determined; therefore, when 1/T1 is measured during the imaging experiment, it is currently 
impossible to differentiate between a complete response, no response, or a partial response. This 
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concentration-dependent nature holds true for many responsive contrast agents that have not 
been specifically designed to address the issue of concentration-dependence. 
 
Figure 1.2. The relaxivities of 1.3 and 1.4 are the slopes of the lines of the paramagnetic 
contribution to relaxation rate (1/T1P) as a function of the concentration of contrast agent. The 
plots illustrate the relaxivity in the presence (1.4, 5.76 mM–1 s–1) and absence (1.3, 3.26 mM–1 s–
1) of calcium ions.35,36 Relaxivity (slope of a linear function) can be expressed as an equation in 
the form of 1/T1P = r1x + b (in this example b = 0 because only the paramagnetic contribution is 
being plotted), where r1 is the relaxivity or slope of the line and x is the concentration of the 
contrast agent. When calcium is present, the concentrations of 1.3 and 1.4 can be expressed as 
x1.3 and x1.4, and the linear equation becomes 1/T1P = (r11.3)x1.3 + (r11.4)x1.4. The vertical dashed 
line is a visual guide to demonstrate that a known concentration of contrast agent (in this 
example 0.60 mM was arbitrarily selected) permits 1/T1P measurements (horizontal dashed lines) 
to indicate the absence (2.0 s–1) or presence (3.5 s–1) of calcium. When the initial concentration 
of contrast agent is known (0.60 mM), the total concentration will remain 0.60 mM because the 
volume of a sample (in vitro) is constant. Accordingly, the total concentration of contrast agent 
bound to calcium can be expressed as x1.4 = 0.60 mM – x1.3. Substituting for x1.4 in 1/T1P = 
(r11.3)x1.3 + (r11.4)x1.4 yields 1/T1P = (r11.3)x1.3 + (r11.4)(0.60 mM – x1.3), which is solvable because 
there is one equation and one variable. In this example, the 1/T1P values for 1.3 and 1.4 are 
boundaries, and the actual value can fall anywhere between the two boundaries. However, the 
1/T1P equation is solvable even for incomplete conversions between 1.3 and 1.4. 
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Figure 1.3. The relaxivities of 1.3 and 1.4 plotted as in Figure 1.2, where 1/T1P = (r11.3)x1.3 + 
(r11.4)x1.4. The horizontal dashed line is a visual guide to demonstrate that a measured 1/T1P value 
(in this example 2.0 s–1 was arbitrarily selected) can be produced by a 0.6 mM solution of 1.3, a 
lower concentration of 1.4, or a mixture of 1.3 and 1.4. Without knowing the concentration of at 
least one of the contrast agents or the total amount of the two agents, the equation for 1/T1P 
contains two unknown variables (x1.3 and x1.4) and, consequently, cannot be solved. 
 
1.1 Chemical Exchange Saturation Transfer 
1.1.1 Ratiometric Chemical Exchange Saturation Transfer 
In contrast-enhanced T1-weighted MRI, contrast agents influence the relaxation times of 
nearby protons. The process is catalytic because of the relatively fast rate of exchange between 
coordinated and bulk water protons, resulting in interactions with a large number of protons in a 
short period of time. If, however, a contrast agent alters the chemical shift of exchanging protons 
such that the shift is distinguishable from the proton resonance of bulk water, a different 
mechanism of contrast can be generated. By selectively saturating the chemically-shifted protons 
with a radiofrequency pulse, the intensity of the signals from these protons are diminished. 
During the saturation event, the shifted protons continue to exchange with bulk water through 
water or proton exchange. The net result is a transfer of nuclear dipole saturation to the bulk 
water signal, which causes a reduction in intensity (Figure 1.4) that is used to generate an image.  
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Figure 1.4. A simplified representation of chemical exchange saturation transfer (CEST) viewed 
as a 1H-NMR spectrum. The signal from an exchangeable proton that is different from bulk 
water is reduced via a selective radiofrequency pulse while the proton is exchanging with protons 
in the bulk water. The combination of these two events results in a reduction of the signal 
intensity from bulk water, which can be measured and expressed as a percent decrease. 
 
The reduction in bulk water signal intensity can be predicted by Eq 1.1 (under the 
assumption that saturation time is long enough for an equilibrium to be established),74,75 where 
MS is the bulk water signal intensity after radiofrequency saturation at a given frequency, MO is 
the bulk water signal intensity in the absence of a radiofrequency pulse, k1 is the pseudo first-
order proton exchange rate, and T1W is the longitudinal relaxation time of bulk water. This 
contrast mechanism is called chemical exchange saturation transfer (CEST). One of the benefits 
of CEST is the ability to influence contrast upon demand, which is possible because CEST can 
only be measured after a selective, intentionally applied radiofrequency pulse. The ability to 
produce contrast upon demand is not possible with most other contrast agent modalities. Even 
with this benefit, the CEST effect is still dependent upon contrast agent concentration as seen in 
Eq 1.2,74 where n is the number of exchange sites on the contrast agent, kCA is the proton 
exchange rate constant, and [CA] is the concentration of contrast agent. The issue of 
concentration was circumvented for pH detection by Balaban and co-workers by using either the 
ratio of two different proton-exchange sites on 1.5 or exchange sites on two molecules, 1.6 and 
1.7, in the same solution (Figure 1.5).74 The key to this ratiometric method was that each proton-
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exchange site had a unique pH dependence, which was determined by pKa values. Two unique 
exchange sites with non-equivalent pH dependence produce two distinct CEST signals, and the 
decrease in bulk water signal intensity for each site can be predicted with Eq 1.3 and Eq 1.4,74 
where S1 and S2 denote the first and second exchange sites. A ratio of the two CEST effects (the 
quotient of Eq 3 and Eq 4) yields Eq 5.  
 
Figure 1.5. Structures of 5,6-dihydrouracil (1.5), 5-hydroxytryptophan (1.6), and 2-
imidazolidinethione (1.7) used to demonstrate the first ratiometric CEST response to pH.74 
Eq 1.1 𝑀𝑆/𝑀𝑂 = (1 +  𝑘1𝑇1𝑊)
–1 
Eq 1.2 𝑘1 =  [CA]𝑛𝑘CA 
Eq 1.3 [(𝑀𝑂  – 𝑀𝑆)/𝑀𝑆]
S1 = [CA]S1𝑛S1𝑘CA
S1 𝑇1𝑊 
Eq 1.4 [
𝑀𝑂 – 𝑀𝑆
MS
]
S2
= [CA]S2𝑛S2𝑘CA
S2 𝑇1𝑊  
Eq 1.5 
[(𝑴𝑶 – 𝑴𝑺)/𝑴𝑺]
𝐒𝟏 
[(𝑴𝑶 – 𝑴𝑺)/𝑴𝑺]𝐒𝟐 
=  
 [𝐂𝐀]𝐒𝟏𝒏𝐒𝟏𝒌𝐂𝐀
𝐒𝟏
 [𝐂𝐀]𝐒𝟐𝒏𝐒𝟐𝒌𝐂𝐀
𝐒𝟐   
 If the two exchange sites reside on separate molecules, knowledge of the concentration of 
the two molecules is still required because they cannot necessarily be assumed to be equal. 
However, if both exchange sites reside within the same molecule, the concentration cancels out 
on the right side of Eq 5, thus circumventing the requirement of knowing concentration. With 
unique pH dependencies, calibrated ratios of CEST effects were used to determine the pH of a 
solution without knowledge of concentration. Soon after the initial report of the ratiometric 
CEST technique, other groups designed ratiometric CEST contrast agents that incorporated LnIII 
ions to induce large chemical shifts.45–47,59 
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1.1.2 Ratiometric CEST with Paramagnetic Compounds 
Often, the more a CEST signal is shifted downfield or upfield from bulk water, the more 
suitable it is for in vivo imaging. This idea is based on magnetization transfer effects that occur in 
vivo between bulk water and macromolecules (for example phospholipid membranes and 
proteins), which tend to broaden the in vivo bulk water signal.76 Therefore, if CEST signals 
within this range are used, the contrast they provide can be drastically reduced or undetectable 
due to the magnetization transfer effects that occur during in vivo experiments. Recently, this 
notion has been challenged by reports of in vivo CEST imaging using saturation frequencies as 
close as 0.8 ppm from bulk water.77 Nevertheless, the development of many CEST agents has 
proceeded with the aim of pushing the chemical shift of exchangeable protons far from the bulk 
water proton signal. A separate reason for using CEST agents with relatively large chemical 
shifts is that the CEST effect is only observable when the chemical shift difference between 
chemically shifted and bulk water protons is greater than the proton-exchange rate. Accordingly, 
large chemical shifts tend to ensure that this requirement is met and allow contrast agents with 
relatively fast exchange rates to be used. To achieve large chemical shift offsets, lanthanide ions 
are routinely incorporated into contrast agents because of their ability to alter chemical shifts.78,79 
 Interestingly, the ground state of EuIII (7F0) does not have a magnetic moment and is 
diamagnetic despite having six unpaired f-electrons. However, some excited states are thermally 
accessible at room temperature (average magnetic moment ≈ 3.5 Bohr magnetons).80 This 
thermally accessible paramagnetic behavior along with luminescent properties that allow for 
characterization of coordination environment, are at least two reasons why EuIII has been used in 
the design of CEST contrast agents.81–83 Using a EuIII-containing contrast agent, Sherry and co-
workers were able to observe the bound water protons on the DOTA-tetra(amide) derivative 1.8 
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(Figure 1.6) at ambient temperatures shifted 50 ppm downfield from bulk water.84 Observing the 
bound-water proton resonance in an aqueous solution was significant because previously Ln-
bound water protons had only been observed on a EuIII-containing complex in deuterated 
acetonitrile.85 The ability to observe the bound-water resonance was recognized by Aime and co-
workers as a step towards ratiometric CEST. Accordingly, Aime and co-workers hypothesized 
that the ability to detect both sets of protons (bound-water and amide) of Ln-tetra(amide) 
complexes would allow for a ratiometric CEST response that would be independent of the 
concentration of the contrast agent using the identical logic exploited by Balaban and co-workers 
in Eq 1.6. Furthermore, LnIII-containing complexes would increase the chemical shifts of both 
the bound water and amide protons to decrease or eliminate overlap with the broadened bulk 
water signal caused by magnetization transfer effects in vivo. Accordingly, Aime and co-workers 
investigated DOTA-tetra(amide) derivatives 1.9 through 1.14 to characterize the bulk water and 
amide proton resonances.45 Each complex displayed a unique amide proton chemical shift, but 
the complexes with the largest chemical shifts did not exhibit the most efficient saturation 
transfer because of differences in the longitudinal relaxation time of coordinated water protons. 
 
Figure 1.6. Structures of LnDOTA-tetra(amide) complexes.45–47,84 
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Eq 1.6  
[(𝑴𝑶 – 𝑴𝑺)/𝑴𝑶]
𝐘𝐛𝐋 
[(𝑴𝑶 – 𝑴𝑺)/𝑴𝑶]𝐄𝐮𝐋 
=
 𝟒[𝐘𝐛𝐋]𝒌𝐍𝐇
𝐘𝐛𝐋
 𝟐[𝐄𝐮𝐋]𝒌𝐇𝟐𝐎
𝐄𝐮𝐋  
Interestingly, in Aime’s study, 1.14 had the highest saturation transfer at 70% despite 
only shifting the amide proton signal 16 ppm upfield from bulk water.45 Some lanthanides 
revealed an increase in saturation transfer (Figure 1.7) despite relatively small chemical shifts 
from bulk water. This phenomenon was attributed to different longitudinal proton relaxation 
times for each complex.45 With longer proton relaxation times, saturation transfer occurs to 
greater extents than with shorter times. Conversely, rapidly relaxing protons do not have enough 
time to transfer saturation to the bulk water proton pool. A striking example of this phenomenon 
was observed with 1.10, where the complex shifted amide protons 77 ppm downfield from bulk 
water, but the relatively short longitudinal relaxation time of the metal complex caused the 
protons near DyIII to relax too quickly for saturation transfer to be observed (Figure 1.7).45 
Taken together, it is a prime example that greater chemical shifts do not necessarily equate to 
greater CEST properties.  
 
Figure 1.7. Percent saturation transfer as a function of radiofrequency irradiation time at the 
same saturation power (B1 = 25 µT) for 1.10 (30 mM,▼), 1.11 (30 mM, ▲), 1.12 (40 mM, ♦), 
1.13 (40 mM, ), and 1.14 (30 mM, ■) at 7 T, 312 K, and pH 8.1. Figure adapted with 
permission from Paramagnetic Lanthanide(III) Complexes as pH-Sensitive Chemical Exchange 
Saturation Transfer (CEST) Contrast Agents for MRI Applications/S. Aime, A. Barge, D. D. 
Castelli, F. Fedeli, A. Mortillaro, F. U. Nielsen and E. Terreno/Magn. Reson. Med., 47/4. 
Copyright © 2002 Wiley-Liss, Inc. 
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 Aime and co-workers followed their initial report with an investigation of 1.9, 1.15, and 
1.16 to explore and, in the case of 1.9, reinvestigate the relevant characteristics for single-
molecule ratiometric CEST.46 They found that each complex had observable amide and 
coordinated water protons that were capable of transferring saturation to bulk water, indicating 
that each complex could be used for single-molecule ratiometric CEST. The amide and 
coordinated water proton resonances at pH 7 from both studies are listed in Table 1.1, and the 
pH-dependence of saturation transfer can be seen in Figure 1.8. The saturation transfer of amide 
protons was affected by changes in solution pH; whereas, the saturation transfer of bound water 
protons was unaffected in the pH range of 5.5 to 7.5. Accordingly, 1.9, 1.15, and 1.16 were 
capable of reporting the pH of a solution without knowledge of contrast agent concentration 
using single-molecule ratiometric CEST. The sensitivity, however, was vastly different upon 
moving from low to high atomic numbers across the lanthanide series (Figure 1.8). Specifically, 
1.15 had the largest and most sensitive ratiometric CEST ratio, and 1.9 had the least sensitive 
ratio. This phenomenon is reminiscent of the saturation transfer trend of 1.9 through 1.14, where 
longitudinal proton relaxation time was attributed to the observed differences in saturation 
transfer regardless of the magnitude of the chemical shifts. Aime and co-workers performed 
additional characterization of the properties relevant to single-molecule ratiometric CEST using 
LnDOTA-tetra(amide) complexes, which included a demonstration of a ratiometric temperature 
response that was independent of contrast agent concentration using 1.15 for in vitro studies.47 
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Table 1.1. Amide and bound water proton chemical shifts relative to bulk water of LnDOTA-
tetra(amide) complexes at pH 7. Both values are required for single-molecule ratiometric CEST. 
 
Compound LnIII Amide 1H (ppm) Bound H2O 
1H (ppm) Ref. 
1.15 PrIII 13 –70 46,47 
1.16 NdIII 11 –50 46,47 
1.9 EuIII –4 40 45 
1.10 DyIII 77 not observed 45 
1.11 HoIII 39 not observed 45 
1.12 ErIII –22 not observed 45 
1.13 TmIII –51 not observed 45 
1.14 YbIII –16 not observed 45 
 
 
Figure 1.8. Saturation transfer (ST) as a function of pH for protons of amides (filled symbols) 
and coordinated water molecules (open symbols) for 1.9 (circles), 1.15 (triangles), and 1.16 
(squares) at 7 T and 312 K after a 4 s irradiation. Figure adapted with permission from Novel 
pH-Reporter MRI Contrast Agents, S. Aime, D. D. Castelli and E. Terreno/Angew. Chem., 
114/22. Copyright © 2002 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.  
 
 In vivo ratiometric CEST imaging of pH was reported by Pagel and co-workers using 
1.17 (Figure 1.9).48 After characterizing a concentration-independent pH response of 1.17 using 
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ratiometric CEST of the amide and amine protons, they injected 1.17 directly into a tumor within 
a mouse. Using a minimum CEST threshold of 2% (corresponding to a 95% probability of the 
CEST effect being attributable to 1.17), an in vivo pH map was generated using the ratio of 
CEST effects after presaturation at 8 ppm downfield and 11 ppm upfield of bulk water.48 The 
frequency offset of these CEST signals was serendipitous because magnetization transfer effects 
were thought to affect both signals equally because they are nearly symmetric about the bulk 
water signal. However, in vivo ratiometric imaging might be complicated using a signal shifted 
relatively close to water and a second signal shifted relatively far from bulk water. This 
complication might arise if magnetization transfer effects influence one of the signals to a greater 
extent than the other. 
 
 
Figure 1.9. Structure of 1.17 used for pH and nitric oxide detection. The YbIII-containing 
product of the nitric oxide and oxygen reaction is 1.18.48,72 
 
  As evidenced through every example highlighted so far, pH is an intuitive target for 
responsive contrast agents because protons can be directly imaged with relatively high spatial 
resolution with MRI, and contrast agents can be readily designed with proton-exchange sites. 
Measuring pH with contrast agents relies on proton exchange because protons associated with 
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the contrast agent must exchange with bulk water protons to generate contrast. Proton exchange 
is temperature-dependent and, consequently, pH measurements are inherently temperature-
dependent. Sherry and co-workers developed single-molecule CEST temperature response 
without the use of ratiometric measurements.59 Instead, they recognized that proton exchange is 
highly temperature-dependent and that small changes in the exchangeable proton chemical shift 
(hyperfine shifts) had the potential to report temperature using MRI. By measuring the bound-
water proton exchange for 1.19 (Figure 1.10), they observed a drastic hyperfine shift from 800 
to 650 ppm upfield from bulk water within a temperature range of 20 to 50 °C, while 1.9 
exhibited smaller hyperfine shifts ranging from 55 to 45 ppm downfield of bulk water within the 
same temperature range. Sherry and co-workers chose 1.9 to demonstrate the temperature 
response in MRI (Figure 1.11), where the temporal resolution was about 3 min per experiment 
for each temperature. 
 
Figure 1.10. Structure of 1.19 investigated for concentration-independent temperature 
response.59 
 
 
Figure 1.11. In vitro temperature maps (1 cm tube diameter) of a solution containing 1.9 (10 
mM) at pH 7.0 with a calibrated color bar on the far right. Tair is the temperature of air flowing 
over the sample. Reprinted with permission from S. Zhang, C. R. Malloy and A. D. Sherry, J. 
Am. Chem. Soc., 2005, 127, 17572. Copyright 2005 American Chemical Society. 
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 Aime and co-workers combined pH and temperature response in dual-response contrast 
agent 1.20 (Figure 1.12), which, like other cyclen-based macrocyclic complexes that contain 
chiral centers, exists as a distribution of stereoisomers in solution.58 Only two of the eight 
isomeric forms (see Figure 1.13 for all isomers) were observable through 1H-NMR 
spectroscopy, and they were assigned as the R and S forms of one conformer. The hydroxyl 
protons of the two observable isomers of 1.20 occurred at 99 and 71 ppm downfield from bulk 
water. The ratio of the CEST effect for each isomer was used for ratiometric pH measurements 
(Figure 1.14) that were independent of the concentration of contrast agent. Additionally, the 
hyperfine shifts of each isomer responded linearly with temperature such that both shifts could 
individually report the solution temperature without knowledge of contrast agent concentration.  
 As previously mentioned, temperature affects ratiometric CEST measurements of pH 
because proton exchange is inherently temperature-dependent. The case is not so clear for using 
changes in hyperfine shift to measure temperature without a pH-dependence because protonation 
and deprotonation of functional groups on a complex can potentially alter chemical and 
conformational structure of the complex and lead to measurable changes in chemical shifts. It 
should be noted that a potential limitation with measuring hyperfine shifts for both of the 
previous examples is that multiple CEST images are required to scan a particular frequency 
range, which can increase total acquisition time. Longer MRI acquisition times are potentially 
limiting because the contrast agent is allowed more time to diffuse. 
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Figure 1.12. Structure of 1.20 used for concentration-independent detection of pH and 
temperature.58 
 
 
 
Figure 1.13. Twisted-square antiprism (TSAP) and square antiprism (SAP) isomeric forms of 
LnHPDO3A related to one another either through arm rotation or ring inversion. The bottom 
chart demonstrates eight possible isomers. Figure adapted with permission from YbIII-HPDO3A: 
A Dual pH- and Temperature-Responsive CEST Agent/D. D. Castelli, E. Terreno and S. 
Aime/Angew. Chem. Int. Ed., 50/8. Copyright © 2011 WILEY-VCH Verlag GmbH & Co. 
KGaA, Weinheim. 
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Figure 1.14. Ratiometric CEST values (calculated using the ratio of the CEST effect of each 
isomer) as a function of pH at 20 (■) and 37 °C (). Error bars represent the standard deviation 
from the mean. Figure adapted with permission from YbIII-HPDO3A: A Dual pH- and 
Temperature-Responsive CEST Agent/D. D. Castelli, E. Terreno and S. Aime/Angew. Chem. Int. 
Ed., 50/8. Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. 
 
 Recently, Bartha and co-workers demonstrated a dual pH and temperature response in 
vivo that was independent of contrast agent concentration using 1.21 (Figure 1.15).57 They 
argued that using single-molecule ratiometric CEST is limited by the assumption that in vivo 
magnetization transfer effects will remain constant during the two separate CEST experiments. 
The assumption might be invalid when two different radiofrequency saturation powers are used. 
Using two saturation powers might cause magnetization transfer effects to be different from one 
anatomical region to the next, potentially altering the saturation transfer measurements. To 
circumvent this issue of heterogeneous magnetization transfer effects, they proposed using a 
magnetization transfer ratio asymmetry (MTRasym) analysis to determine pH. 
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Figure 1.15. Structure of 1.21 used for dual pH and temperature response that was independent 
of the concentration of contrast agent.57 
 
 MTRasym is a plot used to reveal asymmetric features in a CEST spectrum and is 
particularly useful for CEST signals that partially overlap with bulk water or endogenous tissue 
signal. The MTRasym plot is generated by obtaining the difference in bulk water signal intensity 
at equal but opposite frequency offsets from bulk water. The net effect of this analysis is to 
remove the baseline saturation transfer to obtain a signal that corresponds to only one exchange 
site, allowing the linewidth of the CEST signal to be measured without interference from direct 
saturation of either bulk water protons or saturation transfer from endogenous tissues. 
Accordingly, Bartha and co-workers measured the MTRasym linewidth of an amide CEST signal 
at 45 ppm upfield from bulk water using 1.21 and observed pH dependence from 6 to 8.57 
Expectedly, the linewidth was also temperature-dependent because it is a function of exchange 
rate, but temperature was found to only influence linewidth between pH 7.5 and 8 at 
temperatures above 37 °C. Many disease states coincide with pH values below 7, so the 
temperature dependence of linewidth was not considered a barrier to in vivo imaging. As seen in 
previous studies by other groups,58,59 the hyperfine shift varied with temperature to allow for 
accurate temperature measurements. Importantly, neither the MTRasym linewidth nor the 
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hyperfine shift of the signal were concentration-dependent. A pH electrode was used to 
standardize the contrast agent response to pH prior to in vivo imaging. Using the aforementioned 
techniques, Bartha and co-workers successfully imaged in vivo pH and temperature using a 
single molecule (Figure 1.16) with average pH and temperature values of 7.2 ± 0.2 and 37.4 ± 
0.5 °C.57 It should be noted that error within the in vivo CEST spectra were not reported. Similar 
to measuring hyperfine shifts, a limitation to the MTRasym linewidth approach is that numerous 
frequency offset images are required to obtain enough data points to measure the linewidth, and 
acquiring more CEST images can substantially increase total acquisition time. 
 
 
Figure 1.16. (a) CEST spectra of a mouse leg muscle generated pre- (solid line) and post-
injection (dashed line) with MTRasym (bottom left) post-injection at 45 ppm upfield from bulk 
water. Solid and dashed lines were generated using a tenth-order polynomial; (b) pH map 
superimposed onto a pre-injection image of the mouse leg muscle; and (c) temperature map 
superimposed onto a pre-injection image.  Colored pixels represent regions exhibiting CEST 
contrast at ≥95% probability. Figure adapted with permission from Simultaneous In vivo pH and 
Temperature Mapping Using a PARACEST-MRI Contrast Agent/N. McVicar, A. X. Li, M. 
Suchý, R. H. E. Hudson, R. S. Menon and R. Bartha/Magn. Reson. Med., 70/4. Copyright © 
2012 Wiley Periodicals, Inc. 
 
 While lanthanides have been extensively used for concentration-independent 
measurements of pH, work by Morrow and co-workers has developed the use of d-block metals 
for the same purpose.49 Using 1.22 (Figure 1.17) with CoII, four unique amide resonances (112, 
95, 54, and 45 ppm) were observed downfield of bulk water in the CEST spectrum. The four 
resonances were thought to be caused by two bound amide arms that are not related by 
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symmetry. Interestingly, two of the amide resonances were found to have unique pH 
dependencies, which made them prime candidates for ratiometric pH response. Using the two 
most downfield signals at 112 and 95 ppm, a linear relationship with pH was observed (Figure 
18). The ratiometric pH response was not demonstrated to be independent of contrast agent 
concentration, but it was observed that the magnitude of CEST (not the ratio) was dependent on 
contrast agent concentration. 
 
Figure 1.17. Structure of ligand 1.22 used for ratiometric pH detection with CoII.49 
 
Figure 1.18. CEST ratio as a function of pH using the CoII-containing complex of 1.22 (4 mM) 
in 2-(N-morpholino)ethanesulfonic acid or 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
buffer (20 mM) with NaCl (100 mM). Measurements were recorded at 4.7 T and 37 °C. Error 
bars represent standard deviations of three measurements. Adapted from Ref. 49 with permission 
from The Royal Society of Chemistry. 
 
 As demonstrated through the highlighted examples in this section, significant progress 
has been made in concentration-independent imaging of pH and temperature. The choice of both 
pH and temperature responses can be explained by the ease of detecting protons in MRI and the 
inherent temperature-dependence of proton exchange. Although these two parameters were a 
good starting point, they are not the only important targets for concentration-independent 
response. For example, Pagel and co-workers made progress toward new targets for 
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concentration-independent response by demonstrating nitric oxide response in the presence of 
oxygen using 1.17,72 which underwent an irreversible reaction forming a triazene linkage 
between two equivalents of the contrast agent to form 1.18 (Figure 1.9).72 The measurements 
made by Pagel and co-workers using 1.17 and 1.18 were not deemed concentration independent, 
but the covalent incorporation of a secondary CEST agent that does not react with nitric oxide, 
such as 1.13, could facilitate concentration-independent nitric oxide response. 
 Another example of a target other than pH or temperature was demonstrated by Sherry 
and co-workers who achieved a concentration-independent response to singlet oxygen using 1.23 
(Figure 1.19).70 The incorporation of a 9-anthryl group facilitated an irreversible reaction with 
singlet oxygen to form 1.24, and the ~3 ppm (Figure 1.20) chemical shift difference between the 
amide protons before and after response enabled ratiometric CEST imaging. The use of CEST 
imaging allowed for the formation of singlet oxygen to be observed from the disproportionation 
of H2O2 catalyzed by MoO4
2– (Figure 20b) because the CEST ratio is also a ratio of product over 
reactant. In vitro phantom images of singlet oxygen response enabled quantification of singlet 
oxygen after presaturation at 55 and 48 ppm downfield from bulk water. 
 
 
Figure 1.19. Structures of 1.23 and the product of its reaction with singlet oxygen (1.24).70 
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Figure 1.20. (A) Ms/M0 as a function of saturation offset for increasing concentrations of singlet 
oxygen at 9.4 T and 298 K. Inset: Enlarged view. (B) CEST ratio as a function of concentration 
of singlet oxygen. Adapted from Ref. 70 with permission from The Royal Society of Chemistry. 
 
 A new ratiometric CEST method using different radiofrequency powers was recently 
reported by Aime and co-workers.86 In this technique, a ratio, which has been named the ratio of 
radiofrequency power mismatch, is calculated by the quotient of saturation transfer at two 
different radiofrequency powers as seen in Eq 1.7, where ST is the measured saturation transfer 
and RF1 and RF2 are the first and second radiofrequency powers used to measure saturation 
transfer. Importantly, radiofrequency power mismatch is dependent on pH (pH-dependence 
indicates temperature dependence as well, but this was not demonstrated in the report) and 
radiofrequency power, but it is independent of the concentration of contrast agent. Using the 
radiofrequency power mismatch approach, Aime and co-workers demonstrated both in vitro and 
in vivo pH detection using radiofrequency powers of 1.5, 3, and 6 µT.86 
Eq 1.7  𝑟𝑎𝑑𝑖𝑜𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦 𝑝𝑜𝑤𝑒𝑟 𝑚𝑖𝑠𝑚𝑎𝑡𝑐ℎ =
 [(1−ST)/ST]𝑅𝐹1
[(1−ST)/ST]𝑅𝐹2
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 The use of ratiometric imaging has worked well for contrast agents that produce two 
CEST signals with unique pH dependencies. The ratiometric approach, however, is not limited to 
CEST imaging applications. In the next section, examples of ratiometric imaging using 
relaxation rates are highlighted. 
1.2 Ratiometric Relaxation Rates 
The absence of GdIII-containing contrast agents in the previous section is primarily due to 
the relatively slow electronic relaxation time (T1e) of Gd
III compared to other LnIII metal ions.22–
24 The result of a relatively slow T1e is that Gd
III will relax protons efficiently. In fact, GdIII 
relaxes nearby protons so quickly that complexes containing GdIII and exchangeable  protons 
(amine, amide, hydroxyl, and bound water) will not exhibit CEST effect.87 On the other hand, 
GdIII is an efficient positive contrast agent because it can drastically decrease the T1 of nearby 
protons. However, as discussed in the introduction, merely changing the relaxivity of a GdIII-
containing complex will impose a concentration-dependence on the response of the agent, which 
limits its practicality in vivo. Therefore, neither ratiometric CEST nor changes in relaxivity are 
sufficient for the design of concentration-independent responsive contrast agents containing 
GdIII. Instead, changes in both longitudinal and transverse relaxation rates can be used for 
ratiometric imaging. 
 Aime and co-workers proposed using the ratio between the transverse and longitudinal 
paramagnetic contribution to relaxation rates (R2p/R1p) as a concentration-independent handle for 
pH detection.50 The transverse and longitudinal relaxation rates are the inverse of the transverse 
and longitudinal relaxation times T2 and T1, respectively. The rationale for this approach can be 
explained using Eq 1.8–1.10 (commonly used to describe bound water proton contributions to 
relaxation rates), where PM is the mole fraction of water protons bound to Gd
III ([Gd]/55.6), τM is 
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the residence lifetime of the bound water protons, and T2M and T1M are the transverse and 
longitudinal relaxation times of the bound water protons. Individually, R1p and R2p are 
concentration-dependent because of PM (Eq 1.8 and Eq 1.9), whereas PM is cancelled in the ratio 
(equation 10). Neither T1M nor T2M are concentration-dependent, but they are both dependent on 
the rotational correlation time (τR).22–24 Therefore, changes in τR are expected to cause changes in 
both T1M and T2M. Likewise, changes in T1M and T2M are expected to cause changes in the R2p/R1p 
ratio (Eq 1.10), which remains concentration-independent. Accordingly, changes in τR are 
predicted to cause changes in the ratio of relaxation rates. The connection between τR and 
relaxation rates was used for pH response using 1.25 (Figure 1.21) by a reversible, 
conformational transition between α-helical and random coil conformers.50 The change in 
conformation caused a change in τR, which caused a change in the ratio of relaxation rates. Using 
21, a ratiometric response to pH was demonstrated that was independent of the concentration of 
contrast agent (Figure 1.22). 
Eq 1.8  𝑅1p ≃
 𝑃M
 𝑇1M+ 𝜏M 
  
Eq 1.9  𝑅2p ≃
 𝑃M
 𝑇2M+ 𝜏M 
  
Eq 1.10 
𝑅2p
𝑅1p
≃
 𝑇1M+ 𝜏M
 𝑇2M+ 𝜏M 
  
 
Figure 1.21. Structure of 1.25 used for concentration-independent pH measurements using 
ratiometric relaxation rates.50 
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Figure 1.22. Left: Relaxation rate ratio as a function of GdIII concentration at pH 7 (■), 8.5 (), 
10 (▲), and 12 (♦). Right: Relaxation rate ratio as a function of pH. All measurements were 
recorded at 14 T and 25 °C. Adapted with permission from S. Aime, F. Fedeli, A. Sanino and E. 
Terreno, J. Am. Chem. Soc., 2006, 128, 11326. Copyright 2006 American Chemical Society. 
 
 In a recent study, Digilio, Aime, and co-workers applied the R2p/R1p approach to detect 
matrix metalloproteinase-2 activity.88 Instead of relying on reversible changes to molecular 
conformation, an irreversible reaction was used to change R2p/R1p by an enzyme-catalyzed 
cleavage of a peptide. Before enzyme cleavage, 1.26 (Figure 1.23) remained embedded within a 
liposome membrane, which forced the complex to have a relatively long τR because of the slow 
molecular reorientation of liposomes compared to small molecules.89 Upon reacting with matrix 
metalloproteinase-2, 1.27 was cleaved from the liposome membrane and, consequently, 
experienced a decrease in τR.88 As discussed previously, changes in τR induce measurable 
changes in R2p/R1p that are independent of contrast agent concentration. By measuring R2p/R1p of 
1.26 embedded in liposomes exposed to matrix metalloproteinase-2, the activity was measured 
and the response was found to be independent of the concentration of contrast agent (Figure 
1.24).  
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Figure 1.23. Structure of a contrast agent that is responsive to the activity of matrix 
metalloproteinase-2 before (1.26) and after (1.27) peptide cleavage by the enzyme.88 
 
 
Figure 1.24. R2p/R1p as a function of contrast agent concentration (CT) demonstrating 
concentration-independence and that R2p/R1p responds to decreasing mole fraction of 1.26 (χGdL). 
Figure adapted with permission from A R2p/R1p Ratiometric Procedure to Assess Matrix 
Metalloproteinase-2 Activity by Magnetic Resonance Imaging/V. Catanzaro, C. V. Gringeri, V. 
Menchise, S. Padovan, C. Boffa, W. Dastrù, L. Chaabane, G. Digilio and S. Aime/Angew. Chem. 
Int. Ed., 52/14. Copyright © 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. 
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 In the previous examples of ratiometric relaxation rates, the authors observed that the 
R2p/R1p ratio was also dependent on external magnetic field strength. In a different report, a 
ratiometric approach to pH measurement was developed by measuring R1p at two different 
magnetic field strengths.51 A magnetic field strength dependence can be seen in Eq 1.11 and Eq 
1.12, where R1p is determined through r1p, which is field strength-dependent, and Gd
III 
concentration at the respective magnetic field strengths (1 and 0.2 T). The ratio of R1p at different 
magnetic field strengths (Eq 1.13) cancels the requirement for GdIII concentration. Using the 
amphiphilic complex 1.28 (Figure 1.25) in liposomes, Aime and co-workers were able to 
measure solution pH within 3.5% error compared to a pH electrode (Figure 1.26).51 The 
mechanism of pH response was investigated using NMR dispersion profiles. It was proposed that 
acidic pH values facilitated the protonation of the sulfonamide nitrogen, which would prevent 
coordination to GdIII to leave vacant sites for water coordination. Furthermore, when the 
complex remains protonated and neutral, it can embed itself within the hydrophobic region of the 
liposome membrane causing an increase in membrane permeability. Upon changing the pH to 
alkaline values, the nitrogen of the sulfonamide arm could be deprotonated to form an anionic 
complex (1.29). The anionic complex had less affinity for the hydrophobic region of the 
membrane and fewer vacant sites for water coordination. These reversible structural changes 
were used to explain differences in R1p at different pH values. It should be noted that changing 
the external magnetic field strength has been previously used to highlight areas of an albumin-
bound contrast agent in vivo.90 
Eq 1.11 𝑅1p(1 T) = 𝑟1p(1 T) × [Gd]  
Eq 1.12 𝑅1p(0.2 T) = 𝑟1p(0.2 T) × [Gd]      
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Eq 1.13 
𝑅1p(1 T)
𝑅1p(0.2 T)
=
𝑟1p(1 T)
𝑟1p(0.2 T)
  
 
Figure 1.25. Structure of 1.28 and 1.29 used for ratiometric relaxation rate measurements at 
different magnetic field strengths for concentration-independent measurements of pH.51,53 
 
 
Figure 1.26. pH measured using liposome-encapsulated 1.28 and the ratiometric R1P approach vs 
pH measured by an electrode. Adapted with permission from E. Gianolio, S. Porto, R. 
Napolitano, S. Baroni, G. B. Giovenzana and S. Aime, Inorg. Chem., 2012, 51, 7210. Copyright 
2012 American Chemical Society. 
 
 In a cautionary tale, Pierre and co-workers attempted to use ratiometric relaxivity (r1/r2) 
of magnetic iron oxide nanoparticles to circumvent the need for contrast agent concentration.91 
Briefly, magnetic iron oxide nanoparticles can be coated with organic substrates capable of 
inducing nanoparticle aggregation upon exposure to the desired target. The change in the 
relaxivity ratio before and after aggregation can be used to determine response, and the ratio of 
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r1/r2 can be used to circumvent the need to know contrast agent concentration. While this 
technique had been previously reported using magnetic iron oxide nanoparticles for the detection 
of oligonucleotides,92 antibodies,92 enzymes,92,93 proteins,94 and viruses,95 Pierre and co-workers 
observed that aggregation does not result in a constant increase in transverse relaxivity, but 
rather produces a bell-shaped curve as a function of aggregate size. Therefore, they argued that 
using r1/r2 to measure the concentration of analyte without knowledge of contrast agent 
concentration is inaccurate for magnetic iron oxide nanoparticles. 
While ratiometric techniques can be powerful when coupled with the appropriate contrast 
agent, there exists a separate option which does not require ratiometric measurements. To avoid 
ratiometric analysis, one can detect the contrast agent using different imaging modalities instead. 
1.3 Multimodality Imaging 
 An alternative to using ratiometric methods for concentration-independent responsive 
contrast agents is to use two detection modes (dual-mode) for imaging. In dual-mode imaging, 
the contrast agent of interest can be detected using two or more imaging modes such as 1H- (T1-
weighted, T2-weighted, or CEST), 
31P-, and 19F-MRI, positron emission tomography (PET), or 
single-photon emission computed tomography (SPECT). An attractive feature of dual-mode 
imaging is that one mode can be used to detect a response while the other mode can act to 
monitor the location of the contrast agent and, in some cases, its concentration for quantification 
of the target molecule. Measuring the concentration of a contrast agent differentiates dual-mode 
imaging from ratiometric strategies to overcome concentration-dependence because 
determination of concentration is not possible or necessary using the ratiometric CEST or 
relaxation rate techniques described in the previous sections.  
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 Aime and co-workers used a combination of 19F- and 1H-MRI for measuring pH by 
incorporating 1.30 and 1.31 (Figure 1.27) into poly-β-cyclodextrin (polymeric form of β-
cyclodextrin consisting of 8–10 units).55 It had been previously demonstrated that adamantane 
derivatives have a strong binding affinity for β-cyclodextrin,96 and it was assumed that both 1.30 
and 1.31 were anchored into the polymer through the adamantane moiety. By controlling the 
molar ratio of 1.30/1.31/poly-β-cyclodextrin (1:5:20), the 19F-MRI signal was measured and 
quantified using an external standard (25 mM of NaPF6). The external standard was used to 
quantify the amount of 1.31, which was used to infer the concentration of 1.30 because the molar 
ratios were known. The second mode of imaging, 1H-MRI, was used to measure the T1 of the 
solution, which was affected by the protonation state of 1.30. Accordingly, the T1 of the solution 
and the concentration of 1.30 were known, and r1 could be determined to detect the response. It 
should be noted that this method does not circumvent the need for knowledge of concentration, 
but it does provide a way to quantify the concentration of contrast agents to detect responses. A 
benefit of using 19F as a handle for contrast agent quantification is the minimal background 
signal of 19F in vivo; however, relatively slow 19F relaxation times limit the sensitivity of 
detection necessitating millimolar levels of contrast agent in tissues.79 A different isotope, 18F, 
can also be used for dual-mode imaging, but in a much different manner. 
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Figure 1.27. Structure of adamantane-functionalized contrast agents used for 1H- (1.30) and 19F-
MRI (1.31, stereochemistry of hydroxyl group not specified).55 
 
 Caravan and co-workers used 1H-MRI and PET for quantitative pH imaging.52 Their 
method, in a similar fashion to that used in the previous example, relied on external standards to 
quantify the concentration of agent present. Instead of using 19F as the handle for concentration 
determination, they used the positron-emitting isotope 18F. Briefly, PET operates by using a 
positron-emitting isotope (for example, 11C, 13N, 15O, 18F, 64Cu, 66Ga, or 82Rb), which can be 
incorporated into a compound of interest to produce a radiotracer. The radioactive isotope within 
the radiotracer decays through positron emission, and the emitted positron travels until its energy 
is low enough to permit interaction with an electron resulting in an annihilation event. The 
annihilation between a positron and electron produces two gamma rays that travel in opposite 
(~180°) directions. A gamma detector can measure the time difference between two coincident 
gamma rays to calculate the location of the radiotracer. The gamma ray background of humans is 
small relative to the proton background, which makes PET extremely sensitive. Additionally, 
gamma activity can be used to quantify the amount of radiotracer present. Using 1.32 (Figure 
1.28),52 Caravan and co-workers quantified the amount of contrast agent present using PET 
imaging with external standards. The second mode of imaging, T1-weighted 
1H-MRI, was used 
to determine the T1 of the solution. Similar to the previous example, knowing both the T1 of the 
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solution and the contrast agent concentration allows for r1 to be determined, and a quantitative 
response can be measured (Figure 1.29). An important feature of this dual-mode technique is 
that the MRI and PET imaging were performed simultaneously (whereas most other dual-mode 
strategies use sequential imaging), which means that diffusion of the contrast agent would not 
pose a problem in vivo. 
 
Figure 1.28. Structure of 1.32 used for dual-mode PET and 1H-MRI for quantitative pH 
measurements.52 Phosphonates are drawn singly protonated because of the expected pKa values 
of the first (pKa ≈ 2–3) and second (pKa ≈ 7–8) phosphonate oxygen atoms. 
 
 
Figure 1.29. pH determined with the MR/PET technique vs pH determined using a glass 
electrode. The solid line represents a linear fit of the data and the dashed line represents a 
hypothetical 1:1 correspondence between the x- and y-axes. Figure adapted with permission 
from Bimodal MR–PET Agent for Quantitative pH Imaging/L. Frullano, C. Catana, T. Benner, 
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A. D. Sherry and P. Caravan/Angew. Chem., 122/13. Copyright © 2010 WILEY-VCH Verlag 
GmbH & Co. KGaA, Weinheim. 
 
In a similar fashion to the example above, Aime and co-workers used 1H-MRI and 
SPECT to detect changes in pH using 1.28 and its isostructural 166HoIII-containing analogue as a 
radiotracer.53 SPECT operates in a similar fashion to PET, but the radioisotope emits gamma 
rays directly instead of through an indirect annihilation event. The direct emission of gamma 
rays causes SPECT to have lower sensitivity relative to PET because the radiotracer cannot be 
detected through coincident gamma rays. A decrease in sensitivity of SPECT means that 
temporal resolution must suffer to achieve adequate contrast, and longer acquisition periods 
allow for contrast agents to diffuse to a greater extent. In this example, the radiotracer acted as a 
calibration standard to infer the concentration of 1.28. Knowing the concentration of 1.28 
allowed for a pH response to be measured.53 A difference between this MRI-SPECT dual-mode 
strategy and the previously discussed MRI-PET strategy is that the MRI-SPECT strategy 
requires sequential imaging, which can allow contrast agent diffusion to occur resulting in 
increased chances for error. Most of the examples highlighted throughout this chapter focus on 
both responding to and quantification of stimuli. It can be argued, however, that quantification of 
stimuli is not always necessary to obtain important information in a concentration-independent 
way. To detect a response without quantification, a threshold response must be used. 
 1.3.1 Threshold Response 
In the first three examples within the dual-mode section, external standards were used to 
quantify contrast agents that responded to pH. In this manner, the concentration could be inferred 
indirectly. Alternatively, dual-mode can be used without any knowledge of the concentration of 
contrast agent. The use of EuII-containing complexes, such as 1.33 (Figure 1.30), is potentially 
advantageous because r1 increases at ultra-high magnetic field strengths (≥7 T),97–99 whereas the 
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r1 of Gd
III-containing complexes decrease.100 Furthermore, higher magnetic field strengths can 
lead to greater spatial and temporal resolutions that are desirable for diagnostic scans. However, 
a limitation with EuII is its propensity to oxidize to EuIII. The oxidation potential of EuII can be 
modulated through structural modifications to the ligand, and some of the reported modifications 
result in the most positive oxidation potentials (more resistant to oxidation) ever reported in 
aqueous solution.101–103 While the threshold strategy does not quantify the amount of oxidant 
present, it can report if an oxidation threshold has been crossed. The oxidation of EuII-containing 
complexes will be discussed within the context of responsive contrast agents for MRI in the 
remaining chapters of this thesis. 
 
Figure 1.30. Structure of 1.33 used for liposome encapsulation to demonstrate a response to 
oxidation using CEST and T1-weighted 
1H-MRI.73 
 
 The dual-mode examples so far have been used for in vitro imaging, but the next section 
will highlight examples that have used internal standards to indirectly measure the concentration 
of contrast agent, but for in vivo imaging. 
1.4 Dual-Injection Imaging 
An alternative to using external standards or ratiometric techniques is to use an internal 
standard to indirectly monitor the biodistribution of a responsive contrast agent. In doing so, one 
must make the assumption of (or demonstrate) sufficiently similar pharmacokinetics of two 
separate complexes. Raghunand and co-workers monitored the time-dependent distribution of 
1.34 and 1.35 (Figure 1.31) after sequential tail-vein injections.56 Previously, Sherry and co-
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workers had demonstrated the pH-dependency of the r1 of 1.34,
37 where the hydrogen-bonding 
network of the pendant arms was influenced by changes in protonation state. Interestingly, 1.35 
is pH-insensitive despite some structural similarities with 1.34. Ragnhunand and co-workers 
demonstrated that 1.34 and 1.35 had comparable biodistribution within the mouse model and that 
the concentration of 1.34 could be inferred by tracking 1.35 through T1-weighted images. Using 
1.34 and 1.35, in vivo pH maps were generated to demonstrate kidney alkalinization (Figure 
1.32) induced by treatment with the carbonic anhydrase inhibitor acetazolamide.  
 
Figure 1.31. Structure of 1.34, 1.35, 1.36 used to generate in vivo pH maps using a dual-
injection strategy.56,104,105 
 
 
Figure 1.32. Calculated pH maps of mouse kidneys generated using the dual-injection strategy 
of a mouse without (left) and with (right) acetazolamide treatment demonstrating alkalinization 
of kidneys. A pH scale bar is on the far right. Figure adapted with permission from Renal and 
Systemic pH Imaging by Contrast-Enhanced MRI/N. Raghunand, C. Howison, A. D. Sherry, S. 
Zhang and R. J. Gillies/Magn. Reson. Med., 49/2. Copyright © 2003 Wiley-Liss, Inc. 
 
 In a subsequent report, Gillies and co-workers applied the dual-injection strategy using 
1.34 and 1.35 (Figure 1.31) to generate pH maps of tumors,104 which they argued is significantly 
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more difficult than imaging kidneys due to the heterogeneous distribution of blood vessels, 
slower diffusion of agent, and higher protein concentrations of the extracellular fluid. Due to 
these challenges, the authors accounted for the potential of residual 1.35 to be present in the 
tumor microenvironment at the time 1.34 was injected. To correct for residual 1.35, they 
modeled how quickly 1.35 washed out of tumors using a bi-exponential equation on a pixel-by-
pixel basis and the extrapolated residual signal from 1.35 was used as a background subtraction 
for 1.34 pharmacokinetics. Expectedly, the average pharmacokinetics of 1.34 and 1.35 were 
similar, but the authors observed that local differences (pixel-by-pixel) reduced the apparent 
pharmacokinetic correlation of the two contrast agents. To correct for these differences, pH maps 
were calculated using the maximal enhancement per pixel. Using the aforementioned techniques 
to account for tumor heterogeneity, Gillies and co-workers were able to calculate pH maps of 
mouse gliomas.104 
 In the previous two examples of dual-injection imaging, sequential injections were used. 
However, the dual-injection strategy does not require sequential injections. A relatively severe 
limitation of sequential injections is temporal resolution, where images were collected for 1 h 
after the injection of each contrast agent for the previous two examples. To improve the temporal 
resolution, two contrast agents can be injected simultaneously.  
 Recently, a single cocktail approach was developed by Martinez and co-workers using 
1.34 and 1.36 for pH mapping of tumors.105 In the previous approaches, sequential injections 
were required because 1.34 and 1.35 both produce T1 enhancement such that they would be 
indistinguishable if injected simultaneously. By using 1.36 as the pH-insensitive handle to track 
biodistribution, however, the presence of 1.36 could be detected by its influence on the rate of 
phase decoherence of the nuclear dipole moments of neighbouring protons. Importantly, 1.36 
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had a negligible influence on T1. This approach is a dual-injection, dual-mode strategy because 
of the use of two contrast agents and detection with both T1- and T2-weighted imaging. By (1) 
using a contrast agent cocktail with a controlled molar ratio of 1.34/1.36 (1:2) and (2) assuming 
near identical pharmacokinetics of 1.34 and 1.36 based on previous reports comparing 1.34 and 
1.35,104 this strategy was used to produce pH maps of tumors with improved temporal resolution 
relative to sequential injection strategies (20–90 min vs 120 min). 
 Throughout this chapter, pH has been detected in a variety of ways. As previously 
discussed, pH is an intuitive target for detection because 1H-MRI directly detects protons and 
changes in proton-exchange can be used to calculate pH. In the next section, a rather unique 
approach to pH detection is discussed that involves perturbations in the ligand field of lanthanide 
ions. 
1.5 Ligand Field-Induced Chemical Shift 
 LnIII ions were once thought to be static spheres of positive charge with unchanging 
luminescence and magnetic properties due to the limited radial distribution of 4f-orbitals. It has 
been demonstrated, however, that some LnIII ions have spectroscopic and magnetic properties 
that are relatively sensitive to changes in the coordination environment (ligand field) of the metal 
ion.54,106 Of importance to this chapter, ligand field changes can influence the effective magnetic 
moment of LnIII ions, which is likely due to changes in the geometry of ligand distribution about 
the metal ion. Recently, Parker and co-workers demonstrated a pH response using ligand field-
induced chemical shift.54 Upon moving to acidic pH values, the concentration of 1.37 decreased 
as the protonated form 1.38 increased (Figure 1.33). Specifically, the 1H resonance frequency (–
58 ppm) of a nearby (~6.6 Å) tert-butyl group was used to monitor the change in protonation 
state. As the pH was lowered, the signal intensity at –58 ppm decreased. The response was 
38 
 
detected ratiometrically by using an analogous tert-butyl group on 1.39 at –18 ppm. Importantly, 
1.39 did not possess the same pH-dependence as 1.37. Accordingly, the ratio of tert-butyl signal 
intensities (–58 ppm/–18 ppm) in a solution containing 1.37/1.39 (1:1) reported the pH of the 
solution over a range of 4 to 7 (Figure 1.34).  
 It is important to emphasize that this example is not based on a CEST mechanism 
because an exchangeable proton is not being selectively saturated and, therefore, saturation 
transfer is not being used. Instead, the ligand field of a LnIII-containing complex is perturbed 
through a change in protonation state, and the perturbed ligand field influences the effective 
magnetic moment. The altered magnetic moment then influences the chemical shift values of 
nearby protons. While Parker and co-workers did not demonstrate concentration-independence in 
this example, the response is inherently concentration-independent because of its ratiometric 
nature (assuming similar kinetic stability and that the concentration ratio of the two contrast 
agents is known and does not change over the course of imaging). A possible avenue for future 
developments that involve ligand field-induced chemical shifts would be to covalently attach two 
compounds, such as 1.37 and 1.39 (Figure 1.33), to ensure that differences in pharmacokinetics 
are not a concern, but the covalent linkage would need to be long enough to prevent changes in 
the ligand field of one metal center to influence proton resonances on the other. A separate 
avenue could be to revisit some of the contrast agents that respond to changes in water 
coordination number,16 because ligand field-induced chemical shift might offer a platform for 
more ratiometric probes using previously reported chemical responses. 
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Figure 1.33. Structure of 1.37 and its protonated form 1.38 that alter the chemical shift of tert-
butyl protons through changes in ligand field. The ratiometric pH response was measured using 
1.39 as a secondary compound with a different pH dependence.54 
 
 
Figure 1.34. Ratio of tert-butyl proton chemical shift intensities of 1.37 and 1.39 as a function of 
pH. Reproduced from Ref. 54 with permission from The Royal Society of Chemistry. 
 
 The challenge of overcoming concentration-dependence in responsive contrast agents for 
MRI has been approached from many different angles. Ratiometric CEST, ratiometric relaxation 
rates, dual-mode, dual-injection, and ligand field-induced chemical shift strategies have been 
employed to push the field towards in vivo applicability and, in some cases, have already made 
the leap to in vivo imaging. While there have been substantial developments toward the goal of 
overcoming concentration-dependence, there is still work to be done. For instance, much of the 
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effort in the area has focused on concentration-independent pH imaging, but the examples of 
other targets are relatively few. One of the largest limitations of contrast agents that provide 
contrast through proton exchange is relatively low sensitivity (millimolar concentrations in 
tissue) because they must provide contrast that is distinguishable from the relatively large proton 
background in vivo. Coupling MRI with the extremely sensitive PET imaging modality still 
imparts a sensitivity limitation because PET is used to quantify the agent whose response is 
detected through 1H imaging techniques. The ligand field-induced chemical shift approach offers 
an interesting platform for large sensitivity gains because contrast agents can be designed to 
contain large numbers of chemically equivalent protons to boost the sensitivity. Another 
limitation with strategies that use a combination of detection methods (multiple CEST 
frequencies, contrast agents, or pulse sequences) to circumvent concentration-dependence is that 
the error associated with each detection method is propagated to the final measurement. 
Additionally, some strategies forgo practical temporal resolutions to obtain exquisite 
quantification of analyte. Although the results are impressive, the clinical usefulness might not 
be realized until acquisition times are substantially reduced.  
 Regardless of the current set of limitations within the field and within the individual 
strategies, momentum is building toward a new class of contrast agents capable of reporting real 
time responses in vivo. With the advent of the strategies reported in this chapter and, 
undoubtedly, new strategies to come, one may envision a sharp increase in the number of 
contrast agents for MRI undergoing clinical trials. Arguably, one of the biggest barriers 
preventing the clinical application of responsive agents (other than target-specific delivery)107,108 
is concentration-dependence. Accordingly, all progress toward overcoming concentration-
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dependence in responsive contrast agents for MRI has the potential to significantly and 
positively impact diagnostic molecular imaging. 
Research Design 
 This thesis is centered on the ability of the EuII ion to undergo a one-electron oxidation 
resulting the in the loss of detectable positive contrast enhancement. If the oxidation of EuII to 
EuIII occurs quantitatively, all detectable positive contrast enhancement will be lost. The 
quantitative oxidation of EuII can be used to overcome the concentration-dependent response to 
oxidation because, assuming complete oxidation, the concentration of complex is not required to 
infer a response. If the oxidation of EuII is not quantitative, positive contrast enhancement might 
be detected and the response would be dependent upon concentration. Accordingly, the ability to 
detect oxidation in a concentration-independent manner relies on the complete oxidation of EuII 
to EuIII resulting in the complete loss of positive contrast enhancement. Furthermore, to 
differentiate oxidation of EuII from clearance of EuII, the EuIII-containing complex after 
oxidation would need to be detected using a different imaging modality. 
 The use of a divalent lanthanide represents a new approach to contrast-enhanced MRI. 
While EuII is the most stable divalent lanthanide with respect to oxidation, it is still prone to 
oxidation by oxygen. Accordingly, the use of EuII-containing complexes in responsive MRI 
necessitates fundamental studies regarding viable routes of administration, biodistribution, 
persistence in tissues with varying levels of oxygen, detection after oxidation to EuIII, and kinetic 
stability. To uncover this fundamental information, this thesis describes the synthesis, 
characterization, and in vitro and in vivo application of EuII-containing complexes within the 
context of responsive contrast agents for MRI.  
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 In Chapter 2, the evaluation of EuII-based positive contrast enhancement after 
intravenous, intraperitoneal, and subcutaneous injections is described. T1-weighted MRI as a 
function of time reveal a correlation between reported tissue oxygenation and the persistence of 
EuII-based positive contrast enhancement. Biodistribution trends after intravenous and 
intraperitoneal injections are also described. This study provides fundamental information 
regarding the in vivo behavior of a EuII-containing complex that is likely applicable to other EuII-
containing complexes. 
 In Chapter 3, the synthesis and solid- and solution-phase characterization of a 4-
fluorobenzo-functionalized EuII-containing complex is described. The ability of the complex to 
differentiate necrotic (oxygen deficient) from non-necrotic tissue after intratumoral injection is 
described and supported by histological staining. Accordingly, Chapters 2 and 3 describe 
fundamental information regarding route of administration of EuII-containing complexes, the 
transitory nature of EuII-based positive contrast enhancement, and the ability of EuII to 
differentiate necrotic tissue within a tumor model. While the persistence of EuII-based positive 
contrast enhancement can be informative, the loss of EuII-based positive contrast enhancement is 
not meaningful if oxidation and clearance events are indiscernible. The need to discern oxidation 
from clearance motivates the study of EuII-containing complexes that are detectable with MRI 
after oxidation of EuII to EuIII. Accordingly, the focus of this thesis shifts to the detection of 
complexes after oxidation using CEST in the remaining chapters. 
 In Chapter 4, the encapsulation of 1.33 in liposomes with air-free purification and 
characterization is described. Additionally, the detection of the liposomes by T1-weighted and 
CEST imaging are described and demonstrate the ability to visualize the contrast agent before 
and after oxidation of EuII. This proof-of-concept study demonstrates the first EuII-based 
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responsive contrast agent and offers an approach to discerning oxidation from clearance as 
discussed in Chapters 2 and 3.  
In Chapter 5, the synthesis and characterization of a responsive EuII-containing 
tetraglycinate complex is described. This particular study differs from those previously discussed 
in that a commercially available EuIII-containing complex, 1.9, is used as the starting material. 
The use of 1.9 was motivated by its CEST signal being ~50× further from the bulk water proton 
resonance than the CEST signal from liposomes. Furthermore, favorable electron-transfer 
reversibility and kinetic stability are described. The commercial availability, ease of preparation, 
and robust electron-transfer properties provide an excellent starting point for a new class of 
redox sensors based on the EuII/III redox couple. 
Chapter 6 combines the major findings of Chapters 2–5 into a cohesive summary. 
Additionally, this chapter discusses important directions in which the results of this research can 
be built upon. 
 
 
 
 
 
 
 
 
 
44 
 
CHAPTER 2: EVALUATION OF EUROPIUM(II)-BASED POSITIVE CONTRAST 
ENHANCEMENT AFTER INTRAVENOUS, INTRAPERITONEAL, AND 
SUBCUTANEOUS INJECTIONS 
 
Parts of this chapter were adapted with permission from Ekanger, L. A.; Polin, L. A.; Shen, Y.; 
Haacke, E. M.; Allen, M. J. Contrast Media Mol. Imaging [Online early access]. 
10.1002/cmmi.1692. Published Online: March 30, 2016. Copyright © 2016 WILEY-VCH 
Verlag GmbH & Co. KGaA, Weinheim. 
 
2.1 Introduction 
 Redox balance is critical to the homeostasis of living tissues, and redox stress is 
associated with some cancers109–112 and ailments such as cardiovascular,113,114 Alzheimer’s,115–118 
liver,119,120 and chronic kidney disease.121 The ability to noninvasively detect changes in redox 
environments in real time would be invaluable to diagnosing diseases and monitoring responses 
to therapies. MRI offers a noninvasive platform to image opaque objects, but often requires 
responsive contrast agents to relay chemical information regarding the local redox environment. 
The GdIII ion has dominated the clinical landscape and preclinical research in MRI because it 
provides excellent T1-shortening (positive) contrast enhancement,
24,122,123 but GdIII is restricted to 
the 3+ oxidation state under physiological conditions preventing metal-based redox responses.124 
The EuII ion is isoelectronic with GdIII (4f7), and both ions provide positive contrast enhancement 
in MRI.73,97–99,102,125–129 Additionally, EuII can be oxidized by one electron to produce the EuIII 
ion that does not enhance positive contrast.73 The complete loss of positive contrast enhancement 
upon the oxidation of EuII offers a unique platform for concentration-independent redox 
sensing.124 However, there is still much to be learned about the nature of EuII-based contrast 
agents in vivo, including establishing routes of administration and biodistribution trends. In this 
chapter, the evaluation of in vivo EuII-based contrast enhancement in MRI is presented after 
intravenous, intraperitoneal, and subcutaneous injections using 1.33 (Figure 1.30). 
Biodistribution trends are also presented. 
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The ability of 1.33 to impart oxidative stabilization of the 2+ oxidation state of europium 
has been studied,103,130 and recent reports have characterized the aqueous magnetic and 
electrochemical properties of 1.33 and other EuII-containing complexes.73,97–102,125–129,131–133 
Despite increased oxidative stability, the EuII ion of 1.33 is prone to rapid oxidation by oxygen in 
solution.125 Oxidation of EuII in elevated oxygen partial pressures coincides with the loss of 
positive contrast enhancement,73 and this change in contrast enhancement was expected to be 
observable in vivo. The 2+ oxidation state of europium is expected to persist for hours within 
relatively oxygen-deficient tissue (pO2 < 10 mmHg); therefore, regions containing relatively 
higher levels of dissolved oxygen such as the subcutaneous space, fluids of the peritoneal cavity, 
and blood (Figure 2.1) were chosen to evaluate the effect of differing oxygen partial pressures.  
 
Figure 2.1. pO2 ranges in necrotic and non-necrotic tumor (converted from percent hemoglobin 
saturation using a hemoglobin saturation curve),134,135 subcutaneous space,136 venous blood,136 
the peritoneal cavity,137 and arterial blood.136 
 
2.2 Experimental Procedures 
2.2.1 General Procedures 
Commercially available chemicals were of reagent-grade purity or better and were used 
without further purification unless otherwise noted. Water was purified using a PURELAB Ultra 
Mk2 water purification system (ELGA) and degassed prior to use. 
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2.2.2 Preparation of Contrast Agent Solutions 
Contrast agent solutions for intravenous, intraperitoneal, and subcutaneous injections 
were prepared by adding aqueous EuCl2 and aqueous 4,7,13,16,21,24-hexaoxa-1,10-
diazabicyclo[8.8.8]hexacosane in a 1:1 ratio to a 4 mL glass vial equipped with a magnetic stir 
bar under an atmosphere of N2. The resulting clear, colorless solution was stirred for 1 h before 
addition of the 10× phosphate buffered saline (PBS, Fisher BioReagents) and water to achieve a 
final solution of 1.33 (4 mM) in PBS (11.9 mM phosphates, 137 mM NaCl, and 2.7 mM KCl). 
The clear, colorless solution was stirred for 30 min then filtered through a 0.2 µm hydrophilic 
filter. The concentration of europium in the clear, colorless filtrate was determined by ICP–MS 
and was used directly for imaging studies. 
2.2.3 ICP–MS 
ICP–MS measurements were acquired on an Agilent Technologies 7700 series 
spectrometer in the Lumigen Instrument Center at Wayne State University. All dilutions were 
performed with 2% HNO3 that was also used for blank samples during calibration. The 
calibration curve was created using the 153Eu isotope ion count for a 10–100 ppb concentration 
range (diluted from Fluka ICP standard solution, Eu2O3 in aqueous 2% HNO3, 1000 mg Eu/L), 
and samples (with the exception of tissue digestion) were diluted to fall within this range. 
2.2.4 Magnetic Resonance Imaging 
Studies in animals were carried out with the assistance of the Animal Model and 
Therapeutics Evaluation Core of the Barbara Ann Karmanos Cancer Institute after approval from 
the Wayne State University Institutional Animal Care and Use Committee. MRI scans were 
performed in the Elliman Clinical Research Building at Wayne State University with a 7 T 
Bruker Clinscan small animal MRI scanner equipped with a 30 cm bore. T1-weighted images 
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(3D FLASH) were acquired with a body coil while using a warm water circulator set to 37 °C. 
The whole body coronal plane images were acquired using an echo time of 1.5 ms, repetition 
time of 11 ms, flip angle of 40 degrees, 44 image slices at 0.5 mm thickness, and a 31 mm × 90 
mm field of view, and an in plane resolution of 0.352 mm × 0.352 mm. 
For intravenous injections, mice were catheterized before being anesthetized with 
isoflurane. A micro-volume extension set was used to inject the solution of 1.33 into the tail vein 
without removing the mouse from the magnet. A correction volume (0.08 mL) was added to the 
calculated dose volumes for intravenous injections to account for the volume of the phosphate-
buffered saline within the catheter. For intraperitoneal and subcutaneous injections, mice were 
first anesthetized with isoflurane, imaged prior to injection, and then the cradle with the mouse 
was removed from the magnet to perform the injection while still anesthetized. After injections, 
mice were imaged immediately to acquire the first time points post-injection. Intravenous 
injections were triplicated, intraperitoneal injections were duplicated, and the subcutaneous 
injection was performed once. 
2.2.5 Biodistribution Studies 
For biodistribution studies, mice were not catheterized or anesthetized. Mice were 
injected with the same europium dose used for imaging (3 mg/kg) before being sacrificed 1 h 
post-injection at which point the blood, liver, kidneys, spleen, heart, bone (femur), muscle 
(thigh), brain, upper and lower GI tract, stomach, and lungs were harvested. The samples were 
weighed, freeze dried for 72 h, and digested in 25 mL volumetric flasks using 6 mL of 3 M nitric 
acid at 75 °C with constant stirring for 16 h. The entirety of each sample was used for digestion 
with the exception of the liver, which was homogenized with mortar and pestle prior to addition 
to a volumetric flask and a fraction (~130 mg) of the homogenate was added to a volumetric 
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flask. After 16 h, the digests were allowed to cool to ambient temperature before the addition of 
water to achieve a total volume of 25 mL. The digests were transferred to conical tubes (50 mL) 
and insoluble oils were removed by centrifugation. The clear, yellow supernatants were 
immediately transferred to conical tubes (15 mL) for analysis of europium concentration with 
ICP–MS. 
2.3 Results and Discussion 
 To evaluate the nature of positive contrast enhancement of 1.33 as a function of injection 
type, T1-weighted images of mice were acquired after administering 1.33 (0.1 mL, 4 mM, 
europium dose of 3 mg/kg) through intravenous, intraperitoneal, and subcutaneous injections 
(Figure 2.2). Mice were imaged prior to injection and at 3 and 8 min to compare responses with 
the three injection types. Based on these images, the intravenous injection resulted in no positive 
contrast enhancement; the intraperitoneal injection led to positive contrast enhancement in the 
peritoneal cavity that disappeared by 8 min; and the subcutaneous injection produced positive 
contrast enhancement both 3 and 8 min post-injection. The absence of positive contrast 
enhancement after the intravenous injection suggests that 1.33 was oxidized within the first 3 
min in the blood. Although this observation is inconsistent with the low oxygen content of 
venous blood (relative to the peritoneal cavity), the circulation time of blood in a mouse is 
approximately 8 s.138 This rapid circulation suggests that venous and arterial blood exchanged 
~24 times over the course of the scan, allowing for blood solutes (including 1.33) to be exposed 
to a relatively high level of oxygen. Therefore, the exchange between venous and arterial blood 
during circulation can explain these observations. It is unlikely that dilution alone could account 
for the complete loss of observable positive contrast enhancement because no positive contrast 
enhancement was observed in organs associated with clearance (liver, kidneys, or bladder; 
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Figure 2.2), whereas positive contrast enhancement was observed in the kidneys within 3 min 
after intravenous injection of an equivalent dose of 2.1 (Figure 2.3). To ensure that 1.33 had not 
been oxidized prior to the injection, T1-weighted images of the syringe were acquired before and 
after the injection and observed positive contrast enhancement for both, indicating that oxidation 
occurred in vivo. 
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Figure 2.2. Representative T1-weighted images demonstrating the response of 1.33 after 
different injection types. The images are (A) pre-intravenous injection; (B) 3 min post-
intravenous injection; (C) 8 min post-intravenous injection; (D) pre-intraperitoneal injection; (E) 
3 min post-intraperitoneal injection; (F) 8 min post-intraperitoneal injection; (G) pre-
subcutaneous injection; (H) 3 min post-subcutaneous injection; and (I) 8 min post-subcutaneous 
injection. Red arrows denote areas of positive contrast enhancement. The area represented by 
each image is 31 mm × 90 mm. 
 
An intraperitoneal injection placed 1.33 into an intermediate pO2 range (relative to 
intravenous and subcutaneous injections) and allowed positive contrast enhancement to be 
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observed in the 3 min scan. However, the loss of positive contrast enhancement by 8 min 
suggests that 1.33 diffused to regions of high oxygen level (vasculature), oxygen diffused into 
the peritoneal cavity, or both types of diffusion occurred. Relative to the peritoneal cavity, 
subcutaneous space has a lower rate of diffusion and a lower pO2.
136,137,139 Consistent with these 
properties, positive contrast enhancement was observed both 3 and 8 min post-subcutaneous 
injection. Results of the intravenous, intraperitoneal, and subcutaneous imaging experiments 
suggest that both pO2 and diffusion play a role in the persistence of Eu
II-based contrast 
enhancement in vivo. Furthermore, despite oxidation occurring in the mice, no adverse effects 
were observed during any of the in vivo studies reported here. 
 
Figure 2.3. Structure of GdIII-diethylenetriaminepentaacetate (2.1) used as a non-redox-active 
control. 
 
The imaging data presented here demonstrate that 1.33 is oxidized faster than the MRI 
timescale used in experiments for intravenous injections, that intraperitoneal injections offer 
transitory contrast enhancement, and that subcutaneous injections exhibit positive contrast 
enhancement for at least 8 min. These observed trends correlate with reported values of pO2,
134–
137 where lower pO2 values correspond to prolonged contrast enhancement. The lack and loss of 
positive contrast enhancement observed in the intravenous and intraperitoneal injections, 
respectively, inspired the measurement of europium biodistribution, which would be informative 
regarding the route of clearance. 
To understand the biodistribution of europium for the intravenous and intraperitoneal 
injections, inductively coupled plasma mass spectrometry (ICP–MS) was used to quantify 
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europium in the blood, liver, kidneys, spleen, heart, bone (femur), muscle (thigh), brain, upper 
and lower gastrointestinal tract (GI), stomach, lungs, and brain (Figure 2.4). The majority of 
detected europium was found in the liver and kidneys for both types of injections, with the 
relative quantities being higher for intravenous injections. ICP–MS data does not provide insight 
into speciation during clearance, a complex topic that is currently under investigation using 
knowledge of the kinetic stability of EuII/III-containing cryptates;103,130 however, this data 
provides valuable insight into the route of clearance. For intraperitoneal injections, the smaller 
amount of europium detected in the liver, kidneys, and blood might indicate relatively slow 
diffusion from the peritoneal cavity. Evidence of slow diffusion of 1.33 from the peritoneal 
cavity supports a response dependent on the diffusion of oxygen into the peritoneal cavity. 
Furthermore, the presence of europium in detectable quantities after intravenous injections (there 
is no endogenous europium in mice), together with the images in Figure 2.2, suggest that 
oxidation of 1.33 occurs within 3 min of intravenous injection. 
 
 
Figure 2.4. Percent of injected dose of europium retained per organ 1 h post-injection for 
intravenous (white bars) and intraperitoneal (black bars) injections. Error bars represent the 
standard error of the mean of 3 independent experiments. 
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2.4 Conclusions 
 The results presented in this chapter demonstrate that EuII-based contrast enhancement is 
sensitive to the route of administration, with positive contrast enhancement expected for regions 
containing relatively low levels of oxygen and slow rates of diffusion. These results help define 
the boundaries of EuII-based positive contrast enhancement with 1.33 in vivo, and will likely be 
helpful in the preclinical application of other EuII-based complexes. Furthermore, the in vivo use 
of lanthanide-based redox-response is a relatively unexplored realm. Although other redox-active 
molecules might contribute to the oxidation of EuII, the oxidation of EuII by oxygen is expected 
to be responsible for the correlation between oxygen content and the persistence of positive 
contrast enhancement in vivo, and efforts in the Allen laboratory to understand aqueous EuII 
oxidation chemistry are currently underway. Additionally, biodistribution studies revealed 
clearance of europium through the liver and kidneys, but no positive contrast enhancement was 
observed in these organs. These results are an important step towards understanding the scope of 
EuII-based positive contrast enhancement for a new class redox-active contrast agents based on 
lanthanide redox chemistry. 
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CHAPTER 3: A EUROPIUM(II)-CONTAINING CRYPTATE AS A REDOX SENSOR IN 
MRI OF LIVING TISSUE 
 
Parts of this chapter were adapted with permission from Ekanger, L. A.; Polin, L. A.; Shen, Y.; 
Haacke, E. M.; Martin, P. D.; Allen, M. J. Angew. Chem. Int. Ed. 2015, 54, 14398. Copyright © 
2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. 
 
3.1 Introduction 
 MRI is a powerful diagnostic tool for imaging opaque tissues at relatively high spatial 
resolution and nearly unlimited depth penetration.21,140 Paramagnetic complexes are routinely 
used as contrast agents in clinical MRI to provide contrast enhancement in areas of anatomical 
interest. For decades, GdIII has been the paramagnetic metal ion of choice for contrast agents 
largely because it has seven unpaired electrons (S = 7/2) in an isotropic ground-state 
configuration (8S7/2). Eu
II is isoelectronic with GdIII, and both ions enhance contrast in MRI.97,124 
Furthermore, the EuII center has a propensity to oxidize to EuIII, resulting in a diamagnetic 
ground state (7F0) and a thermally accessible excited state (
7F1) that do not noticeably enhance 
contrast in MRI.73 Therefore, the oxidation of EuII offers the opportunity for metal-based redox-
responsive contrast enhancement that is unachievable with GdIII-based contrast agents. However, 
despite several groups exploring EuII-based complexes as contrast agents for MRI,73,97–
99,101,124,126,127,129,131–133 there has been no reported use of EuII in vivo. Herein, first in vivo use of a 
EuII-containing cryptate is reported. Characterization that reveals a discrepancy in the 
coordination environment of the complex between the solid and solution phases is also 
discussed. 
3.2 Experimental Procedures 
 3.2.1 General Procedures 
 Commercially available chemicals were of reagent-grade purity or better and were used 
without further purification unless otherwise noted. Phosphate-buffered saline (10×) was 
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purchased from Fisher BioReagents. Water was purified using a PURELAB Ultra Mk2 water 
purification system (ELGA) and degassed prior to use. Triethylamine was distilled from CaH2. 
 Flash chromatography was performed using silica gel 60, 230–400 mesh (EMD 
Chemicals). Analytical thin-layer chromatography (TLC) was performed on ASTM TLC plates 
pre-coated with silica gel 60 F254 (250 µm thickness). TLC visualization was achieved using UV 
irradiation (254 nm) followed by charring with potassium permanganate stain (3 g KMnO4, 20 g 
K2CO3, 5 mL 5% w/v aqueous NaOH, 300 mL H2O). 
 1H- and 13C-NMR spectra were obtained using a Varian MR-400 (400 MHz 1H, 101 MHz 
13C) spectrometer. 19F-NMR spectra were obtained using a Mercury 400 (376 MHz 19F) 
spectrometer. Chemical shifts are reported relative to residual solvent signals unless otherwise 
noted (CDCl3: 
1H: δ 7.27, 13C: δ 77.23; (CD3)2SO: 1H: δ 2.50, 13C: δ 39.52; CD3CN: 1H: δ 1.94, 
13C: δ 118.26; CFCl3 (internal standard): 19F: δ 0.00). NMR data are assumed to be first order, 
and the apparent multiplicity is reported as “s” = singlet, “d” = doublet, “dd” = doublet of 
doublets, “ddd” = doublet of doublet of doublets, “t” = triplet, “td” = triplet of doublets, “m” = 
multiplet, or “brs” = broad singlet. Italicized elements are those that are responsible for the shifts. 
Correlation spectroscopy (COSY), distortionless enhancement by polarization transfer (DEPT), 
and heteronuclear multiple quantum coherence (HMQC) spectra were used to assign spectral 
peaks. High-resolution electrospray ionization mass spectra (HRESIMS) were obtained on a 
Waters LCT premier time-of-flight high-resolution mass spectrometer. 
 Molar conductivity was calculated from three independently prepared solutions of 3.6 
(1.00 mM, 5.00 mL) measured in water under an atmosphere of N2 and ambient temperature 
using an Omega CDH 280 portable conductivity meter that was calibrated with aqueous KCl 
(0.01 M, 1.413 mS cm–1). Results are reported as mean ± standard error. 
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 Tumor digestion was accomplished by adding the whole tumor to a solution of nitric acid 
(70%, 2 mL) in water (5 mL) in a 25.0 mL volumetric flask. The mixture was heated at 95 °C for 
48 h with vigorous stirring to produce a clear, yellow solution. The solution was diluted to 25.0 
mL after the removal of the stir bar, and filtered through a 0.2 µm hydrophilic filter. The filtrate 
was diluted (1:10) for analysis by inductively coupled plasma mass spectrometry (ICP–MS). 
ICP–MS measurements were acquired on an Agilent Technologies 7700 series ICP–MS 
instrument at the Lumigen Instrument Center in the Department of Chemistry at Wayne State 
University. All dilutions were performed with aqueous 2% HNO3, which was also used for blank 
samples during calibration. The calibration curve was created using the 153Eu isotope ion count 
for a 1–200 ppb concentration range (diluted from Fluka ICP standard solution, Eu2O3 in 
aqueous 2% HNO3, 1000 mg Eu/L). All samples were diluted to fall within this range. 
3.2.2 Synthetic Procedures and Characterization 
Scheme 3.1. Synthetic route used to synthesize 3.5. 
 
Dimethyl 2,2’-((4-fluoro-1,2-phenylene)bis(oxy))diacetate (3.2): A mixture of 4-
fluorobenzene-1,2-diol (3.1, 0.501 g, 3.91 mmol, 1 equiv), acetone (20 mL), potassium carbonate 
(2.55 g, 18.5 mmol, 4.7 equiv), and methylbromoacetate (2.11 mL, 22.3 mmol, 5.7 equiv) was 
heated at reflux for 2 h, cooled to ambient temperature, and filtered through a fritted funnel 
(medium). Solvent was removed from the filtrate under reduced pressure to afford a pale yellow 
oil. The oil was dissolved in ethyl acetate (15 mL) and washed with water (3 × 10 mL). The 
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organic layer was dried over anhydrous magnesium sulfate before solvent was removed under 
reduced pressure to yield 0.986 g (92%) of 3.2 as a pale yellow oil. 1H NMR (400 MHz, CDCl3): 
δ = 3.77–3.82 (m, 6H; CH3), 4.68–4.72 (m, 4H; CH2), 6.59–6.67 (m, 2H; FCCH), 6.90 ppm (dd, 
3J(H,H) = 8.8 Hz, 4J(H,F) = 5.4 Hz, 1H; OCCHCH); 13C NMR (101 MHz, CDCl3): δ = 52.4 
(CH3), 52.5 (CH3), 66.5 (CH2), 67.7 (CH2), 103.4 (d, 
2J(C,F) = 28.2 Hz, FCCH), 108.3 (d, 
2J(C,F) = 21.2 Hz, FCCH), 117.5 (d, 3J(C,F) = 10.0 Hz, OCCHCH), 144.3 (d, 4J(C,F) = 3.0 Hz), 
149.1 (d, 3J(C,F) = 10.5 Hz), 158.3 (d, 1J(C,F) = 241.8 Hz, CF), 169.1, 169.7 ppm; 19F NMR 
(376 MHz, CDCl3, CFCl3): δ = –118.7 to –118.6 ppm (m, F); HRESIMS (m/z): [M + Na]+ calcd 
for C12H13O6FNa, 295.0594; found, 295.0594. 
2,2’-((4-Fluoro-1,2-phenylene)bis(oxy))diacetic acid (3.3): To a mixture of 3.2 (0.874 
g, 3.21 mmol, 1 equiv) and water (25 mL) was added DOWEX (200 mesh, 50W×8, hydrogen 
form) resin (0.456 g). The mixture was heated at reflux without stirring for 60 h at which point it 
was filtered while hot through Whatman number 1 filter paper. Solvent was removed under 
reduced pressure to afford 0.742 g (96%) of 3.3 as an off-white solid. 1H NMR (400 MHz, 
(CD3)2SO): δ = 4.65 (s, 2H; CH2), 4.74 (s, 2H; CH2), 6.70 (td, 3J(H,H,F) = 8.6 Hz, 4J(H,H) = 2.9 
Hz, 1H; FCCHCH), 6.84 (dd, 3J(H,F) = 10.3 Hz, 4J(H,H) = 2.9 Hz, 1H; FCCHCO), 6.91 (dd, 
3J(H,H) = 8.8 Hz, 4J(H,F) = 5.4 Hz, 1H; OCCHCH), 13.00 ppm (brs, 2H; OH); 13C NMR (101 
MHz, (CD3)2SO): δ = 65.1 (CH2), 65.8 (CH2), 102.1 (d, 2J(C,F) = 27.9 Hz, FCCHCO), 106.4 (d, 
2J(C,F) = 24.4 Hz, FCCHCH), 115.2 (d, 3J(C,F) = 10.5 Hz, OCCHCH), 143.8 (d, 4J(C,F) = 3.0 
Hz), 148.4 (d, 3J(C,F) = 10.3 Hz), 156.8 (d, 1J(C,F) = 237.4 Hz, CF), 169.9, 170.3 ppm; 19F 
NMR (376 MHz, (CD3)2SO, CFCl3): δ = –119.9 to –119.8 ppm (m, F); HRESIMS (m/z): [M + 
Na]+ calcd for C10H9O6FNa, 267.0281; found, 267.0278. 
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Diamide (3.4): To 3.3 (0.571 g, 2.34 mmol, 1 equiv) was added thionyl chloride (10 mL, 
0.14 mol, 60 equiv) under an atmosphere of Ar. The mixture was heated at reflux for 2 h (the 
mixture turned to a clear, yellow solution during this time) before excess thionyl chloride was 
removed under reduced pressure to afford a dark yellow oil. The dark yellow oil was dissolved in 
anhydrous toluene (50 mL). A separate solution of 4,13-diaza-18-crown-6-ether (0.613 g, 2.34 
mmol, 1 equiv), triethylamine (3.0 mL, 22 mmol, 9.4 equiv), and chloroform (7 mL) in 
anhydrous toluene (40 mL) was prepared. Both solutions were simultaneously added dropwise 
over 1 h to a flask containing anhydrous toluene (500 mL) at 0 °C under an atmosphere of Ar. 
After the additions, the reaction mixture was allowed to warm to ambient temperature and was 
stirred for 5 h before solvent was removed under reduced pressure. Purification was performed 
using silica gel chromatography (8:1 dichloromethane/methanol) to yield 0.646 g (59%) of 3.4 as 
a white solid. 1H NMR (400 MHz, CD3CN): δ = 2.69–2.82 (m, 2H; CH2), 3.20–3.33 (m, 2H; 
CH2), 3.38–3.77 (m, 18H; CH2), 4.13 (ddd, 2J(H,H) = 14.4 Hz, 3J(H,H) = 4.8 Hz, 3J(H,H) = 2.8 
Hz, 1H; CH2CH2), 4.23 (ddd, 
2J(H,H) = 14.2 Hz, 3J(H,H) = 6.2 Hz, 3J(H,H) = 2.9 Hz, 1H; CH2), 
4.64 (d, 2J(H,H) = 14.7 Hz, 1H; CH2CH2), 4.75 (d, 
2J(H,H) = 14.7 Hz, 1H; CH2), 5.27 (d, 
2J(H,H) = 14.7 Hz, 1H; CH2), 5.40 (d, 
2J(H,H) = 14.7 Hz, 1H; CH2), 6.60 (td, 
3J(H,H,F) = 8.6 
Hz, 4J(H,H) = 2.9 Hz, 1H; FCHCH), 6.75 (dd, 3J(H,F) = 10.3 Hz, 4J(H,H) = 2.9 Hz, 1H; 
OCCHCF), 6.93 ppm (dd, 3J(H,H) = 8.8 Hz, 4J(H,F) = 5.9 Hz, 1H; OCHCH); 13C NMR (101 
MHz, CD3CN): δ = 48.7 (CH2), 49.0 (CH2), 49.1 (CH2), 49.4 (CH2), 67.8 (CH2), 68.9 (CH2), 
69.9 (CH2), 70.0 (CH2), 70.2 (CH2), 70.5 (CH2), 71.5 (CH2), 71.6 (CH2), 71.8 (CH2), 71.9 (CH2), 
104.3 (d, 2J(C,F) = 27.1 Hz, OCCHCF), 107.6 (d, 2J(C,F) = 23.2 Hz, FCHCH), 118.7 (d, 3J(C,F) 
= 9.9 Hz, OCHCH), 145.4 (d, 4J(C,F) = 3.0 Hz), 150.2 (d, 3J(C,F) = 10.7 Hz), 158.5 (d, 1J(C,F) 
= 237.8 Hz, CF), 169.3, 169.6 ppm; 19F NMR (376 MHz, CDCl3, CFCl3): δ = –121.0 to –120.9 
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ppm (m, F); TLC: Rf = 0.53 (8:1 dichloromethane/methanol); HRESIMS (m/z): [M + Na]
+ calcd 
for C22H31N2O8FNa, 493.1962; found, 493.1956. 
5,6-(4-Fluorobenzo)-4,7,13,16,21,24-hexaoxa-1,10-diazabicyclo[8.8.8]hexacos-5-ene 
(3.5): To 3.4 (0.549 g, 1.17 mmol, 1 equiv) was added borane tetrahydrofuran complex (1.0 M, 
35.0 mL, 35.0 mmol, 30 equiv) under an atmosphere of Ar. The solution was heated at reflux for 
23 h before the reaction was allowed to cool to ambient temperature. To the reaction solution 
was slowly added hydrochloric acid (3.0 M, 50 mL, 15 mmol, 13 equiv) over 10 min, and the 
resulting white, turbid mixture was heated at reflux for 3 h to form a clear, colorless solution 
before it was allowed to cool to ambient temperature. The pH of the reaction solution was 
adjusted to 11 with the addition of concentrated ammonium hydroxide (20 mL) before solvent 
was removed under reduced pressure to afford a white solid. Purification was achieved using 
silica gel chromatography (8:1 dichloromethane/methanol) to yield a white oily solid that was 
dissolved in a concentrated cesium carbonate solution (pH <10) and extracted with chloroform (3 
× 15 mL). The organic layers were combined, dried over anhydrous magnesium sulfate, filtered 
through a fine glass frit, and solvent was removed under reduced pressure to yield 0.417 g (81%) 
of 3.5 as a colorless oil. 1H NMR (400 MHz, CDCl3): δ = 2.68–2.79 (m, 8H; CH2), 2.90 (t, 
3J(H,H) = 6.4 Hz, 2H; CH2), 2.95 (t, 
3J(H,H) = 5.4 Hz, 2H; CH2), 3.51–3.68 (m, 16H; CH2), 
4.05–4.13 (m, 4H; CH2), 6.56 (td, 3J(H,H,F) = 8.6 Hz, 4J(H,H) = 2.9 Hz, 1H; FCCHCH), 6.62 
(dd, 3J(H,F) = 9.8 Hz, 4J(H,H) = 2.9 Hz, 1H; FCCHCO), 6.82 ppm (dd, 3J(H,H) = 8.8 Hz, 
4J(H,F) = 5.4 Hz, 1H; OCHCH); 13C NMR (101 MHz, CDCl3): δ = 55.1 (CH2), 55.4 (CH2), 56.1 
(CH2), 56.4 (CH2), 68.1 (CH2), 69.8 (CH2), 70.2 (CH2), 70.4 (CH2), 70.9 (CH2), 71.2 (CH2), 
102.8 (d, 2J(C,F) = 26.5 Hz, FCCHCO), 106.6 (d, 2J(C,F) = 21.7 Hz, FCCHCH), 117.2 (d, 
3J(C,F) = 10.8 Hz, OCHCH), 145.4 (d, 4J(C,F) = 2.4 Hz), 150.7 (d, 3J(C,F) = 10.8 Hz), 158.0 
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ppm (d, 1J(C,F) = 238.3 Hz, CF); 19F NMR (376 MHz, CDCl3, CFCl3): δ = –120.2 to –120.0 
ppm (m, F); TLC: Rf = 0.32 (8:1 dichloromethane/methanol); HRESIMS (m/z): [M + Na]
+ calcd 
for C22H35N2O6FNa, 465.2377; found, 465.2384. 
3.2.3 Preparation of Solutions Containing 3.6 
Contrast agent solutions were prepared by adding aqueous EuCl2 (100.5 µL, 199.1 mM) 
and aqueous 3.5 (379.5 µL, 52.7 mM) in a 1:1 stoichiometry to 420.0 µL water in a 4 mL glass 
vial equipped with a magnetic stir bar under an inert atmosphere. The resulting clear, colorless 
solution was stirred for 1 h before addition of degassed 10× phosphate-buffered saline  and water 
to achieve a solution of 3.6 (approximate concentration of 20 or 10 mM) in phosphate-buffered 
saline (11.9 mM phosphates, 137 mM sodium chloride, 2.7 mM potassium chloride, pH 7.4). 
The clear, colorless solution was stirred for 30 min then filtered through a 0.2 µm hydrophilic 
filter (uncomplexed EuII precipitates as phosphate salts).98 Solutions for T1 mapping and 
17O-
NMR studies were prepared in the same manner. Eu concentrations after filtration were 
determined by ICP–MS to be 19.4 and 6.9 mM for 3.6 used for injections; 0.93, 0.64, and 0.32 
mM 3.6 used for T1 mapping; and 9.58 mM 3.6 used for 
17O-NMR studies. 
X-ray quality crystals of 3.6 were prepared by dissolving EuCl2 (7.2 mg, 0.032 mmol, 1 
equiv) and 3.5 (19 mg, 0.043 mmol, 1.3 equiv) in methanol (0.25 mL) under an atmosphere of 
N2. The resulting clear, yellow solution was stirred for 1 h before the addition of tetrahydrofuran 
(3.0 mL). Solvent was slowly evaporated to afford pale yellow needle-like crystals. 
3.2.4 Animal Models 
 Studies in animals were carried out with the assistance of the Animal Model and 
Therapeutics Evaluation Core of the Barbara Ann Karmanos Cancer Institute after approval from 
the Wayne State University Institutional Animal Care and Use Committee. Methods of protocol 
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design, toxicity evaluation, drug treatment, and use of transplantable tumor model systems have 
been previously reported.141,142 A brief description of the methods as they apply to this work is as 
follows: Female BALB/cAnNCr mice (National Cancer Institute Animal Breeding Program; 
Charles River) were implanted with the syngeneic murine mammary tumor model 4T1.143 
Tumors were maintained in the mouse strain of origin (BALB/c) and housed in animal facilities 
accredited by the Association for Assessment and Accreditation of Laboratory Animal Care with 
24/7 veterinary oversight of care and husbandry. Animals were pooled, implanted bilaterally 
subcutaneously with 30–60 mg tumor fragments with a 12 gauge trocar, and imaged when 
tumors reached approximately 700–1000 mg in size (determined by caliper measurements: tumor 
mass (mg) ≈ [tumor length (mm) × tumor width2 (mm2)]/2). All mice were a minimum of 18 g 
before entering the study and were provided food and water ad libitum. 
3.2.5 Magnetic Resonance Imaging 
 Magnetic resonance imaging (MRI) was performed using a 7 T Bruker Clinscan small 
animal MRI scanner with a 30 cm bore in the MR Research Facility at Wayne State University. 
Whole body coronal plane images were acquired using a 3D FLASH sequence with an echo time 
of 1.5 ms, repetition time of 11 ms, flip angle of 40°, 44 image slices at 0.5 mm thickness, a 30 
mm × 90 mm field of view, and an in-plane resolution of 0.352 mm × 0.352 mm. 
 Imaging studies were performed with female tumor bearing BALB/cAnNCr mice. 
Animals were first anesthetized (1.5–2% v/v isoflurane in oxygen) and immobilized on a bed 
heated by circulating temperature-controlled water (37 °C). Mice were imaged before injections, 
briefly removed from the magnet (while still stably positioned on the bed), injected, then 
returned to the magnet imaged immediately to acquire the first time point (3 min) post-injection 
and imaged again at a subsequent times of 20 and 120 min post-injection. Intratumoral injections 
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were performed using tuberculin syringes (1 mL) fitted with 27 gauge × 0.5 in. needles. After all 
necessary measurements and images were obtained, animals were immediately humanely 
euthanized. Flank tumors were removed immediately and placed directly into 10% buffered 
formalin for histology or dissolved nitric acid for analysis of Eu content. 
3.2.6 Histology 
 Fixed tissue paraffin embedding, hematoxylin and eosin staining, paraffin sectioning, and 
optical microscopy of stained sections were performed at the Biobanking and Correlative 
Sciences Core of the Barbara Ann Karmanos Cancer Institute. 
3.2.7 Relaxivity Data 
 T1 maps were acquired using a published procedure for the accurate determination of T1 
in the presence of radiofrequency-field inhomogeneities and flip-angle miscalibration.144 The 
relaxivity plots were triplicated measurements of independently prepared samples (Figure S1). 
The slopes of the relaxivity plots were used to calculate the mean relaxivity plus or minus the 
standard error of the mean. 
 
Figure 3.1. Longitudinal relaxation rate vs 3.6 concentration in phosphate-buffered saline. 
3.2.8 17O-NMR Spectroscopy Data 
 Variable-temperature 17O-NMR measurements of 3.6 (9.58 mM) in phosphate-buffered 
saline (pH = 7.4) and a pH = 7.4 blank of phosphate buffered saline were obtained on a Varian-
500S (11.7 T) spectrometer. 17O-enriched water (20% H2
17O, Cambridge Isotope Laboratories, 
63 
 
Inc.) was added to samples to achieve 1% enrichment in 17O. Line widths at half height were 
measured at 30, 40, 50, 60, and 70 °C. The 17O-NMR data are presented in Table 3.1. 
Table 3.1. 17O linewidths for 3.6 and phosphate buffer as a function of temperature. 
Temperature (°C) Linewidth (Hz) 
 3.6 phosphate buffer 
70 45 30 
60 57 35 
50 77 42 
40 103 53 
30 144 72 
 
3.2.9 Crystallographic Data 
 Crystal structure analysis was performed on a Bruker APEX-II Kappa geometry 
diffractometer with Mo radiation and a graphite monochromator using a Bruker charge coupled 
device based diffractometer equipped with an Oxford Cryostream low-temperature apparatus. 
The data was measured at a temperature of 100 K. The structure was solved by the direct method 
using the SHELXS-97 program that is part of APEX II2 and refined by the least squares method, 
SHELXL 2012 incorporated into ShelXle.5 Single crystals of 3.6 contained one cation composed 
of the complex with a single coordinated chloride and one outer sphere chloride counter ion in 
the asymmetric unit. The structure was solved with a resolution of 0.59 Å in space group 
P121/n1. All non-hydrogen atoms were refined anisotropically. CCDC 1415606 contains the 
supplementary crystallographic data for this paper. These data are provided free of charge by 
The Cambridge Crystallographic Data Centre. 
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Table 3.2. Crystallographic properties of 3.6. 
Chemical formula C22H35Cl2EuFN2O6 
Formula weight 665.38 
Temperature 100(2) K 
Wavelength 0.71073 Å 
Crystal system monoclinic 
Space group P 1 21/n 1 
Unit cell dimensions a = 10.6274(9) Å α = 90° 
 
b = 17.8644(14) Å β = 99.036(4)° 
c = 13.6797(12) Å γ = 90° 
Volume 2564.9(4) Å3 
Z 4 
Density (calculated) 1.723 g cm–3 
Absorption coefficient 2.701 mm–1 
F(000) 1340 
 
3.3 Results and Discussion 
Complex 3.6 (Figure 3.2) was chosen for in vivo imaging because it has a relatively 
positive oxidation peak potential (0.366 V versus the normal hydrogen electrode).101 More 
positive potentials favor the 2+ oxidation state that is desirable for imaging. However, 3.6 is 
prone to oxidation by molecular oxygen, and the EuII ion in this cryptate was expected to be 
oxidized to the EuIII  ion in tissues containing appreciable levels of molecular oxygen or other 
strong oxidants. In healthy tissue, intracellular environments tend to be reducing whereas 
extracellular environments tend to be oxidizing, but in necrotic tissue, dead cells leach 
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components of the cytosol into the extracellular space to create a relatively reducing 
environment.145,146 It was hypothesized that the reducing environment of necrotic tissue would 
prevent oxidation of 3.6 and, consequently, contrast enhancement would be observed in necrotic 
tissue in the presence of 3.6. Before imaging in vivo, 3.6 was characterized using solid- and 
solution-phase techniques. 
 
Figure 3.2. (a) Proposed solution-phase structure of 3.6 with non-coordinated chloride 
counteranions and one or two coordinated water molecules (n = 1 or 2). (b) X-ray crystal 
structure of 3.6 with a coordinated chloride ion (hydrogen atoms and the outer sphere chloride 
counteranion are not shown for clarity). R-factor = 0.0248. Resolution = 0.59 Å. Thermal 
ellipsoids are drawn at the 50% probability level. 
 
The X-ray crystal structure of 3.6 (Figure 3.2) features a nine-coordinate metal center in 
an eclipsed hula-hoop geometry.147 Eight coordination sites are occupied by six oxygen and two 
nitrogen atoms of 3.5 and the ninth site is occupied by a coordinated chloride counteranion. 
Interestingly, this nine-coordinate geometry is different than the ten-coordinate geometry of a 
SrII-containing [2.2.2] cryptate (without the fluorobenzo group) that contains a coordinated water 
molecule and coordinated trifluoromethanesulfonate anion.127 This difference is noteworthy 
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because SrII and EuII have similar ionic radii, and SrII is often used as a diamagnetic analog for 
EuII. Because coordination environment is a key parameter in the characterization of contrast 
agents for MRI, the coordination environment of 3.6 in was interrogated in solution. 
To test whether chloride remained coordinated in solution, molar conductivity of 3.6 in 
water was measured. The molar conductivity was 211 ± 1 S cm2 mol–1, which is consistent with 
compounds exhibiting a 2:1 dissociation in water.148 This observation indicates that, on average, 
no chlorides are coordinated to EuII in solution. However, because molar conductivity is a 
colligative property, it does not provide further information regarding the coordination 
environment of 3.6 in solution. 
To further characterize the coordination environment of 3.6 in solution, variable-
temperature 17O-NMR spectroscopy was used to investigate water coordination. Using 1% 
enriched H2
17O in phosphate-buffered saline, paramagnetic broadening of the 17O-NMR signal 
upon addition of 3.6 was observed. The line broadening is consistent with the presence of inner 
sphere water. This observation coupled with a 2:1 dissociation suggests that in solution 3.6 is 
present either as a nine-coordinate species with chloride displaced by a water molecule or as a 
ten-coordinate species, based on the ability of EuII to adopt ten-coordinate geometries,149 with 
two coordinated water molecules after chloride dissociation (Figure 3.3). It is unlikely that more 
than two water molecules coordinate because 3.5 occupies eight coordination sites and because 
to the best of my knowledge, no eleven-coordinate molecular EuII-containing complexes have 
yet been reported. After studying the coordination environment of 3.6, in vitro MRI was used to 
characterize its ability to influence contrast.  
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Figure 3.3. (a) X-ray crystal structure (viewed along the N–Eu–N axis) of 3.6 (hydrogen atoms 
are not shown for clarity) alongside a cartoon representation of the solid-phase geometry in the 
same orientation as the crystal structure. Outer sphere chloride, Cl00, related by symmetry is 
included in the image. (b) Cartoon representation of the proposed solution-phase geometry of 3.6 
with one or two coordinated water molecules viewed along the N–Eu–N axis. The blue and teal 
spheres in the cartoons represent nitrogen and europium, respectively, and the bold lines 
represent the cryptands. R-factor = 0.0248. Resolution = 0.59 Å. Thermal ellipsoids are drawn at 
the 50% probability level. 
 
To characterize the ability of 3.6 to provide contrast enhancement, the relaxivity of 3.6 in 
phosphate-buffered saline was measured using T1-weighted MRI. The relaxivity (24 °C, 7 T) of 
3.6 in phosphate-buffered saline was 6.5 ± 0.3 mM–1 s–1. This relaxivity value in phosphate-
buffered saline is in agreement with other EuII-containing cryptates.97 Additionally, phosphate 
can bind lanthanide ions in a bidentate manner to displace two water molecules when the metal 
ion contains two adjacent coordinated water molecules.150 Nonadjacent water would be 
consistent with water molecules replacing the two chloride ions (Figure 3.3). While not 
coordinated, the outer sphere chloride is 5.383 Å from EuII (the coordinated chloride is 2.793 Å 
from EuII), and if both chloride ions are replaced by water molecules, a closer approach could be 
envisioned due to the smaller size of oxygen relative to chloride. Accordingly, the 17O line 
broadening, crystal structure, and relaxivity suggest that if two water molecules are coordinated 
to 3.6 in solution, that they are likely not adjacent to each other. 
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To test whether 3.6 would enhance contrast in necrotic tissue, T1-weighted MRI was 
performed before and after intratumoral injection of 3.6 (50 µL, 19.4 mM) into a 4T1 mammary 
carcinoma. The 4T1 carcinoma model is an aggressive tumor that typically develops a necrotic 
core,151 and imaging was performed when tumors reached approximately 700–1000 mg to 
maximize the probability of necrosis. Images were acquired before and at 3, 20, and 120 min 
after intratumoral injection (Figure 3.4). Positive contrast enhancement was observed for the 
entirety of the 120 min experiment, but the location of positive contrast enhancement changed 
over time. Specifically, heterogeneous positive contrast enhancement was observed along nearly 
the entire length of the tumor immediately post injection, but was only observed in a localized 
core of the tumor after 120 min. These observations demonstrate that EuII persists within a tumor 
for at least 120 min, and this duration of positive contrast enhancement was consistent in all 
seven of the attempted imaging experiments with independently injected tumors. The presence of 
contrast enhancement is consistent with the persistence of the 2+ oxidation state of europium in 
the core of the tumor, and the reduced oxidation state is suggestive of a lack of oxygen. 
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Figure 3.4. T1-weighted in vivo sagittal plane images of a 4T1 tumor injected with 3.6 (a) pre-
injection; (b) 3 min, (c) 20 min, and (d) 120 min post-intratumoral injection; (e) difference 
between the 120 min and pre-injection images (image d minus image a) colored using the ImageJ 
green lookup table; (f) hematoxylin- and eosin-stained slice of tumor imaged in a–e; and (g) sum 
of images e and f. All images are on the same scale. Imaging parameters included an echo time 
of 1.5 ms, repetition time of 11 ms, flip angle of 40°, field of view of 30 mm × 90 mm, and an 
in-plane resolution of 0.352 mm × 0.352 mm. 
 
To verify the presence of necrotic tissue in the tumor, the mouse was sacrificed directly 
after the 120 min post-injection image and performed histological staining. The tumor was 
removed in whole, fixed in formalin, mounted in paraffin, and cut to a thickness of 5 µm before 
being stained with hematoxylin and eosin (Figure 3.4). Hematoxylin is a dye that stains nuclei, 
and eosin stains elements of the cytoplasm as a counterstain to differentiate areas that are nuclei-
abundant (blue) from those that are nuclei-deficient (pink).152 Areas associated with necrosis are 
expected to stain pink to a greater extent than non-necrotic areas because of the lack of cells and 
their corresponding nuclei in necrotic regions. The stained slice revealed nuclei-deficient regions 
consistent with necrosis that were particularly pronounced in the mid-to-upper half of the tumor. 
The leftmost region of the slice stained pink from the presence of tumor ulceration through the 
mouse epidermis. Consistent with staining, the majority of positive contrast enhancement 
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observed 120 min post-injection was in the mid-to-upper half of the tumor, suggesting that 3.6 
provided positive contrast enhancement in the necrotic core of the tumor (Figure 3.4). No 
contrast enhancement was observed in the leftmost region of the tumor likely because of direct 
contact between tumor ulceration and oxygen in the air. It is worth reiterating that an 
intratumoral injection was used, which may have placed a bolus in the tumor core and the lack of 
oxygen allowed EuII to persist.  
To better understand the potential mechanism of differentiation, an intratumoral injection 
of 3.6 (50 µL, 6.9 mM) was performed and contrast enhancement was monitored over the course 
of 3 h before sacrificing the mouse and removing the injected tumor for analysis of Eu content 
by inductively coupled plasma mass spectrometry. At 3 h post-injection, a decrease in positive 
contrast enhancement (~85%) was observed in the tumor relative to the initial image and a 
decrease of in the Eu content (~80%) was observed in the tumor relative to the injected dose. 
These close values suggest clearance of 3.6 played a major role in the loss of positive contrast 
enhancement. Clearance was not directly observed in T1-weighted MRI because 3.6 likely 
oxidized in tissues or fluids of relatively higher oxygen content, and the product of oxidation, 
EuIII, does not produce positive contrast enhancement. Furthermore, when 3.7 (Figure 3.5) (50 
µL, 20.5 mM) was injected into a tumor in a separate experiment, the bladder of the mouse was 
bright with contrast within minutes of the injection. This phenomenon was observed in two 
independently injected tumors. This non-redox-active control indicates that the concentration of 
EuII injected should be enough to visualize in the bladder if clearance occurred without 
oxidation. The evidence of clearance based on Eu content and the lack of contrast enhancement 
observed outside of the tumor demonstrates the lack of background enhancement possible with 
EuII-based imaging agents in redox-active environments. While the connection between positive 
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contrast enhancement and necrotic tissue is intriguing, more detailed experiments are required to 
evaluate the nature of 3.6 clearance over time. Regardless of the mechanism of differentiation, 
these in vivo imaging data demonstrate the first reported use EuII for in vivo contrast-enhanced 
MRI. 
 
Figure 3.5. Structure of GdIII-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate (3.7). 
To investigate the in vitro stability of 3.6 with respect to oxygen exposure, T1 (37 °C, 1.4 
T) of 3.6 was measured in phosphate-buffered saline to monitor the oxidation of EuII as a 
function of air exposure while stirring. Under an atmosphere of N2 (pO2 ≈ 0 mmHg), 3.6 
remained in the 2+ oxidation for at least 118 d. However, upon stirring in open air (pO2 ≈ 160 
mmHg), the observed T1 enhancement was completely lost within 5 min. This rapid oxidation 
with elevated oxygen exposure suggests that 3.6 is oxidized upon clearance from the oxygen-
deficient 4T1 necrotic core (pO2 ≤ 10 mmHg)134,135 into relatively oxygenated vasculature (pO2 ≈ 
40–100 mmHg).136 Collectively, the persistence of the 2+ oxidation state over a 120 min period, 
the correlation between necrotic tissue and contrast enhancement, the lack of positive contrast 
enhancement in organs associated with clearance (bladder, liver, or kidneys), and the rapid 
oxidation observed in elevated air exposure suggest that 3.6 persists in the poorly oxygenated 
necrotic core of the tumors and oxidizes elsewhere. 
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3.4 Conclusions 
Solid- and solution-phase characterization of 3.6 indicated that the complex is nine-
coordinate in the solid state and nine- or ten-coordinate in solution. The ability to differentiate 
necrotic from non-necrotic tissue in vivo coupled with the tunable oxidation potential of EuII is 
expected to enable bracketing of tissue redox environments associated with both hypoxic and 
hyperoxic tissues relevant to the study of many diseases. 
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CHAPTER 4: OXIDATION-RESPONSIVE EUROPIUM(II/III)–LIPOSOMAL 
CONTRAST AGENT FOR DUAL-MODE MRI 
 
Parts of this chapter were adapted with permission from Ekanger, L. A.; Ali, M. M.; Allen, M. J. 
Chem. Commun. 2014, 50, 14835. Reproduced by permission of The Royal Society of 
Chemistry. 
 
4.1 Introduction 
The power of MRI resides in the ability to ascertain anatomical information at high 
resolution for clinical (1 mm isotropic) and preclinical (0.025 mm isotropic) applications.153 
Molecular information can also be obtained with MRI using responsive paramagnetic complexes 
(contrast agents) that alter water proton signal intensities in response to chemical events. Some 
contrast agents respond to changes in pH,40–42,154–156 temperature,59,61,157 metal ion 
concentration,35,63,65 enzyme activity,33,158,159 or partial pressure of oxygen,66 the presence of free 
radicals,72,160 antioxidants,68 phosphate diesters,161 singlet oxygen,70 reduced glutathione and 
hydrogen peroxide,71 or oxygen, dithionite, and cysteine.69 Of particular interest are targets that 
cause changes in redox behavior because they are associated with cancer,109,111 inflammation,162 
and cardiovascular diseases.113 Accordingly, responsive contrast agents that target redox changes 
have the potential to greatly improve the diagnostic capabilities of MRI. However, a critical 
limitation of responsive contrast agents that hinders their use in vivo is that determination of 
molecular information requires knowledge of the concentration of contrast agent, which is 
exceedingly difficult to measure in vivo. Some systems have achieved concentration 
independence in contrast-enhanced MRI through ratiometric techniques (longitudinal vs 
transverse relaxation rates),50 ratiometric chemical exchange saturation transfer (CEST) 
techniques,70,154 or the use of orthogonal detection modes with a multimodal agent;163 however, 
to the best of my knowledge, no reported system demonstrates a concentration-independent 
response to general oxidizing events based on tunable oxidation potentials. An ideal metal ion 
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for multimodal redox response is EuII because the EuII and EuIII oxidation states orthogonally 
enhance T1-weighted and CEST images, respectively, in MRI. Furthermore, Eu
II has a tunable 
oxidation potential101 and outperforms clinically approved T1-shortening contrast agents at ultra-
high magnetic field strengths.97,98 To address the need for a concentration-independent, 
oxidation-responsive contrast agent, it was hypothesized that encapsulating 1.33 in liposomes 
(Figure 4.1) would produce an oxidation-responsive dual-mode contrast agent because it would 
enhance either T1-weighted images or CEST images depending on the oxidation state of Eu. 
The response to oxidation was based on the oxidation of EuII to EuIII because these two 
oxidation states offer orthogonal modes of detection by MRI and the EuII/III oxidation state 
switch offers an ideal platform for oxidation-responsive contrast enhancement.66,127 The use of 
this switch has awaited sufficient stabilization of EuII that the Allen laboratory demonstrated 
through modifications to 1.33 ligand structure.101 Furthermore, changes to ligand structure made 
the corresponding oxidation potential of EuII tunable over a physiologically relevant range.101 
Here, the encapsulation of 1.33 in liposomes and distinct oxidation-responsive, dual-mode 
imaging behavior is reported. This system is expected to open the door for concentration-
independent diagnostic imaging of redox-active disease states using the chemistry of Eu. 
 
Figure 4.1. Representation of the oxidation of liposome-encapsulated 1.33 (T1 enhancement and 
CEST effect) to form liposomes containing 4.1 (T1 silent with CEST effect). On the far right is a 
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depiction of the liposomal phospholipid bilayer with ovals as cholesterol molecules. For clarity, 
only one complex is shown in each liposome and coordinated water molecules are not drawn. 
 
4.2 Experimental Procedures 
Commercially available chemicals were of reagent-grade purity or better and were used 
without further purification unless otherwise noted. Water was purified using a PURELAB Ultra 
Mk2 water purification system (ELGA) and degassed prior to use. NMR spectroscopy and 
inductively coupled plasma optical emission spectroscopy (ICP–OES) analyses were performed 
at the Lumigen Instrument Center in the Department of Chemistry at Wayne State University and 
in the Department of Chemistry at Oakland University. In vitro phantom imaging was performed 
at Henry Ford Hospital. 
Inversion-recovery T1 measurements were obtained using a Varian VNMRS 500 (499.48 
MHz, 11.7 T) spectrometer before air exposure or after 24 h of air exposure. Deuterium oxide 
(300 mOsm NaCl) was added to make liposome suspensions 5% D2O (v/v) for the purpose of 
locking and shimming. 
4.2.1 Phantom Imaging 
MRI scans were performed with a 7 T Varian small animal MRI scanner (299.44 MHz, 
7.0 T) equipped with a 12 cm bore magnet and a 38 mm diameter homemade transmit/receive 
quadrature birdcage coil. Samples included liposomes that were not exposed to air, liposomes 
that were exposed to air for 24 h, and water. The T1-weighted images were acquired at ambient 
temperature (echo time: 11 ms; repetition time: 320 ms; seven image slices at 1 mm thickness; 
24 × 24 mm field of view; and four averages). The liposome-encapsulated EuIII (chemical 
exchange saturation transfer, CEST) effects were measured at ambient temperature under the 
same parameters used in a previous CEST MRI study.164 A RARE MRI pulse sequence with a 
RARE factor of 8 (repetition time/echo time, 4.0 s/11 ms) was applied with a 17 μT saturation 
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power for 2 s. A total of 64 s was required to acquire a single MR image with 128 × 128 pixels 
that covered a 24 × 24 mm field of view, a single slice with a thickness of 1 mm, and a single 
average. The water signal was measured for each phantom when saturation was applied between 
5 and –5 ppm in 0.2 ppm increments to measure the CEST effect of liposomes, and CEST 
images were generated by subtracting images acquitted at 1.2 ppm (SΔω) and –1.2 ppm (S–Δω).  
Varian flexible data format (FDF) files were converted to tagged image file format 
(TIFF) files with a MATLAB code.165 TIFF files were processed to produce chemical exchange 
saturation transfer (CEST) spectra by measuring pixel intensities with ImageJ 1.47.166 Percent 
CEST (%CEST) was calculated using Eq 4.1.167 
Eq 4.1. %CEST = (1 −
𝑀𝑧
𝑀0
) 100 
In Eq 4.1, MZ and M0 are the average signal intensities (calculated with ImageJ) of the 
same phantom tube slice at 360 Hz (1.2 ppm) and –360 Hz (–1.2 ppm), respectively. The CEST 
image was created by subtracting the TIFF slice at 360 Hz (1.2 ppm) from the identical slice at –
360 Hz (–1.2 ppm) and the difference was divided by the slice at 360 Hz (–1.2 ppm). 
The %CEST scale bar was created by calibrating the pixel range of the CEST image to the 
maximum %CEST value obtained from Eq 4.1 using a linear fit. 
4.2.2 Dynamic Light Scattering 
Dynamic light scattering data were obtained using a Malvern Zetasizer Nano-ZS 
instrument (ZEN3600) operating with a 633 nm wavelength laser. Dust was removed from 
samples by filtering through 0.2 μm hydrophilic filters (Millex–LG, SLLGR04NL). Liposome 
samples were prepared for light scattering experiments by diluting purified liposome suspensions 
in iso-osmolar phosphate-buffered saline (PBS, 1:10, 29 mM Na2HPO4, 46 mM NaH2PO4, 57 
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mM NaCl, and 2.1 mM KCl). For liposome size measurements with no air exposure, air-tight 
cuvettes were filled in a glovebox under an atmosphere of Ar. 
4.2.3 Elemental Concentration Measurements 
ICP–OES measurements were acquired on a Jobin Yvon Horiba Ultima or PerkinElmer 
Optima 7000 DV spectrometer. All samples were diluted with 2% HNO3, which was also used 
for blank samples during calibration. The calibration curves were created using the Eu emission 
intensity at 381.965 nm for a 1–60 ppm concentration range (diluted from Alfa Aesar Specpure 
AAS standard solution, Eu2O3 in 5% HNO3, 1000 μg/mL) and the Sr emission intensity at 
407.771 nm for a 0.5–5 ppm concentration range (diluted from Fluka Analytical Sr ICP standard, 
1000 mg/L), and all samples were diluted to fall within the concentration range of standards for 
the respective element. 
4.2.4 Preparation of Hydration Solution  
The hydration solution was prepared by stirring an aqueous solution of EuCl2 and 
4,7,13,16,21,24-hexaoxa-1,10-diazabicyclo[8.8.8]hexacosane for 12 h under an atmosphere of 
Ar followed by a phosphate-buffer-workup.98 To account for loss of phosphate during the 
precipitation step of this experiment, a PBS stock solution was prepared with a high 
concentration of phosphate (1 M). The purpose of the high phosphate concentration was to 
ensure PBS buffer capacity was not lost upon phosphate precipitation in the presence of 
uncomplexed EuIII in the oxygen-exposed samples and to maintain physiological osmolality (300 
mOsm). This PBS solution was prepared in a glovebox under an atmosphere of Ar by dissolving 
anhydrous dibasic sodium phosphate (42.6 g, 0.300 mol), monobasic sodium phosphate 
monohydrate (27.6 g, 0.200 mol), sodium chloride (22.3 g, 0.381 mol), and potassium chloride 
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(1.01 g, 13.6 mmol) in H2O (500 mL). The pH of the resulting solution was brought to 7.0 with 
the addition of solid sodium hydroxide (3.87 g, 96.8 mmol).  
To a 4 mL glass vial equipped with a magnetic stir bar was added aqueous EuCl2 or SrCl2 
and aqueous ligand under an atmosphere of Ar to form 1.33 or 4.2 (Figure 4.2), respectively. 
The resulting clear, colorless solution was stirred for 12 h before addition of the PBS solution 
described above (390 mM Na2HPO4, 610 mM NaH2PO4, 762 mM NaCl, 27.2 mM KCl, pH 7.0) 
and water to bring the osmolality of the solution to 300 mOsm. Upon addition of PBS, a slightly 
turbid suspension formed that was stirred for 1 h and then filtered through a 0.2 μm hydrophilic 
filter. The final concentrations of Eu (13, 24, 40 and 45 mM) or Sr (28 mM) of the clear, 
colorless filtrates were determined by ICP–OES. This filtrate was used for liposome preparation. 
The hydration solution used to prepare blank liposomes consisted of iso-osmolar (300 mOsm) 
PBS prepared by dilution of the PBS solution described above. 
 
Figure 4.2. Structure of the diamagnetic control 4.2. 
4.2.5 Preparation of Liposomes  
Liposomes were prepared via the thin-film hydration technique.51 To a 4 mL vial was 
added 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (4.3 in Figure 4.3) (22.0 mg, 2.89 
μmol, 1.4 equiv), cholesterol (4.4 in Figure 4.3) (8.0 mg, 2.1 μmol, 1 equiv), and chloroform (1 
mL) to produce a clear, colorless solution. Avoid exposing the lipids to air for extended periods 
of time because they tend to be hygroscopic. It is advisable to partition lipids into vials, remove 
air and moisture under reduced pressure on a Schlenk line, and backfill multiple times with Ar 
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before returning to extended storage in the freezer. Removing air and moisture and storing under 
Ar will increase the longevity of lipids that are hygroscopic and prone to oxidation or hydrolysis. 
Solvent was removed under reduced pressure to afford a visible film on the bottom of the vial. 
Under an atmosphere of Ar, the hydration solution (1.15 mL) and vial containing the lipid thin 
film were placed in a water bath at 55 °C for 30 min, and then the hydration solution was added 
to the vial containing the thin film. The resulting white suspension was stirred at 55 °C for 1 h. 
Extrusion of the suspension was accomplished using a mini-extruder and heating block (Avanti 
Polar Lipids, Alabaster, AL, USA) heated to 55 °C (4 passes through a 0.2 μm polycarbonate 
filter followed by 15 passes through a 0.1 μm polycarbonate filter). Do not apply too much 
pressure when extruding liposomes suspensions as the glass syringes are somewhat fragile. 
Ensure that the syringes are not clogged prior to use, and never clean them with anything other 
than water, aqueous detergent, or isopropanol. After extrusion, the suspension was allowed to 
cool to ambient temperature within the Ar-filled glovebox for 1 h. To prevent clogged 
equipment, clean out the syringes and filter assembly immediately after use. 
 
Figure 4.3. Structures of 4.3 and 4.4. 
Non-encapsulated MII-containing cryptate (M = Eu, Sr) was removed from the liposome 
suspension in an Ar-filled glovebox via spin filtering (Amicon Ultra regenerated cellulose 3,000 
molecular weight cut off). The liposome suspension was filtered in aliquots because the volume 
of the suspension exceeded the volume of the spin filter. When the volume of suspension in the 
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filter reached 0.3 mL after spinning, the volume was brought to 0.5 mL with the addition of iso-
osmolar (300 mOsm) PBS prepared by dilution of the PBS solution described above. The filtrate 
fractions (150 µL each) were collected until Eu or Sr was not detectable by ICP–OES (~17 
fractions). It should be noted that the rate of filtration decreases as the volume of the liposome 
suspension decreases and that the liposome suspension is naturally slow to filter because it is 
relatively concentrated. For these two reasons, the spin filtering process is relatively lengthy 
(collecting 17 fractions may require up to 24 h). One cannot simply leave the filtration 
unattended for extended periods of time and expect expedient results. This process will require 2 
or 3 days, depending on length of time in lab, of adding PBS every 20 minutes. If filtrate is not 
observed during spin filtering, a centrifuge capable of higher rotations per minute is advised. I 
found that a Fisher Scientific Mini Centrifuge (Catalog number 05-090-100) worked sufficiently, 
while a GeneMate Bioexpress Mini Centrifuge (Catalog number C-1301-PC) did not work well 
for spin filtering liposome suspensions. Adding a small amount of PBS every 20 minutes helped 
to keep the filtration going smoothly. Accordingly, it is important to plan for 2 or 3 days of spin 
filtering alone before scheduling imaging time or before sending samples out to collaborators. It 
may be advantageous to screen spin filters with larger molecular weight cut off thresholds. Spin 
filtering was also attempted using 10,000 molecular weight cut off filters, but the rate of 
filtration did not appear to improve. Using a relatively high molecular weight cut off filter that 
still retains liposomes could potentially expedite the process. The spin filtering process is 
tedious, but there is an alternative. Exhaustive dialysis could be used in theory, but would require 
the degassing of copious amounts of pure water (~3 L water per liposome batch depending on 
the amount of material to be purified) to bring into the glovebox. Additionally, a large amount of 
degassed PBS would be required to maintain an appropriate salt concentration of the outer 
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solution to prevent an osmotic pressure gradient from damaging the liposomes. Spin filtering was 
chosen because it is resource efficient.  
4.2.6 CEST Imaging Data  
In vitro phantom image intensities were plotted as a function of frequency offset of 
presaturation for blank liposomes, liposomes containing 28 mM 4.2, liposomes containing 13 
mM 1.33, liposomes containing 24 mM 1.33, liposomes containing 40 mM 1.33, and liposomes 
containing 45 mM 1.33 (Figure 4.4). These data were used for Lorentzian curve fitting. 
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Figure 4.4. CEST spectra (7 T, ambient temperature) of raw image intensity data before (hollow 
circles) and after (solid circles) air exposure of (a) blank liposomes, (b) liposomes containing 28 
mM 4.2, (c) liposomes containing 13 mM 1.33, (d) liposomes containing 24 mM 1.33, (e) 
liposomes containing 40 mM 1.33, and (f) liposomes containing 45 mM 1.33.  
 
 
 
 
a b 
c d 
e f 
83 
 
4.2.7 Lorentzian Function Fitting  
The raw CEST imaging data before and after air exposure was modeled with 
Mathematica 9.0 using a sum of two Lorentzian functions (Eq 4.2) optimized with least squares 
fitting. 
Eq 4.2  𝑦 =  
𝑎1𝑘1
𝑘1
2+(𝑥−𝑥1)2
+
𝑎2𝑘2
𝑘2
2+(𝑥−𝑥2)2
 
In Eq 4.2, a1, a2, k1, k2, x1, and x2 are the fitting variables optimized with least squares to 
produce a Lorentzian function for imaging data. The CEST data for liposomes before and after 
air exposure were modeled with Mathematica commands in Figure 4.5. These commands 
included a calculation and plot of relative error per data point, which was plotted with the fitted 
function for blank liposomes (Figure 4.6). 
 
Figure 4.5. Mathematica commands or Lorentzian curve fitting CEST imaging data and relative 
error per data point for blank liposomes. 
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Figure 4.6. Mathematica output for blank liposomes of (a) fitted variables, (b) Lorentzian 
function plotted with raw CEST data, and (c) relative error calculated for each data point. 
 
 The Lorentzian function reported in the results and discussion section was generated 
using the fitted variables defined in Eq 4.2, but plotted in the form of Eq 4.3. 
Eq 4.3  𝑦 = 1 − (
𝑎1𝑘1
𝑘1
2+(𝑥−𝑥1)2
+
𝑎2𝑘2
𝑘2
2+(𝑥−𝑥2)2
) 
85 
 
 4.2.8 Dynamic Light Scattering Data 
Figure 4.7. Intensity percent vs size of liposomes containing 45 mM 1.33 used for in vitro CEST 
imaging prior to air exposure.  
 
Figure 4.8. Intensity percent vs size of liposomes that contained 45 mM 1.33 used for in vitro 
CEST imaging after 24 h of air exposure.  
 
Figure 4.9. Intensity percent vs size of liposomes containing 45 mM 1.33 used for in vitro T1-
weighted imaging prior to air exposure. 
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Figure 4.10. Intensity percent vs size of liposomes that contained 45 mM 1.33 used for in vitro 
T1-weighted imaging after 24 h of air exposure. 
4.3 Results and Discussion 
Liposomes were used because their aqueous inner cavity can encapsulate water-soluble 
contrast agents to improve the sensitivity of CEST by increasing the ratio of chemically shifted 
water protons (associated with liposomes) to bulk water protons (not associated with 
liposomes).168,169 Liposome composition was adapted from a report that used 1-palmitoyl-2-
oleoyl-sn-glycero-3-phosphocholine and cholesterol,51 and liposomes were characterized using 
dynamic light scattering. The average diameter measured before and after air exposure was 110 
± 7 and 106 ± 6 nm, respectively, where the diameter error is the standard error calculated from 
the average polydispersity index values. The average liposome polydispersity index value before 
and after air exposure was 0.14 ± 0.01 and 0.10 ± 0.06, respectively, where the polydispersity 
index error is the standard error at the 95% confidence interval. These size distribution data 
indicate that average liposome size was not different before and after oxidation (Student’s t-test) 
and, consequently, not affected by the intraliposomal formation of EuIII.  
To evaluate the response of the liposomes, 45 mM 1.33 was encapsulated because of 
previous studies that loaded similar or higher concentrations of paramagnetic complexes into 
liposomes.61,168,169 After removing non-encapsulated 1.33 by spin filtering, suspensions of 
liposomes containing 1.33 were characterized before and after exposure to air. Molecular oxygen 
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within air was chosen as a convenient source of oxidant to demonstrate a response corresponding 
to oxidation of 1.33. This mechanism of response is most likely diffusion of oxygen into the 
buffer and across the liposome membrane. Once oxygen has crossed the membrane, it can 
oxidize 1.33 (T1 enhancing agent) to form 4.1 (T1 silent), and consequently, the response to 
oxidation can be detected by loss of T1 enhancement. Support for the oxygen diffusion 
mechanism was found by measuring the change in T1 as a function of air exposure for liposome 
suspensions containing 1.33. Without stirring, 1.33 within liposomes required 7 h to oxidize in 
air. Upon stirring, however, 1.33 within liposomes oxidized within 10min of air exposure. 
Stirring the solution would facilitate an increased rate of oxygen diffusion, which would 
accelerate the rate of oxidation. To ensure complete oxidation of 1.33 to form 4.1 within the 
oxidized samples, liposomes were exposed to air for 24 h without stirring because of the small 
size of the sample tube prior to imaging. After air exposure an 86% decrease in T1 (0.4 and 2.8 s 
for the same sample before and after air exposure, respectively, at 24 °C, 11.7 T, and 45 mM in 
Eu) was observed, which is a response similar to or greater than other reported contrast 
agents.33,67,88,170–176 A rationale for the large change in T1 is that Eu
II is isoelectronic with GdIII, 
but EuIII is diamagnetic in its ground state and is not expected to dramatically influence T1. The 
observation of T1 changing upon air exposure is in good agreement with the T1-shortening nature 
of 1.33 (relaxivity was 3.99 mM–1 s–1 outside of liposomes and 0.2 mM–1 s–1 inside of liposomes 
at 20 °C and 11.7 T. The lower relaxivity is expected for T1-shortening contrast agents 
encapsulated in spherical liposomes).97,98,177 Furthermore, the change in T1 upon air exposure 
indicates that oxidation to form 4.1 caused the observed lengthening of T1. 
To characterize the dual-mode behavior of Eu-containing liposomes, CEST response 
before and after air exposure by measuring in vitro image intensities as a function of frequency 
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offset of presaturation at 7 T was measured (Figure 4.11). The intensity data was modeled with a 
Lorentzian function using least squares fitting to reference the upfield signal to 0 ppm (Figure 
4.12). Lorentzian fitting was use because the sample images were acquired simultaneously and 
the bulk water signals were not centered at 0 ppm. Averaging the CEST spectra was performed 
because it appeared that both the proximity to the bulk water signal and inhomogeneity in the 
magnetic field led to variability in the intensity measurements. The average CEST spectra 
(Figure 2) revealed that liposomes before and after 24 h air exposure exhibited an exchangeable 
proton signal at 1.2 ppm relative to bulk water. Although this shift is small, it is possible to 
image such shifts in vivo:77,178–182 in vivo CEST has been observed between bulk water and 
exchangeable protons of liposomes shifted by as little as 0.8 ppm.77 
To investigate the cause of CEST effect before oxidation of Eu, CEST spectra were 
acquired for a series of samples including blank liposomes containing only phosphate-buffered 
saline, liposomes containing 4.2 (28 mM Sr) as a diamagnetic analogue, and liposomes 
containing four different concentrations of 1.33 (13, 24, 40, and 45 mM Eu). CEST effect was 
observed for each sample as a broad signal in the chemical shift range of 1–2 ppm relative to 
bulk water. Furthermore, there was no correlation between Eu concentration and CEST effect. 
These experiments suggest that the observed CEST effect is due to the liposome membrane itself 
rather than Eu within the liposome cavity. These results are fully consistent with a recent 
demonstration of a CEST effect using diamagnetic liposomes that contained cholesterol and, of 
particular importance, the proton signal at ~1 ppm downfield from bulk water was assigned to 
hydroxyl protons.77 Additional support for these observations can be found in a previous report 
of magnetization transfer for a lipid and cholesterol system in which magnetization transfer 
exhibited a strong dependence on cholesterol concentration (30–60 mol %),183 and the 
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concentration of cholesterol in the system reported here (42 mol %) falls in this range. 
Furthermore, these data provide an explanation for the observation of CEST before oxidation of 
EuII by revealing an exchange between the liposome membrane and bulk water. In this proposed 
exchange mechanism, 1.33 is confined to the intraliposomal cavity and, consequently, would not 
interact with protons exchanging on the outer surface of the liposome. 
 
Figure 4.11. CEST spectra (7 T, ambient temperature) of 1.33-containing liposomes before () 
and after () 24 h air exposure. Data points represent the mean of six independently prepared 
samples [liposomes containing only phosphate-buffered saline; 4.2 (28 mM Sr); and 1.33 (13, 
24, 40, and 45 mM Eu)], and error bars represent the standard error of the mean. The upfield 
signal was referenced to 0 ppm using the Lorentzian-fitted spectra and signal intensities were 
calculated from in vitro images after a 2 s presaturation with a 17 µT radiofrequency pulse from 
5 to –5 ppm in 0.2 ppm increments.  
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Figure 4.12. Lorentzian-fitted CEST spectrum (7 T, ambient temperature) of liposomes filled 
with phosphate-buffered saline. The upfield signal was referenced to 0 ppm, and signal 
intensities were calculated from in vitro images after a 2 s presaturation with a 17 µT 
radiofrequency pulse from 5 to –5 ppm in 0.2 ppm increments.  
 
To visualize the nature of the EuII/III responses, in vitro images of liposome suspensions 
were acquired before and after air exposure (Figure 4.13). The T1-weighted images confirmed 
positive contrast enhancement for the 1.33-containing liposomes and also revealed no significant 
difference in signal intensity between water and the oxidized EuIII-containing liposomes at the 
95% confidence interval (Student’s t-test). Additionally, there was an 81% decrease in signal 
intensity in T1-weighted images before and after oxidation. To quantify the CEST effect, the 
phantom image intensities were used to calculate %CEST defined as (1 – Mz/M0)100, where Mz 
and M0 are the average signal intensities at the on- and off-resonance positions.
167 The CEST 
map confirmed the presence of exchangeable protons before and after oxidation and that %CEST 
was not significantly different after oxidation based on the standard error of the CEST effect 
measurements in Figure 4.11. Based on control experiments, the change in CEST effect is not 
due to the presence of Eu, despite the influence of T1 on the CEST effect.
184 Nevertheless, these 
data demonstrate a distinct dual-mode response and reveal the oxidation state of Eu without 
knowledge of its concentration. Therefore, (1) if T1 enhancement and CEST effect are both 
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present, the agent has not responded. Similarly, (2) if T1 enhancement is no longer observed and 
CEST effect is still present, then the agent has responded. If neither forms of contrast are 
detected, then (3) the agent is no longer present or is present at a level below the detection limit 
of MRI. Based on these three scenarios, one can determine the oxidation state of Eu (and 
therefore a response) without knowledge of the concentration of Eu. This method does not 
quantify the amount of oxidant present, but reports on the oxidation itself in a concentration-
independent manner by using two orthogonal detection modes (one of which changes and one of 
which does not change in response to oxidation).  
With this demonstration of distinct orthogonal imaging, tracking the migration of the 
contrast agent could be achieved with T1-weighted imaging. Upon disappearance of T1 
enhancement, the imaging mode of detection would be changed to CEST. The presence of CEST 
effect would indicate oxidation, and an absence of CEST effect would indicate clearance of the 
contrast agent. Furthermore, CEST effect could be used to indicate one or more specific disease 
states because the oxidation potential, and consequently loss of T1 enhancement, of 1.33 is 
tunable through ligand structure modifications.101 Accordingly, these in vitro data provide a 
strong framework for optimizing this system for in vivo imaging. 
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Figure 4.13. MR phantom images (5 mm tube diameter) at 7 T and ambient temperature of 
water, non-oxidized liposomes containing EuII, and oxidized liposomes containing EuIII. In the 
top row are T1-weighted images and on the bottom is a CEST map generated by subtracting 
presaturation at 1.2 ppm from presaturation at –1.2 ppm and the difference was divided by 
presaturation at –1.2 ppm. %CEST represents the decrease in bulk water signal intensity as a 
result of presaturation exchangeable water protons associated with liposomes. 
 
The kinetic stability of 4.1 relative to 1.33 is of importance because of the toxic nature of 
uncomplexed trivalent lanthanide ions. It has been demonstrated that 4.1 is less kinetically stable 
relative to 1.33,103 which is primarily due to the reduction in size of Eu upon oxidation. To 
demonstrate that liposomes did not leach Eu, the oxidized liposomes were filtered, and the Eu 
concentration of the filtrate was measured to be below the detection limit (<66 nM) of 
inductively coupled plasma optical emission spectroscopy. This result indicates that the liposome 
traps uncomplexed EuIII, which is likely present as a species coordinated with phosphate from 
the buffer, phosphate from the phospholipid membrane, or as the free aqua ion. 
4.4 Conclusions 
The first oxidation-responsive dual-mode contrast agent for MRI based on the redox 
chemistry of Eu was demonstrated. Contrast enhancement in orthogonal imaging modes allows 
for the detection of Eu oxidation states without knowledge of contrast agent concentration. 
Notably, the response of this system is irreversible due to the stability of EuIII with respect to 
93 
 
reduction. Irreversible response is potentially advantageous in vivo because the contrast agent is 
in a dynamic environment and can indicate oxidation even if no longer in the oxidizing region. 
For these reasons, this system is expected to open the door for molecular imaging using the 
EuII/III redox switch, and the scope of the system is being explored to identify physiologically 
relevant oxidants and the kinetics of intraliposomal EuII oxidation. 
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CHAPTER 5: SPECTROSCOPIC CHARACTERIZATION OF THE 3+ AND 2+ 
OXIDATION STATES OF EUROPIUM IN A MACROCYCLIC TETRAGLYCINATE 
COMPLEX 
 
Parts of this chapter have been adapted with permission from Ekanger, L. A.; Mills, D. R.; Ali, 
M. M.; Polin, L. A.; Shen, Y.; Haacke, E. M.; Allen, M. J. Inorg. Chem. [Online early access]. 
DOI 10.1021/acs.inorgchem.6b00629. Published online May 31, 2016. Copyright 2016 
American Chemical Society.  
 
5.1 Introduction 
The majority of lanthanide chemistry occurs in the 3+ oxidation state, where the relative 
stability of this valency makes metal-based redox chemistry somewhat uncommon. However, 
there is growing interest in the formation, characterization, stabilization, and application of 
complexes containing lanthanides outside of the 3+ oxidation state.73,125,131,185–194 For example, it 
was only in 2013 that the full series of divalent lanthanides was reported.187 The 2+ oxidation 
state for all lanthanides is air sensitive, but the half-filled 4f7 electronic configuration of EuII 
makes it the most stable divalent lanthanide with respect to oxidation. This stability permits the 
study of EuII-containing complexes in aqueous media. The study of aqueous EuII-containing 
complexes is important because they are redox-active complexes relevant to responsive magnetic 
resonance imaging (MRI).73,125,194 
MRI permits non-invasive imaging at high spatial resolution and nearly unlimited depth 
penetration.21,140 Images acquired using MRI can be enhanced through the use of paramagnetic 
complexes (contrast agents) that influence the properties of the nuclei being imaged, which are 
often the protons on water molecules. In addition to highlighting spatial information using 
paramagnetic complexes, contrast agents have been designed to relay molecular information via 
changes in ligand structure or metal oxidation state.33,40,66,69,71–73,125,194–196 However, the majority 
of responsive contrast agents are limited by concentration-dependent responses that make 
distinguishing pre- and post-response states difficult in vivo.124 A promising platform for 
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concentration-independent responsive imaging is the EuIII/II redox couple. EuII is analogous to the 
commonly used GdIII ion in providing longitudinal-relaxation-time (T1)-shortening (positive) 
contrast enhancement.73,97–99,102,125–129 However, unlike GdIII, EuII is redox active under 
physiologically relevant conditions. The EuII ion can undergo a one-electron oxidation to the 3+ 
oxidation state that does not noticeably influence positive contrast enhancement,8,9 and the first 
use of EuII-containing complexes as redox-active contrast agents were reported in vivo.9,10 
In chapter 3, complex 3.6 persisted in the 2+ oxidation state in necrotic (oxygen-
deficient) tumor tissue of a mammary carcinoma after an intratumoral injection.9 The persistence 
of EuII within the necrotic tissue allowed the visualization of necrotic tissue using positive 
contrast enhancement. These data suggested that EuII was oxidized and cleared from non-
necrotic tissue that permitted differentiation of necrotic tissue by 120 min post injection. 
However, the products of oxidation were not detectable by MRI in these studies, which 
motivated the synthesis and characterization of a complex detectable in both the 3+ and 2+ 
oxidation states of Eu. To enable visualization of the Eu-based contrast agent after oxidation, 
EuII was combined with a ligand used for chemical exchange saturation transfer (CEST) contrast 
in MRI. In this chapter, spectroscopic characterization of a EuIII/II tetraglycinate complex is 
reported demonstrating the conversion from the 3+ to 2+ and 2+ to 3+ oxidation states. 
Furthermore, selective suppression of T1 or CEST contrast based on the oxidation state of Eu was 
demonstrated. 
One-electron reduction of a EuIII-containing MRI contrast agent was hypothesized to 
produce a EuII-containing complex that provides positive contrast enhancement in T1-weighted 
MRI, but could be oxidized to the original complex that provides CEST contrast in MRI. 
Demonstrating conversion between oxidation state changes is necessary for a thorough 
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understanding of the solution-phase behavior of each oxidation state. Accordingly, 
luminescence, electron paramagnetic resonance (EPR), nuclear magnetic resonance (NMR), and 
UV–visible spectroscopies were selected to characterize both oxidation states in solution. 
Because the potential applications of these complexes are in aqueous solution, the focus was 
solution characterization for this study. Accordingly, gas- or solid-phase analyses were not 
performed as they do not convey the stability or solution-phase properties of complexes.  
EuIII-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis(acetamidoacetate) (5.1) was 
chosen because it contains chelated EuIII, is commercially available, and is among the tetraamide 
group of contrast agents that are well-characterized with respect to CEST imaging.45,68,70,84,85,196–
200 CEST imaging is an MRI technique that produces contrast via selective radiofrequency 
presaturation of exchangeable protons. During the saturation event, saturated protons on the 
contrast agent exchange with non-saturated water protons (commonly referred to as bulk water 
protons). The saturation event results in a decrease in the bulk water proton signal intensity, and 
this decrease is used to produce contrast in the resulting images. The ability to detect CEST 
contrast is affected by the difference in bound- and bulk-water proton resonance frequencies that 
are often expressed as chemical shifts (units of ppm). Under certain circumstances, relatively 
small diamagnetic chemical shift differences (<3 ppm) can be imaged in vivo;77 however, 
magnetization transfer effects between lipids and other macromolecules broaden the bulk water 
signal in vivo, making contrast agents with relatively large chemical shift offsets desirable.  
Complex 5.1 paramagnetically shifts bound-water protons downfield from bulk water by 
55 ppm, and similar shifts have been imaged in vivo.68 Upon reduction of 5.1 to 5.2, the EuII ion 
was expected to relax the nuclear dipole moments of nearby protons resulting in the complete 
quenching of saturation transfer effects. Instead of CEST contrast, 5.2 was expected to enhance 
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contrast in T1-weighted MRI in accordance with previously reported Eu
II-based complexes:73,97–
99,102,125–129,194 5.2 would provide positive contrast enhancement until it was oxidized to 5.1, at 
which point it would display CEST contrast (Figure 5.1). Here, luminescence, electron 
paramagnetic resonance (EPR), NMR, and UV–visible spectroscopic data characterizing the 
conversion from the 3+ to 2+ and 2+ to 3+ oxidation states of EuIII/II-DOTA-4AmC are reported. 
 
Figure 5.1. Reduction of a commercially available CEST contrast agent (5.1) to the T1-
shortening EuII-containing analogue (5.2) using Zn0 under an atmosphere of N2. Oxidation to the 
3+ oxidation state yields the original complex. The table compares magnetic and spectroscopic 
properties between EuIII- and EuII-containing complexes in the ground state. 
 
5.2 Experimental Procedures 
Commercially available chemicals were of reagent-grade purity or better and were used 
without further purification unless otherwise noted. Phosphate-buffered saline (PBS, 10×) was 
purchased from Fisher BioReagents. 5.1 was purchased from Macrocyclics. Water was purified 
using a PURELAB Ultra Mk2 water purification system (ELGA) and degassed under reduced 
pressure prior to use. 
DOWEX 50Wx8 sulfonic acid resin was converted to the sodium form (DOWEX-Na+) 
by swirling the resin (3 g) in aqueous NaOH (1 M, 10 mL) for 5 min before allowing the resin to 
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settle and decanting the supernatant. Excess NaOH was removed by washing the resin with water 
(10 × 10 mL) until the pH of the washings was 7. Residual solvent was removed from the resin 
under reduced pressure before the resin was brought into a wet glovebox with an atmosphere of 
N2 at which point it was swelled with degassed water. 
5.2.1 Cyclic Voltammetry. Cyclic voltammetry was performed using a three electrode 
setup composed of a glassy carbon working electrode, a platinum wire auxiliary electrode, and a 
Ag/AgCl reference electrode coupled with a Pine Wavenow USB or BAS 50W potentiostats. 
Acquisition parameters for the cyclic voltammogram of EuII/III-DOTA-4AmC (Figure 5.4A) 
were 8 segments, initial potential of –1.4 V (rising), upper potential of 0 V, lower potential of –
1.4 V, final potential of –1.4 V, and a sweep rate of 150 mV/s. Acquisition parameters for the 
cyclic voltammogram of EuII/III-DOTA-4AmC (Figure 5.4B) were 8 segments, initial potential 
of 0.5 V (falling), lower potential of –1.4 V, upper potential of 0.5 V, final potential of 0.5 V, 
and a sweep rate of 100 mV/s. Samples were prepared by dissolving 5.1 and 
tetraethylammonium perchlorate or potassium chloride in water. The pH of the resulting solution 
was 4 and was adjusted to 7 using aqueous NaOH (1 M) for the potassium chloride solution. The 
solutions were sparged with Ar while stirring for 5 min prior to measurements, but were not 
sparged or stirred during the measurements. The standard potential is reported as mean ± 
standard error of 3 independently prepared samples. 
5.2.2 Reduction of 5.1 with Zn0. 5.2 was prepared by vigorously stirring 5.1 (4.0 mg, 4.2 
µmol, 1 equiv) with Zn dust (50.0 mg, 760 µmol, 181 mol equiv, 362 electron equiv) in water 
(0.700 mL) for 1 min to produce a yellow supernatant. Excess Zn dust was removed by filtering 
the mixture through a 0.2 µm hydrophilic filter. The yellow filtrate was mixed with DOWEX-
Na+ (0.1 g) for 1 min before resin was removed by filtering through a 0.2 µm hydrophilic filter, 
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and this process was repeated twice more. This cation-exchange step reduced the concentration 
of ZnII to below the detection limit (<1 ppb) of inductively coupled plasma mass spectrometry 
(ICP–MS). To the remaining yellow filtrate was added 10× PBS and water to bring the final 
concentration to 4 mM Eu in 1× PBS (pH = 7.4 ± 0.2). Subsequent dilutions were performed 
with degassed 1× PBS under an atmosphere of N2. 
5.2.3 Elemental concentration measurements. The concentrations of Eu and Zn were 
determined using ICP–MS or energy dispersive X-ray fluorescence (EDXF) spectroscopy. ICP–
MS measurements were acquired on an Agilent Technologies 7700 series ICP–MS instrument at 
the Lumigen Instrument Center in the Department of Chemistry at Wayne State University. All 
dilutions were performed with aqueous 2% HNO3, which was also used for blank samples during 
calibration. Calibration curves were created using the 153Eu isotope ion count for a 1–200 ppb 
concentration range (diluted from Fluka ICP standard solution, 1000 mg Eu/L) or the 64Zn 
isotope ion count for a 1–200 ppb concentration range (diluted from Fluka ICP standard solution, 
1000 mg Zn/L). EDXF measurements were performed with a Shimadzu EDX-7000 spectrometer 
(Shimadzu Scientific Instruments). Calibration curves were created using the Eu fluorescence 
intensity at 5.845 keV for a 250–1000 ppm concentration range (diluted from Fluka ICP standard 
solution, 1000 mg Eu/L). 
5.2.4 Luminescence spectroscopy. Emission spectra were acquired on a HORIBA Jobin 
Yvon FluoroMax-4 spectrofluorometer and samples were loaded into quartz cuvettes and sealed 
with air-tight caps under an atmosphere of N2. An emission range of 550–725 nm was recorded 
with excitation at 395 nm (1 nm slit widths and 1 nm resolution). 
5.2.5 Minimum detectable concentration of 5.1. The minimum detectable 
concentration of 5.1 was determined by a textbook procedure.201 The absolute emission intensity 
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at 595 nm was measured after excitation at 395 nm (1 nm slit widths and 1 nm resolution) as a 
function of concentration of 5.1 (Figure 5.2). The emission intensity of 5.1 (0.0662 mM) was 
measured using 7 independently prepared samples, and the standard deviation of the emission 
intensities was 2200 units. Using Eq 5.1,201 where σ and m [(3.15 ± 0.01) × 105 units mM–1] are 
the standard deviation and slope of emission intensity vs concentration, respectively, the 
minimum detectable concentration of 5.1 was 20.9 µM. 
 
Figure 5.2. Absolute intensity vs concentration of 5.1. The lowest point was measured 7 times 
using independently prepared samples to determine the minimum detectable concentration as 
described in the experimental section of this chapter. 
 
Eq 5.1  𝑚𝑖𝑛𝑖𝑚𝑢𝑚 𝑑𝑒𝑡𝑒𝑐𝑡𝑎𝑏𝑙𝑒 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 =  
3𝜎
𝑚
 
5.2.6 EPR spectroscopy. EPR spectroscopy was performed on a Bruker EMX X-band 
spectrometer equipped with an Oxford variable-temperature cryostat. EPR samples were 
prepared and sealed with wax under an atmosphere of N2 and were a total volume of 0.3 mL in 
Norell SEPR250S EPR tubes. Aqueous solutions in EPR tubes were frozen in liquid nitrogen 
prior to loading into the sample cavity. EPR spectra were acquired of 5.1 and 5.2 in water. 
Acquisition parameters included a temperature of 110 K, microwave frequency of 9.378654 
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GHz, microwave power of 1.992 mW, modulation frequency of 100 kHz, receiver gain of 30 dB, 
and modulation amplitude of 4.0 G. 
5.2.7 1H-NMR spectroscopy. NMR spectra were acquired on a Varian VNMRS-500 
(499.48 MHz, 11.7 T) in the Lumigen Instrument Center in the Chemistry Department at Wayne 
State University. 
5.2.8 UV–visible spectroscopy and dissociation kinetics. UV–visible spectra were 
acquired on a Shimadzu UVmini-1240 spectrophotometer and samples were loaded into quartz 
cuvettes and sealed with air-tight caps under an atmosphere of N2. Extinction coefficients were 
calculated by dividing the absorbance maxima by the concentration of Eu in the sample for a 1 
cm path length. 
The dissociation rate of 5.2 was calculated by monitoring absorbance at 425 nm as a 
function of time in 0.1 M HCl. This method was chosen based on reports that characterize the 
kinetic stability of similar complexes.202 The absorbance at 425 nm was chosen because it is 
within an absorbance range specific to the EuII-containing complex (415–485 nm), whereas the 
EuII aqua ion (a product of dissociation) does not absorb beyond 415 nm. The UV–visible spectra 
of 5.2 in the 415–485 nm range revealed a decrease in the concentration of 5.2 as a function of 
time. The concomitant formation of the EuII aqua ion absorbance profile ruled out the possibility 
of oxidation being responsible for the loss of 5.2 in this experiment. The absorbance values at 
425 nm as a function of time were used to calculate the dissociation rate based on Eq 5.2,198 
where kd is the calculated first-order dissociation rate constant; t is time; and A0, At, and Ae are 
the absorbance values measured at the start of the reaction (t = 0 s), at time t, and at a final time 
of t = 5400 s, respectively. 
Eq 5.2  𝑘𝑑 =  
1
𝑡
𝑙𝑛 (
𝐴0 − 𝐴𝑒
𝐴𝑡− 𝐴𝑒
) 
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5.2.9 CEST measurements. CEST spectra were acquired on the same spectrometer used 
to acquire 1H-NMR spectra with a sample temperature of 22 °C using a saturation frequency 
array with saturation time of 4 s, a saturation power of 24 µT, a 45 degree observe pulse, an 
initial frequency of 100 ppm (50,000 Hz), and a final frequency of –100 ppm (–50,000 Hz) in 1 
ppm (500 Hz) increments. All samples were in 1× PBS (pH = 7.4 ± 0.2) and included 5.1, 5.2, 
and 5.1 after oxidation of 5.2 by exposure to air. The concentration of Eu in all samples was 4 
mM. 
5.2.10 Relaxivity measurements. T1 measurements were performed on a Bruker 
Minispec mq60 NMR (1.4 T) spectrometer at 37 °C by measuring T1 with inversion recovery 
experiments. Relaxivity was obtained from the slope of 1/T1 vs concentration of either 5.1 or 5.2 
using a linear regression fitting (Figure 5.3). All samples were measured in 1× PBS (pH = 7.4 ± 
0.2). Measurements were performed in triplicate with independently prepared solutions, and the 
relaxivity values are reported as the mean ± standard error of the mean of the independent 
measurements. 
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Figure 5.3. Longitudinal relaxation rate (1/T1) vs concentration of independently prepared 
solutions of 5.2 (top row) or 5.1 (bottom row). 
 
5.2.11 Magnetic resonance imaging. Details for the mouse imaging experiments have 
been described in chapter 3.125 Magnetic resonance imaging was performed with a Varian small 
animal scanner (299.44 MHz, 7.0 T) at Henry Ford Hospital equipped with a 12 cm bore magnet 
and a 38 mm diameter homemade transmit–receive quadrature birdcage coil. All samples, with 
the exception of water, were in 1× PBS (pH = 7.4 ± 0.2) and included 5.1, 5.2, and 5.1 after 
oxidation of 5.2 by exposure air. The concentration of Eu in all samples was 4 mM, with the 
exception of water that was 0 mM. The T1-weighted images were acquired at ambient 
temperature with an echo time of 15.68 ms, repetition time of 800 ms, 13 slices at 1 mm 
thickness, 24 mm × 24 mm field of view, and 4 averages. CEST images were acquired of the 
exact same samples in the same instrument using a magnetization transfer pulse sequence with a 
7 µs (500°) saturation pulse at 55 ppm (16,500 Hz) and –55 ppm (–16,500 Hz). 
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5.3 Results and Discussion 
 5.3.1 Monitoring EuIII/II oxidation state changes and reversibility. To characterize the 
electrochemical potential of 5.1, cyclic voltammetry (Figure 5.4) was performed and a reversible 
one-electron redox couple with an E1/2 of –0.879 ± 0.001 V vs Ag/AgCl (Epa – Epc = 57 mV) was 
observed. This value is inconsistent with a report published during the preparation of this 
chapter.203 The other report claimed the reduction potential of 5.2 to be more positive than the 
reduction potential of the EuII aqua ion. The observation in the other report is unexpected based 
on the presence of four amide functional groups that are known to exhibit delocalization of 
negative charge onto the amide carbonyl oxygens through resonance, but the cyclic 
voltammograms in that manuscript did not scan to a negative enough potential to observe the 
same E1/2 observed in Figure 5.4. To match the conditions of the other report, a separate cyclic 
voltammogram was acquired using potassium chloride as the supporting electrolyte at pH 7. 
Under these conditions, an E1/2 of –0.903 V vs Ag/AgCl was measured. The similar E1/2 values at 
pH 4 and 7 are not surprising given that the electron transfer is not proton coupled. Without 
sparging the solution with Ar, a similar signal to that in the other report was observed;203 
however, this signal was no longer observed after sparging with Ar. Furthermore, the measured 
potentials are consistent with electrochemical studies of EuIII/II-based 
complexes.101,102,126,128,132,133 In those reports, there is a correlation between increasing numbers 
of anionic donor functional groups, such as carboxylates, and increasingly more negative 
reduction potentials. This trend is consistent with what would be expected for electron-rich metal 
ions like EuII.  
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Figure 5.4. Cyclic voltammograms of (A) EuII/III-DOTA-4AmC (3 mM) with 
tetraethylammonium perchlorate (50 mM) as the supporting electrolyte (pH = 4) and (B) EuII/III-
DOTA-4AmC (10 mM) with potassium chloride (100 mM) as the supporting electrolyte (pH = 
7). 
 
In addition to having an E1/2 that is reasonable for a tetraamide complex of EuIII/II, the 
reversible nature of the cyclic voltammograms in this report are consistent with a complex 
exhibiting reversible electron transfer characteristics. This observation is of fundamental 
importance when studying cyclen-based ligands that contain carboxylate groups because of the 
potential for incomplete chelation with these types of complexes. This phenomenon is well-
documented with trivalent lanthanide ions and ligands bearing acetate functional groups on 
cyclen rings.204 The rate of chelation is determined, in part, by the protonation state of the 
ligand.204 While the addition of hydroxide accelerates the rate of chelation, the rate decreases 
with decreasing charge density, which is inversely proportional to ionic radius, of the lanthanide 
being used.204 EuII is larger (ionic radius of ~117 pm) than the largest trivalent lanthanide ion, 
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LaIII (ionic radius of ~103 pm),205 and EuII also has a lower charge than LaIII. The relatively large 
radius and low charge would be expected to cause EuII to form a complex with cyclen-based 
ligands much more slowly than any trivalent lanthanide ion. Therefore, it appears that starting 
from a EuIII-containing precursor is beneficial when studying the electron transfer chemistry of 
poly(amino carboxylate) or poly(amino glycinate) complexes. 
Based on the E1/2 of EuIII/II-DOTA-4AmC, Zn0 (E1/2 = –0.960 V vs Ag/AgCl)206 was 
expected to be a suitable reductant for the EuIII ion in this complex. Upon stirring aqueous 5.1 in 
the presence of Zn0 under an atmosphere of N2, a rapid (<1 min) formation of a yellow color 
from the previously colorless solution was observed. 
To probe for the presence of EuIII in the yellow solution, luminescence spectroscopy was 
performed. The emission spectrum of 5.1 contained the characteristic emission bands from the 
radiative decay of the 5D0 excited state of EuIII to the 7F manifold (Figure 5.5), and the yellow 
solution did not produce observable EuIII-based emissions despite having the same concentration 
of Eu. To quantify the loss of EuIII, the minimum detectable concentration of EuIII using the 
emission of 5.1 at 595 nm was measured. The minimum detectable concentration of 5.1 was 20.9 
µM, indicating that the reduction reaction removed ≥99.0% of the initial EuIII. However, 
bubbling air into the yellow solution resulted in a colorless solution that produced an emission 
spectrum identical to 5.1 in both emission wavelength and absolute intensity. These data suggest 
that the reaction with Zn0 was responsible for the absence of EuIII-based emissions in the yellow 
solution, and that the species responsible for the yellow color reacts with air to reform 5.1. 
Additionally, the complete recovery of the 5D0 to 7F2 emission at 615 nm, which is 
hypersensitive to coordination environment, strongly suggests that the EuIII coordination 
environment of the 5.1 starting material and the complex formed after oxidation of the reduced 
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species are the same. Although luminescence experiments offered evidence for the absence and 
quantitative recovery of EuIII, EPR spectroscopy was used to detect the presence of EuII. 
To verify the formation of EuII, EPR spectra of 5.1 and the yellow solution at equal 
concentrations of Eu were acquired. The EPR spectrum of aqueous 5.1 was consistent with that 
of a diamagnetic sample (Figure 5.5). The diamagnetic behavior of EuIII is expected because of 
its 4f6 ground state electronic configuration where the total angular momentum quantum number 
is 0, causing the effective magnetic moment to be 0 Bohr magnetons despite the presence of 6 
unpaired electrons. The reason EuIII exhibits paramagnetic behavior at non-cryogenic 
temperatures is because excited states with nonzero effective magnetic moments are thermally 
accessible. The EPR spectrum of the yellow solution contained a broad resonance (g-factor = 
1.99) consistent with the presence of EuII.129 Additionally, a lack of precipitation upon the 
addition of phosphate indicates that the EuII species remains chelated in solution. The 
luminescence and EPR data combined with the lack of a precipitate in the presence of phosphate 
indicate that the yellow solution contained 5.2.  
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Figure 5.5. (A) Emission spectra (395 nm excitation) of 5.1 (– –), 5.2 (—), and 5.1 after 
oxidation of 5.2 by exposure to air (··). The dashed and dotted lines overlap exactly. All solutions 
were 2 mM in degassed water under an atmosphere of N2 for EuII or air for the oxidized sample. 
(B) EPR spectra of 5.1 (– –) and 5.2 (—) in H2O at 110 K under an atmosphere of N2. 
 
The chelation of EuII within DOTA-4AmC was further interrogated by acquiring 1H-
NMR spectra of 5.1, 5.2, and 5.1 after oxidation of 5.2 by exposure to air (Figure 5.6). To better 
the chances of observing free ligand in the NMR experiment, the concentration of the complex 
was increased by roughly an order of magnitude relative to all of the other experiments (from 2 
to 23 mM). Signals for the EuIII-containing samples were observed and are consistent with the 
chemical shifts of a previously reported ester analogue of 5.1.197 In the reduced sample, broad 
peaks were observed in the range of 0 to 5 ppm that were assigned to the EuII-containing 
complex, as would be expected for protons of ligands bound to the isotropic EuII ion. Isotropic 
ions, such as EuII and GdIII, are known to shorten relaxation times of nearby nuclei leading to a 
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broadening effect. Anisotropic ions, such as EuIII and TbIII, shift the resonance of nearby nuclei 
without the degree of line broadening observed with isotropic ions. The absence of free ligand198 
in the 5.1 spectrum after oxidation of the reduced sample provides further evidence that no 
detectable dissociation occurred during the reduction or oxidation. This study corroborated the 
absence of 5.2 dissociation indicated by cyclic voltammetry, emission spectroscopy, and 
phosphate solubility observations. The apparent lack of dissociation upon producing 5.2 
motivated the measurement of dissociation kinetics, and the yellow color suggested that UV–
visible spectroscopy could be used to monitor dissociation rates. 
 
Figure 5.6. 1H-NMR spectra of 5.1 (top), 5.2 (middle), and 5.1 after oxidation of 5.2 by 
exposure to air (bottom). All solutions contained 23 mM of complex in degassed D2O under an 
atmosphere of N2 for EuII or air for the oxidized sample. 
 
5.3.2 Conditional kinetic stability of 5.2 in acid. The kinetic stability of a Ln-
containing contrast agent is a critical piece of characterization because low kinetic stability can 
lead to undesired dissociation of the metal ion from the complex. The dissociation rate of 5.1 (8.1 
× 10–6 s–1 corresponding to a dissociation half-life of 237 h) has been reported at pH 1;202 
therefore, the UV–visible spectrum of 5.1 and 5.2 (Figure 5.7) were acquired at pH 1 to enable 
comparisons between the kinetic stabilities of these two complexes. It should be noted that acid-
catalyzed dissociation kinetics are not representative of kinetic stability under physiological 
110 
 
conditions, but these kinetics are of use when comparing complexes whose dissociation was 
measured under the same conditions. The UV–visible spectrum of 5.1 contained a small charge-
transfer band centered at 250 nm (extinction coefficient of 5.16 × 102 M–1 cm–1) that has been 
reported for this complex.198 However, the UV–visible spectrum of the 5.2 at pH 1 at the initial 
time point contained two broad absorptions centered at 250 and 353 nm (extinction coefficients 
of 1.77 × 103 and 9.36 × 102 M–1 cm–1, respectively). These absorptions are consistent with EuII-
based transitions.207 A 33 nm bathochromic shift of the longer wavelength absorption maximum 
of 5.2 relative to EuCl2(aq) (353 vs 320 nm, respectively) caused the absorption profile of 5.2 to 
extend to 485 nm (imparting a yellow color to the solution), while the absorption of EuCl2 only 
extended to 415 nm. Therefore, to measure the kinetic stability of 5.2, absorption at 425 nm was 
measured as a function of time (Figure 5.7).  
The dissociation rate of 5.2 was 9.2(5) × 10–4 s–1, which corresponds to a dissociation 
half-life of 13 min. This dissociation rate of 5.2 is ~110× faster than the dissociation rate of 5.1. 
A faster dissociation is not surprising upon reduction of EuIII to EuII: The EuII ion is a relatively 
soft Lewis acid compared to EuIII; consequently, a relatively weaker binding interaction is 
expected between the oxygen atoms of the amide functional groups and EuII compared to EuIII. 
However, despite a decrease in kinetic stability, the dissociation rate of 5.2 is between the 
dissociation rates of two clinically approved contrast agents, 2.1 and 3.7, that have dissociation 
rates of 1.2 × 10–3 and 2.1 × 10–5 s–1, respectively.202 These data suggest that the kinetic stability 
of 5.2 is not a hindrance for in vitro solution-phase characterization or preclinical in vivo 
imaging, but further investigation is warranted. 
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Figure 5.7. (A) UV–visible absorption spectra of 5.1 (– –), 5.2 at t = 0 s (—) and t = 5400 s (— · 
—), and EuCl2 (— · · —). All samples were measured in 0.1 M HCl. (B) 5.2 absorption at 425 
nm as a function of time in 0.1 M HCl. Error bars represent the standard error of the mean of 
three independent measurements. 
 
5.3.3 In vitro CEST and T1 measurements of EuIII/II-DOTA-4AmC. To evaluate the 
effect of the 2+ oxidation state of Eu on CEST, CEST spectra of 5.1, 5.2, and 5.1 produced from 
the oxidation of 5.2 (Figure 5.8) were acquired. The CEST spectrum of 5.1 matched the reported 
CEST spectrum with a signal 55 ppm downfield from bulk water.208 Upon reduction to 5.2, the 
CEST spectrum was devoid of signal other than from the direct saturation of bulk water. 
Oxidization of 5.2 to 5.1 resulted in the restoration of the original CEST signal at 55 ppm, which 
is consistent with the reversibility observed in the emission spectra. Magnetization-transfer ratio 
asymmetry analyses (MTRasym) revealed the net asymmetry between upfield and downfield 
regions of the CEST spectra (inset of Figure 5.8). The MTRasym for 5.1 and 5.2 revealed 
asymmetries of 22 and 0%, respectively. The lack of CEST contrast for 5.2 is likely due to the 
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ability of the EuII ion to shorten the T1 of nearby protons resulting in the complete quenching of 
saturation transfer effects. CEST modulation was recently reported using silica nanoparticle-,209 
p-nitrophenylamide-,200 N-methylquinolinium-,196 and nitrone-functionalized68 analogues of 5.1 
in which a change in proton- or water-exchange rate or the presence of unpaired electrons on the 
ligand resulted in diminished CEST contrast. These results, however, demonstrate that the 2+ 
oxidation state of europium can suppress CEST contrast below a detectable threshold (inset of 
Figure 5.8) and that oxidation to the 3+ oxidation state results in the recovery of the original 
CEST signal. Furthermore, the complete recovery of the CEST signal, which is specific to 5.1, 
indicates that dissociation of europium ions did not occur during or after the electron transfer 
events. 
 
Figure 5.8. CEST spectra (pH 7.4) and MTRasym plots (inset) of 5.1 (– –), 5.2 (—), and 5.1 after 
oxidation of 5.2 by exposure to air (· ·). 
 
Before performing phantom imaging experiments, the relaxivity (r1) of 5.1 and 5.2 were 
measured using inversion recovery experiments. 5.1 did not display T1 shortening at imaging-
relevant concentrations, while the relaxivity (1.4 T, 37 °C) of 5.2 was 3.72 ± 0.04 mM–1 s–1. The 
lack of detectable relaxivity for 5.1 is expected because, despite EuIII exhibiting a small amount 
of paramagnetic behavior at 37 °C from thermally accessible excited states, the anisotropic 
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nature of the 3+ oxidation state is not conducive with expediting the relaxation of nearby 
nuclei.24 The 2+ oxidation state of europium is isotropic. Accordingly, the relatively efficient 
relaxation of proton nuclei is expected. The relaxivity of 5.2 is similar to clinically approved 
GdIII-containing contrast agents, but lack of positive contrast enhancement for 5.1 demonstrates 
the lack of T1 shortening by the anisotropic 3+ oxidation state of Eu. 
5.3.4 CEST and T1-weighted imaging of EuIII/II-DOTA-4AmC at 7 T. To visualize the 
responsive behavior of 5.1 and 5.2, T1-weighted and CEST phantom images (7 T, ambient 
temperature) were acquired. The T1-weighted image revealed positive contrast enhancement only 
from 5.2, but not from 5.1, 5.1 after oxidation of 5.2, or water (Figure 5.9). The CEST difference 
image (colored red) revealed CEST contrast from 5.1 and 5.1 from the oxidation of 5.2. 5.2 and 
water exhibited no CEST contrast. These images are consistent with observations regarding the 
formation of 5.2 and its ability to completely quench CEST effects. The images in Figure 5.9 
demonstrate the ability to provide selective suppression of T1 shortening or CEST contrast with 
the EuIII/II couple. 
 
Figure 5.9. (A) T1-weighted image and (B) CEST difference image (55 ppm image subtracted 
from the –55 ppm image) of 5 mm diameter NMR tubes containing (1) 5.1, (2) 5.2, (3) 5.1 after 
oxidation of 5.2, and (4) water. 
 
While the reduction potential is negative relative to the EuII aqua ion and to the more 
oxidatively stable EuII-containing cryptates,101 5.2 may be used in a similar manner to reported in 
vivo studies.125 The oxygen-sensitive nature of the complex is expected to permit the 
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differentiation of necrotic tissue while oxidizing elsewhere. Additionally, the transitory behavior 
of EuII in vivo was described in chapter 2.194 Tissues associated with rapid clearance and high 
oxygenation lead to rapid oxidation of EuII, while EuII persists in tissues with relatively slow 
clearance and low oxygenation. 
5.4 Conclusions 
Luminescence, NMR, EPR, and UV–visible spectroscopies were used to monitor changes 
in oxidation state between the commercially available contrast agent, 5.1, and its EuII analogue. 
The hypersensitive emissions, reversible electrochemistry, reversible CEST signal at 55 ppm, 
and stability in the presence of phosphate indicate that Eu remains chelated in both oxidation 
states. The kinetic stability of 5.2 was lower than that of 5.1 but in the range of the kinetic 
stabilities of clinically approved contrast agents. The assignment of 5.2 is based on rigorous 
solution-phase characterization and use of 5.1 as the starting material. These data does not 
provide insight into the coordination number or geometry of 5.2, but it does unambiguously 
defend the assignment of a complex with a molecular form that can be described as 5.2. This 
report highlights the unique magnetic and spectroscopic properties of the 3+ and 2+ oxidation 
states of Eu within the ligand framework of DOTA-4AmC. These results are expected to be 
applicable to a wide range of chemists interested in expanding the scope of lanthanide redox 
chemistry. 
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CHAPTER 6: CONCLUSIONS AND FUTURE DIRECTIONS 
Conclusions 
 The EuII/III redox couple is an ideal platform from which redox-responsive complexes can 
be designed. The change in electronic configuration from 4f7 to 4f6 causes large differences in 
magnetic and spectroscopic properties between the 2+ and 3+ oxidation states of europium. For 
EuII, the 4f7 ground state configuration is isotropic (L = 0), paramagnetic (µeff ≈ 7.9 Bohr 
magnetons), and has low-lying 4f65d1 excited states that permit f–d transitions with UV–visible 
light. For EuIII, the 4f6 ground state configuration is anisotropic (L = 3), diamagnetic (µeff = 0), 
and displays typical LnIII luminescence arising from f–f transitions. From these examples it 
becomes clear that one electron drastically alters the properties of the 2+ and 3+ oxidation states 
of europium, where EuII exhibits positive contrast enhancement and EuIII does not. This thesis 
describes research that capitalizes on the change in magnetic properties between these two 
oxidation states using a variety of ligand frameworks and techniques. The ability to differentiate 
europium oxidation states in response to redox stimuli has implications in detecting diseased 
tissue. This thesis also describes the first report of a divalent lanthanide in vivo, which motivates 
further studies. 
 The use of T1-weighted MRI, CEST imaging, and NMR spectroscopy demonstrated that 
positive contrast enhancement was rapidly lost upon exposing EuII-containing complexes to 
molecular oxygen within air while CEST can be used to detect the complex after oxidation. The 
demonstration of EuII-based oxidation response represented a new avenue for responsive contrast 
agents. However, at the onset of this doctoral work, nothing was known regarding the behavior 
of EuII in vivo including practical routes of administration. In chapter 2, the transitory behavior 
of EuII was described after intravenous, intraperitoneal, and subcutaneous injections. The 
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longevity of positive contrast enhancement directly correlated with tissue oxygenation and rates 
of diffusion. These data demonstrated that EuII-based positive contrast enhancement is sensitive 
to the route of administration.  
 In chapter 3, the loss of EuII-based positive contrast enhancement to differentiate necrotic 
from non-necrotic tissue in a mammary carcinoma model was described. Histological staining 
revealed a correlation between specific regions of the tumor that contained EuII that were also 
necrotic. Oxygen deprivation in necrotic tissue allowed EuII to persist in necrotic regions of the 
tumor while oxidizing and clearing elsewhere. The loss of positive contrast enhancement 
coincided with the loss of europium from the tumor itself, but it was not clear whether or not 
oxidation and clearance occurred simultaneously or sequentially. Regardless, the ability of EuII 
to differentiate necrotic tumor tissue was demonstrated. 
 In chapter 4, the combination of EuII-based positive contrast enhancement with CEST 
was described. CEST at 1.2 ppm was observed before and after oxidation likely due to exchange 
between hydroxyl protons of cholesterol within the lipid bilayer. Dynamic light scattering was 
used to determine that size and polydispersity of the liposomes were unchanged by oxidation of 
EuII, indicating that the liposome membrane was not damaged. While these results demonstrated 
that positive contrast enhancement and CEST could be coupled to enable indirect detection of 
EuIII after oxidation, the CEST signal at 1.2 ppm was not ideal because of the proximity to the 
bulk water proton resonance. 
 In chapter 5, the reduction of a well characterized, commercially available EuIII-
containing poly(amino glycinate) complex with Zn dust was described. The reduction potential 
of the complex was measured at pH 4 and 7 using cyclic voltammetry. The similarity in 
reduction potential at both pH values indicated the electron transfer process was not proton 
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coupled. Changes in oxidation state were monitored using luminenesnce, EPR, UV–visible, and 
NMR spectroscopies. These data, coupled with the lack of precipitation in the presence of 
phosphate, strongly indicated that EuII remained chelated during electron transfer processes. 
Furthermore, an acid-catalyzed dissociation experiment was used to measure the kinetic stability 
of the EuII-containing complex, which was in the range of clinically approved GdIII-containing 
complexes. The reversibility of the complex was demonstrated using T1-weighted and CEST 
imaging in which the 2+ oxidation state produced positive contrast enhancement and no CEST 
effect, while the 3+ oxidation state produced CEST effect and no observable positive contrast 
enhancement. 
Future Directions 
The kinetic stability of a EuII/III-containing complex is important. While dissociation of 
EuIII from cryptates can be addressed by liposome encapsulation, this route is limited by time-
intensive purification. The ability of the poly(amino glycinate) complex in chapter 5 to be 
kinetically stable with europium in both oxidation states is a promising direction to avoid issues 
associated with dissociation of the complex. Additionally, starting with kinetically stable EuIII-
containing complexes ensures that the 3+ oxidation state is stable. Therefore, when considering a 
new EuII-containing complex for responsive MRI, whether it be a cryptate or cyclen-based 
macrocyclic complex, it is advisable to consider the kinetic stability of its EuIII-containing 
analogue. For new complexes, this will involve measuring the kinetic stability and comparing to 
relatively kinetically stable complexes under identical conditions. 
Complexes combining functional groups conducive to kinetic (carboxylate and amide) 
and oxidative (polyether, polythioether, and thiol) stability can be envisioned to balance these 
stabilities. If the donor atoms are primarily carboxylate or amide oxygens, the kinetic and 
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oxidative stabilities are expected to increase and decrease, respectively. If the donor atoms are 
primarily polyether, polythioether, or thiols, the kinetic and oxidative stabilities are expected to 
decrease and increase, respectively. Complexes with a mixture of these functional groups are 
expected to have moderate kinetic and oxidative stability. However, the payoff in increased 
oxidative stability must outweigh the limitation of decreased kinetic stability because, as of now, 
all EuII-containing complexes are prone to oxidation in air. Accordingly, given that all EuII-
containing complexes are oxidized by air, kinetic stability should be the top priority. If a EuII-
containing complex can be made air-stable for even a relatively short amount of time, such as 
hours with negligible oxidation, a loss in kinetic stability would be justified. 
While EuII-based positive contrast enhancement was informative during in vivo studies, 
the species responsible for oxidizing EuII are currently unknown. One of the most likely 
contributors to oxidation is molecular oxygen, but the scope of biologically relevant oxidants 
capable of oxidizing EuII-containing complexes is not known. Potential oxidants worth exploring 
include nitric oxide, hydrogen peroxide, bromate, and oxidized glutathione. Measuring the rate 
of oxidation can be accomplished using UV–visible absorptions specific to EuII. The rate of 
oxidation can be viewed as a function of the EuII reduction potential, oxidant strength, and pH. 
These apparent thermodynamic driving forces and oxidation kinetics will shed light on the nature 
of EuII oxidation chemistry. 
In addition to uncovering oxidants capable of reacting with EuII, the products of oxidation 
are equally important from a toxicity standpoint. Assuming the complex itself does not dissociate 
to release EuIII, the species it reduced may or may not be toxic depending on its location and 
concentration. A likely product of the reaction between EuII and molecular oxygen is superoxide. 
Furthermore, if hydrogen peroxide is an intermediate in the reduction of oxygen to water, it is 
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possible that EuII could react with hydrogen peroxide resembling Fenton chemistry to generate 
hydroxyl radical and hydroxide.  
At first glance, the potential formation of superoxide or hydroxyl radicals in vivo does not 
necessarily bode well for EuII-containing complexes. However, this chemistry may be exploited 
through direct injections described in chapters 2 and 3 of this thesis. Specifically in chapter 3 
where intratumoral injections were described, the effect of EuII oxidation within tumor tissue was 
not explored. If the majority of EuII oxidized in tumor tissue, it may have generated reactive 
oxygen species such as superoxide. A bolus of superoxide might damage tissue near the site of 
injection where oxidation of EuII occurs. Perhaps the oxidation of EuII could be used for 
therapeutic purposes when directly injected into tumors. The most promising path forward for 
such a project would involve the poly(amino glycinate) complex of chapter 5 because of its 
robust kinetic stability in both oxidation states of europium and the ability to detect positive 
contrast or CEST depending on the oxidation state of europium. This experiment would involve 
the mammary carcinoma model described in chapter 3, where the size of the tumor can be 
monitored as a function of time using caliper measurements. Tumor growth could be compared 
between mice that received intratumoral injections of the EuII-containing complex, the EuIII-
containing complex, and a phosphate-buffered saline blank. The hypothesis would be that if the 
oxidation of EuII inside of tumors produces reactive oxygen species, then the tumor growth will 
be diminished when injected with the EuII-containing complex when compared to the control 
injections. Furthermore, MRI could be used to observe the behavior of the poly(amino glycinate) 
complex after intratumoral injection. Even if the growth of tumors is not diminished, 
fundamental information would be uncovered that might guide the path forward for EuII-
containing complexes for responsive MRI. 
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APPENDIX A 
 
1H- AND 13C- NMR SPECTRA 
 
Figure A1. 1H-NMR spectrum of 3.2. 
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Figure A2. 13C-NMR spectrum of 3.2. 
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Figure A3. 1H-NMR spectrum of 3.3. 
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Figure A4. 13C-NMR spectrum of 3.3. 
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Figure A5. 1H-NMR spectrum of 3.4. 
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Figure A6. 13C-NMR spectrum of 3.4. 
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Figure A7. 1H-NMR spectrum of 3.5. 
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Figure A8. 13C-NMR spectrum of 3.5. 
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APPENDIX B 
Crystallography Data for Complex 3.6 
Table B1. Data collection and structure refinement for 3.6. 
 Theta range for data collection  1.89 to 37.04° 
 Index ranges  –17 ≤ h ≤ 17, –30 ≤ k ≤ 30, –23 ≤ l ≤ 23 
 Reflections collected  146813 
 Independent reflections  12933 [R(int) = 0.0381] 
 Coverage of independent reflections  99.0% 
 Absorption correction  multi-scan 
 Refinement method  Full-matrix least-squares on F2 
 Refinement program  SHELXL-2014/7 (Sheldrick, 2014) 
 Function minimized  Σ w(Fo2 – Fc2)2 
 Data / restraints / parameters  12933 / 0 / 307 
 Goodness-of-fit on F2  1.044 
 Δ/σmax  0.004 
 Final R indices 
 10835 data;  
 I>2σ(I) 
 R1 = 0.0248, wR2 = 0.0582 
  all data  R1 = 0.0348, wR2 = 0.0615 
 Weighting scheme 
 w = 1/[σ2(Fo2) + (0.0287P)2 + 1.8719P] 
 where P = (Fo
2 + 2Fc
2)/3 
 Largest diff. peak and hole  3.469 and –1.129 eÅ–3 
 R.M.S. deviation from mean  0.120 eÅ–3 
 
Table B2. Atomic coordinates and equivalent isotropic atomic displacement parameters (Å2) for 
3.6. 
 x/a y/b z/c U(eq) 
 Eu1  0.72371(2)  0.88852(2)  0.80721(2)  0.00950(2) 
 Cl00  0.85158(4)  0.14111(2)  0.48492(3)  0.01885(7) 
 Cl1  0.71290(4)  0.03621(2)  0.87236(3)  0.01922(7) 
 F1  0.72587(16)  0.86595(13)  0.29102(11)  0.0559(5) 
 O1  0.89236(11)  0.86458(8)  0.96842(9)  0.0191(2) 
 O2  0.64902(11)  0.84955(7)  0.97661(8)  0.0162(2) 
 O3  0.55957(11)  0.92393(7)  0.63940(8)  0.0161(2) 
 O4  0.79636(11)  0.93805(7)  0.63314(8)  0.0173(2) 
 O5  0.59323(11)  0.76285(6)  0.75252(9)  0.0158(2) 
 O6  0.85365(11)  0.77825(6)  0.74146(9)  0.0159(2) 
 N1  0.98346(12)  0.91368(8)  0.79521(10)  0.0141(2) 
 N2  0.46156(13)  0.88466(7)  0.81690(10)  0.0148(2) 
 C1  0.04613(15)  0.93161(10)  0.89633(12)  0.0193(3) 
 C2  0.02606(16)  0.87158(11)  0.97026(13)  0.0201(3) 
 C3  0.85758(17)  0.80576(10)  0.02992(13)  0.0213(3) 
 C4  0.73581(17)  0.82887(11)  0.06290(12)  0.0208(3) 
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 C5  0.52310(16)  0.86173(11)  0.99722(13)  0.0206(3) 
 C6  0.45400(16)  0.91150(10)  0.91777(13)  0.0195(3) 
 C7  0.40528(15)  0.94224(9)  0.74564(13)  0.0182(3) 
 C8  0.42418(15)  0.92592(10)  0.64135(13)  0.0190(3) 
 C9  0.59385(16)  0.90965(9)  0.54876(12)  0.0172(3) 
 C10  0.5098(2)  0.88917(10)  0.46459(13)  0.0243(3) 
 C11  0.5574(2)  0.87445(12)  0.37704(15)  0.0329(5) 
 C12  0.6852(3)  0.88084(13)  0.37640(14)  0.0342(5) 
 C13  0.7719(2)  0.90231(12)  0.45878(13)  0.0259(4) 
 C14  0.72431(16)  0.91724(10)  0.54551(11)  0.0178(3) 
 C15  0.92157(15)  0.96867(10)  0.62833(12)  0.0190(3) 
 C16  0.98334(15)  0.98154(9)  0.73384(13)  0.0181(3) 
 C17  0.40019(15)  0.81081(9)  0.79683(13)  0.0182(3) 
 C18  0.49404(15)  0.74648(9)  0.80951(13)  0.0173(3) 
 C19  0.67432(16)  0.69958(9)  0.74779(13)  0.0175(3) 
 C20  0.77504(15)  0.72189(9)  0.68785(12)  0.0182(3) 
 C21  0.95770(15)  0.79704(9)  0.69101(12)  0.0173(3) 
 C22  0.04719(15)  0.84970(9)  0.75482(12)  0.0168(3) 
  
Table B3. Bond lengths (Å) for 3.6. 
Eu1-O6  2.6432(11) Eu1-O1  2.6490(12) 
Eu1-O2  2.6576(11) Eu1-O5  2.6827(11) 
Eu1-O3  2.7304(11) Eu1-O4  2.7616(11) 
Eu1-Cl1  2.7931(4) Eu1-N2  2.8107(14) 
Eu1-N1  2.8269(13) F1-C12  1.334(2) 
O1-C2  1.423(2) O1-C3  1.430(2) 
O2-C5  1.427(2) O2-C4  1.4278(19) 
O3-C9  1.370(2) O3-C8  1.444(2) 
O4-C14  1.369(2) O4-C15  1.450(2) 
O5-C19  1.4288(19) O5-C18  1.4362(19) 
O6-C21  1.4322(19) O6-C20  1.4342(19) 
N1-C1  1.473(2) N1-C16  1.474(2) 
N1-C22  1.479(2) N2-C6  1.475(2) 
N2-C7  1.477(2) N2-C17  1.478(2) 
C1-C2  1.512(2) C1-H2  0.99 
C1-H1  0.99 C2-H34  0.99 
C2-H35  0.99 C3-C4  1.494(3) 
C3-H4  0.99 C3-H3  0.99 
C4-H33  0.99 C4-H32  0.99 
C5-C6  1.503(3) C5-H31  0.99 
C5-H5  0.99 C6-H30  0.99 
C6-H29  0.99 C7-C8  1.500(2) 
C7-H6  0.99 C7-H16  0.99 
C8-H15  0.99 C8-H14  0.99 
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C9-C10  1.391(2) C9-C14  1.401(2) 
C10-C11  1.397(3) C10-H13  0.95 
C11-C12  1.364(4) C11-H7  0.95 
C12-C13  1.393(3) C13-C14  1.386(2) 
C13-H8  0.95 C15-C16  1.506(2) 
C15-H12  0.99 C15-H11  0.99 
C16-H9  0.99 C16-H10  0.99 
C17-C18  1.514(2) C17-H17  0.99 
C17-H28  0.99 C18-H26  0.99 
C18-H27  0.99 C19-C20  1.501(2) 
C19-H25  0.99 C19-H18  0.99 
C20-H24  0.99 C20-H23  0.99 
C21-C22  1.513(2) C21-H21  0.99 
C21-H22  0.99 C22-H19  0.99 
C22-H20  0.99   
 
Table B4. Bond angles (°) for 3.6. 
O6-Eu1-O1 80.89(4) O6-Eu1-O2 110.19(4) 
O1-Eu1-O2 59.17(4) O6-Eu1-O5 63.65(4) 
O1-Eu1-O5 110.46(4) O2-Eu1-O5 79.16(4) 
O6-Eu1-O3 100.69(4) O1-Eu1-O3 175.37(4) 
O2-Eu1-O3 123.71(4) O5-Eu1-O3 74.07(4) 
O6-Eu1-O4 73.36(4) O1-Eu1-O4 121.69(4) 
O2-Eu1-O4 176.40(4) O5-Eu1-O4 103.29(4) 
O3-Eu1-O4 55.18(3) O6-Eu1-Cl1 149.60(3) 
O1-Eu1-Cl1 86.75(3) O2-Eu1-Cl1 86.35(3) 
O5-Eu1-Cl1 146.53(3) O3-Eu1-Cl1 89.80(3) 
O4-Eu1-Cl1 90.20(3) O6-Eu1-N2 124.92(4) 
O1-Eu1-N2 120.19(4) O2-Eu1-N2 61.21(4) 
O5-Eu1-N2 61.31(4) O3-Eu1-N2 62.50(4) 
O4-Eu1-N2 117.51(4) Cl1-Eu1-N2 85.26(3) 
O6-Eu1-N1 62.07(4) O1-Eu1-N1 62.28(4) 
O2-Eu1-N1 121.36(4) O5-Eu1-N1 125.70(4) 
O3-Eu1-N1 114.52(4) O4-Eu1-N1 59.42(4) 
Cl1-Eu1-N1 87.58(3) N2-Eu1-N1 172.22(4) 
C2-O1-C3 113.82(13) C2-O1-Eu1 122.94(10) 
C3-O1-Eu1 113.87(9) C5-O2-C4 112.35(12) 
C5-O2-Eu1 123.38(9) C4-O2-Eu1 123.09(9) 
C9-O3-C8 115.39(12) C9-O3-Eu1 119.48(9) 
C8-O3-Eu1 119.81(9) C14-O4-C15 117.00(13) 
C14-O4-Eu1 118.33(10) C15-O4-Eu1 122.88(9) 
C19-O5-C18 111.28(12) C19-O5-Eu1 112.68(9) 
C18-O5-Eu1 114.22(9) C21-O6-C20 110.48(12) 
C21-O6-Eu1 118.25(9) C20-O6-Eu1 113.81(9) 
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C1-N1-C16 108.41(13) C1-N1-C22 110.65(13) 
C16-N1-C22 112.47(13) C1-N1-Eu1 106.36(9) 
C16-N1-Eu1 104.49(9) C22-N1-Eu1 114.04(9) 
C6-N2-C7 108.36(13) C6-N2-C17 112.12(13) 
C7-N2-C17 112.19(13) C6-N2-Eu1 103.66(9) 
C7-N2-Eu1 104.68(9) C17-N2-Eu1 115.14(9) 
N1-C1-C2 112.54(14) N1-C1-H2 109.1 
C2-C1-H2 109.1 N1-C1-H1 109.1 
C2-C1-H1 109.1 H2-C1-H1 107.8 
O1-C2-C1 107.22(13) O1-C2-H34 110.3 
C1-C2-H34 110.3 O1-C2-H35 110.3 
C1-C2-H35 110.3 H34-C2-H35 108.5 
O1-C3-C4 106.90(14) O1-C3-H4 110.3 
C4-C3-H4 110.3 O1-C3-H3 110.3 
C4-C3-H3 110.3 H4-C3-H3 108.6 
O2-C4-C3 107.43(13) O2-C4-H33 110.2 
C3-C4-H33 110.2 O2-C4-H32 110.2 
C3-C4-H32 110.2 H33-C4-H32 108.5 
O2-C5-C6 108.31(13) O2-C5-H31 110.0 
C6-C5-H31 110.0 O2-C5-H5 110.0 
C6-C5-H5 110.0 H31-C5-H5 108.4 
N2-C6-C5 113.07(14) N2-C6-H30 109.0 
C5-C6-H30 109.0 N2-C6-H29 109.0 
C5-C6-H29 109.0 H30-C6-H29 107.8 
N2-C7-C8 113.04(14) N2-C7-H6 109.0 
C8-C7-H6 109.0 N2-C7-H16 109.0 
C8-C7-H16 109.0 H6-C7-H16 107.8 
O3-C8-C7 107.76(13) O3-C8-H15 110.2 
C7-C8-H15 110.2 O3-C8-H14 110.2 
C7-C8-H14 110.2 H15-C8-H14 108.5 
O3-C9-C10 124.80(16) O3-C9-C14 114.58(14) 
C10-C9-C14 120.62(16) C9-C10-C11 119.2(2) 
C9-C10-H13 120.4 C11-C10-H13 120.4 
C12-C11-C10 119.01(19) C12-C11-H7 120.5 
C10-C11-H7 120.5 F1-C12-C11 116.7(2) 
F1-C12-C13 120.0(2) C11-C12-C13 123.39(19) 
C14-C13-C12 117.5(2) C14-C13-H8 121.2 
C12-C13-H8 121.2 O4-C14-C13 124.95(16) 
O4-C14-C9 114.76(14) C13-C14-C9 120.27(16) 
O4-C15-C16 106.21(12) O4-C15-H12 110.5 
C16-C15-H12 110.5 O4-C15-H11 110.5 
C16-C15-H11 110.5 H12-C15-H11 108.7 
N1-C16-C15 112.42(14) N1-C16-H9 109.1 
C15-C16-H9 109.1 N1-C16-H10 109.1 
C15-C16-H10 109.1 H9-C16-H10 107.9 
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N2-C17-C18 113.13(13) N2-C17-H17 109.0 
C18-C17-H17 109.0 N2-C17-H28 109.0 
C18-C17-H28 109.0 H17-C17-H28 107.8 
O5-C18-C17 108.05(13) O5-C18-H26 110.1 
C17-C18-H26 110.1 O5-C18-H27 110.1 
C17-C18-H27 110.1 H26-C18-H27 108.4 
O5-C19-C20 107.56(13) O5-C19-H25 110.2 
C20-C19-H25 110.2 O5-C19-H18 110.2 
C20-C19-H18 110.2 H25-C19-H18 108.5 
O6-C20-C19 108.38(13) O6-C20-H24 110.0 
C19-C20-H24 110.0 O6-C20-H23 110.0 
C19-C20-H23 110.0 H24-C20-H23 108.4 
O6-C21-C22 109.30(13) O6-C21-H21 109.8 
C22-C21-H21 109.8 O6-C21-H22 109.8 
C22-C21-H22 109.8 H21-C21-H22 108.3 
N1-C22-C21 114.37(13) N1-C22-H19 108.7 
C21-C22-H19 108.7 N1-C22-H20 108.7 
C21-C22-H20 108.7 H19-C22-H20 107.6 
 
Table B5. Anisotropic atomic displacement parameters (Å2) for 3.6. 
 U11 U22 U33 U23 U13 U12 
Eu1 0.00922(3) 0.00950(3) 0.00978(3) -0.00072(2) 0.00156(2) 0.00028(2) 
Cl00 0.01749(16) 0.02056(17) 0.01868(16) -0.00237(14) 0.00335(12) 0.00031(13) 
Cl1 0.02206(17) 0.01122(14) 0.02576(18) -0.00374(13) 0.00810(14) -0.00116(12) 
F1 0.0571(11) 0.0865(13) 0.0256(7) -0.0112(8) 0.0111(7) 0.0158(9) 
O1 0.0136(5) 0.0241(6) 0.0187(5) 0.0084(5) -0.0007(4) -0.0011(4) 
O2 0.0162(5) 0.0205(5) 0.0125(4) 0.0014(4) 0.0038(4) 0.0006(4) 
O3 0.0129(5) 0.0217(5) 0.0130(5) 0.0006(4) 0.0002(4) 0.0006(4) 
O4 0.0142(5) 0.0254(6) 0.0126(5) 0.0029(4) 0.0037(4) 0.0014(4) 
O5 0.0148(5) 0.0121(5) 0.0212(5) 0.0003(4) 0.0047(4) -0.0008(4) 
O6 0.0156(5) 0.0143(5) 0.0191(5) -0.0043(4) 0.0066(4) -0.0016(4) 
N1 0.0125(5) 0.0148(5) 0.0151(5) -0.0001(4) 0.0024(4) 0.0001(4) 
N2 0.0122(5) 0.0154(6) 0.0172(6) 0.0011(5) 0.0033(4) 0.0006(4) 
C1 0.0139(6) 0.0237(8) 0.0193(7) -0.0027(6) -0.0001(5) -0.0055(5) 
C2 0.0136(6) 0.0282(8) 0.0170(7) 0.0012(6) -0.0021(5) -0.0006(6) 
C3 0.0210(7) 0.0231(8) 0.0183(7) 0.0080(6) -0.0014(6) -0.0011(6) 
C4 0.0251(8) 0.0257(8) 0.0108(6) 0.0036(6) 0.0011(5) -0.0018(6) 
C5 0.0208(7) 0.0249(8) 0.0183(7) 0.0005(6) 0.0104(6) 0.0004(6) 
C6 0.0175(7) 0.0222(7) 0.0208(7) -0.0005(6) 0.0090(6) 0.0031(6) 
C7 0.0122(6) 0.0182(7) 0.0240(7) 0.0038(6) 0.0026(5) 0.0029(5) 
C8 0.0127(6) 0.0224(8) 0.0207(7) 0.0049(6) -0.0013(5) -0.0004(5) 
C9 0.0225(7) 0.0154(6) 0.0128(6) -0.0001(5) -0.0004(5) 0.0019(5) 
C10 0.0316(9) 0.0217(8) 0.0170(7) -0.0015(6) -0.0048(6) -0.0020(7) 
C11 0.0507(13) 0.0302(10) 0.0156(8) -0.0054(7) -0.0020(8) 0.0032(9) 
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C12 0.0558(14) 0.0339(11) 0.0131(7) -0.0034(7) 0.0058(8) 0.0125(9) 
C13 0.0324(9) 0.0317(9) 0.0148(7) 0.0024(6) 0.0076(6) 0.0116(7) 
C14 0.0233(7) 0.0188(7) 0.0114(6) 0.0017(5) 0.0029(5) 0.0058(6) 
C15 0.0169(7) 0.0217(7) 0.0202(7) 0.0067(6) 0.0080(5) 0.0026(6) 
C16 0.0154(6) 0.0157(7) 0.0240(7) 0.0027(6) 0.0060(5) -0.0017(5) 
C17 0.0127(6) 0.0189(7) 0.0232(7) 0.0020(6) 0.0035(5) -0.0017(5) 
C18 0.0152(6) 0.0140(6) 0.0227(7) 0.0017(5) 0.0035(5) -0.0039(5) 
C19 0.0187(7) 0.0112(6) 0.0228(7) -0.0023(5) 0.0035(5) -0.0004(5) 
C20 0.0214(7) 0.0137(6) 0.0200(7) -0.0063(5) 0.0047(6) -0.0008(5) 
C21 0.0174(7) 0.0168(7) 0.0193(7) -0.0011(5) 0.0081(5) 0.0022(5) 
C22 0.0127(6) 0.0175(7) 0.0210(7) 0.0012(5) 0.0047(5) 0.0029(5) 
 
Table B6. Hydrogen atomic coordinates and isotropic atomic displacement parameters (Å2) for 
3.6. 
 x/a y/b z/c U(eq) 
H2 1.0122 0.9797 0.9171 0.023 
H1 1.1387 0.9380 0.8963 0.023 
H34 1.0623 0.8235 0.9521 0.024 
H35 1.0684 0.8858 1.0374 0.024 
H4 0.9250 0.7983 1.0878 0.026 
H3 0.8457 0.7583 0.9923 0.026 
H33 0.7005 0.7869 1.0974 0.025 
H32 0.7509 0.8718 1.1091 0.025 
H31 0.5266 0.8858 1.0628 0.025 
H5 0.4778 0.8134 0.9982 0.025 
H30 0.3633 0.9148 0.9262 0.023 
H29 0.4906 0.9625 0.9258 0.023 
H6 0.4441 0.9913 0.7658 0.022 
H16 0.3128 0.9459 0.7480 0.022 
H15 0.3851 0.8772 0.6196 0.023 
H14 0.3835 0.9653 0.5962 0.023 
H13 0.4211 0.8853 0.4666 0.029 
H7 0.5017 0.8602 0.3188 0.04 
H8 0.8602 0.9066 0.4557 0.031 
H12 0.9143 1.0163 0.5910 0.023 
H11 0.9725 0.9331 0.5952 0.023 
H9 1.0723 0.9983 0.7346 0.022 
H10 0.9373 1.0220 0.7629 0.022 
H17 0.3535 0.8103 0.7283 0.022 
H28 0.3372 0.8034 0.8422 0.022 
H26 0.5306 0.7405 0.8802 0.021 
H27 0.4505 0.6993 0.7861 0.021 
H25 0.6245 0.6568 0.7162 0.021 
H18 0.7140 0.6845 0.8152 0.021 
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H24 0.8274 0.6779 0.6764 0.022 
H23 0.7349 0.7417 0.6228 0.022 
H21 0.9250 0.8213 0.6270 0.021 
H22 1.0039 0.7510 0.6774 0.021 
H19 1.0946 0.8209 0.8107 0.02 
H20 1.1101 0.8693 0.7150 0.02 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
135 
 
APPENDIX C 
PERMISSION/LICENSE AGREEMENTS FOR COPYRIGHTED MATERIALS 
 
 
 
 
 
 
 
 
 
 
 
136 
 
 JOHN WILEY AND SONS LICENSE TERMS AND 
CONDITIONS  
Nov 04, 2014  
This is a License Agreement between Levi A Ekanger ("You") and John Wiley and Sons ("John Wiley 
and Sons") provided by Copyright Clearance Center ("CCC"). The license consists of your order 
details, the terms and conditions provided by John Wiley and Sons, and the payment terms and 
conditions.  
All payments must be made in full to CCC. For payment instructions, please see 
information listed at the bottom of this form.  
License Number  3474840587379  
License date  Sep 23, 2014  
Order Content Publisher  John Wiley and Sons  
Order Content Publication  Angewandte Chemie  
Order Content Title  Novel pH-Reporter MRI Contrast Agents  
Licensed copyright line  © 2002 WILEY-VCH Verlag GmbH & Co. 
KGaA, Weinheim  
Order Content Author  Silvio Aime,Daniela Delli Castelli,Enzo 
Terreno  
Order Content Date  Nov 12, 2002  
Start page  4510  
End page  4512  
Type of use  Journal/Magazine  
Requestor type  University/Academic  
Is the reuse sponsored by or associated with a 
pharmaceutical or medical products company?  
no  
Format  Electronic  
Portion  Figure/table  
Number of figures/tables  2  
Original Wiley figure/table number(s)  Figure 2 Figure 3  
Will you be translating?  No  
Circulation  1  
Title of new article  Overcoming concentration-dependence in 
responsive contrast agents for MRI  
Publication the new article is in  Metallomics  
 
You are hereby granted a personal, non-exclusive, non-sub licensable (on a stand-alone basis), non-
transferable, worldwide, limited license to reproduce the Wiley Materials for the purpose specified in 
the licensing process. This license is for a one-time use only and limited to any maximum distribution 
number specified in the license. The first instance of republication or reuse granted by this licence must 
be completed within two years of the date of the grant of this licence (although copies prepared before 
the end date may be distributed thereafter). The Wiley Materials shall not be used in any other manner 
or for any other purpose, beyond what is granted in the license. Permission is granted subject to an 
appropriate acknowledgement given to the author, title of the material/book/journal and the publisher. 
You shall also duplicate the copyright notice that appears in the Wiley publication in your use of the 
Wiley Material. Permission is also granted on the understanding that nowhere in the text is a previously 
published source acknowledged for all or part of this Wiley Material. Any third party content is expressly 
excluded from this permission.  
137 
 
 
 
PERMISSION/LICENSE IS GRANTED FOR YOUR ORDER AT NO CHARGE 
 
This type of permission/license, instead of the standard Terms and Conditions, is sent to you 
because no fee is being charged for your order. Please note the following: 
 
 Permission is granted for your request in both print and electronic formats, and 
translations. 
 If figures and/or tables were requested, they may be adapted or used in part. 
 Please print this page for your records and send a copy of it to your publisher/graduate 
school. 
 Appropriate credit for the requested material should be given as follows: “Reprinted 
(adapted) with permission from (COMPLETE REFERENCE CITATION). Copyright 
(YEAR) American Chemical Society.” Insert appropriate information in place of the 
capitalized words. 
 One-time permission is granted only for the use specified in your request. No additional 
uses are granted (such as derivative works or other editions). For any other uses, please 
submit a new request. 
 
 
If credit is given to another source for the material you requested, permission must be obtained 
from that source. 
 
 
Copyright © 2015 Copyright Clearance Center, Inc. All Rights Reserved. Privacy statement. 
Terms and Conditions. 
Comments? We would like to hear from you. E-mail us at customercare@copyright.com 
 
 
 
138 
 
 JOHN WILEY AND SONS LICENSE TERMS AND 
CONDITIONS  
Nov 04, 2014  
This is a License Agreement between Levi A Ekanger ("You") and John Wiley and Sons ("John Wiley 
and Sons") provided by Copyright Clearance Center ("CCC"). The license consists of your order 
details, the terms and conditions provided by John Wiley and Sons, and the payment terms and 
conditions.  
All payments must be made in full to CCC. For payment instructions, please see 
information listed at the bottom of this form.  
License Number  3475460077557  
License date  Sep 24, 2014  
Order Content Publisher  John Wiley and Sons  
Order Content Publication  Magnetic Resonance in Medicine  
Order Content Title  Simultaneous in vivo pH and temperature 
mapping using a PARACEST-MRI contrast 
agent  
Licensed copyright line  Copyright © 2012 Wiley Periodicals, Inc.  
Order Content Author  Nevin McVicar,Alex X. Li,Mojmír 
Suchý,Robert H. E. Hudson,Ravi S. 
Menon,Robert Bartha  
Order Content Date  Nov 19, 2012  
Start page  1016  
End page  1025  
Type of use  Journal/Magazine  
Requestor type  University/Academic  
Is the reuse sponsored by or associated with a 
pharmaceutical or medical products company?  
no  
Format  Electronic  
Portion  Figure/table  
Number of figures/tables  1  
Original Wiley figure/table number(s)  Figure 8  
Will you be translating?  No  
Circulation  1  
Title of new article  Overcoming concentration-dependence in  
 
You are hereby granted a personal, non-exclusive, non-sub licensable (on a stand-alone basis), non-
transferable, worldwide, limited license to reproduce the Wiley Materials for the purpose specified in 
the licensing process. This license is for a one-time use only and limited to any maximum distribution 
number specified in the license. The first instance of republication or reuse granted by this licence must 
be completed within two years of the date of the grant of this licence (although copies prepared before 
the end date may be distributed thereafter). The Wiley Materials shall not be used in any other manner 
or for any other purpose, beyond what is granted in the license. Permission is granted subject to an 
appropriate acknowledgement given to the author, title of the material/book/journal and the publisher. 
You shall also duplicate the copyright notice that appears in the Wiley publication in your use of the 
Wiley Material. Permission is also granted on the understanding that nowhere in the text is a previously 
published source acknowledged for all or part of this Wiley Material. Any third party content is expressly 
excluded from this permission.  
139 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
140 
 
 
 
 
PERMISSION/LICENSE IS GRANTED FOR YOUR ORDER AT NO CHARGE 
 
This type of permission/license, instead of the standard Terms and Conditions, is sent to you 
because no fee is being charged for your order. Please note the following: 
 
 Permission is granted for your request in both print and electronic formats, and 
translations. 
 If figures and/or tables were requested, they may be adapted or used in part. 
 Please print this page for your records and send a copy of it to your publisher/graduate 
school. 
 Appropriate credit for the requested material should be given as follows: “Reprinted 
(adapted) with permission from (COMPLETE REFERENCE CITATION). Copyright 
(YEAR) American Chemical Society.” Insert appropriate information in place of the 
capitalized words. 
 One-time permission is granted only for the use specified in your request. No additional 
uses are granted (such as derivative works or other editions). For any other uses, please 
submit a new request. 
 
 
If credit is given to another source for the material you requested, permission must be obtained 
from that source. 
 
 
Copyright © 2015 Copyright Clearance Center, Inc. All Rights Reserved. Privacy statement. 
Terms and Conditions. 
Comments? We would like to hear from you. E-mail us at customercare@copyright.com 
 
141 
 
 
 
PERMISSION/LICENSE IS GRANTED FOR YOUR ORDER AT NO CHARGE 
 
This type of permission/license, instead of the standard Terms and Conditions, is sent to you 
because no fee is being charged for your order. Please note the following: 
 
 Permission is granted for your request in both print and electronic formats, and 
translations. 
 If figures and/or tables were requested, they may be adapted or used in part. 
 Please print this page for your records and send a copy of it to your publisher/graduate 
school. 
 Appropriate credit for the requested material should be given as follows: “Reprinted 
(adapted) with permission from (COMPLETE REFERENCE CITATION). Copyright 
(YEAR) American Chemical Society.” Insert appropriate information in place of the 
capitalized words. 
 One-time permission is granted only for the use specified in your request. No additional 
uses are granted (such as derivative works or other editions). For any other uses, please 
submit a new request. 
 
 
If credit is given to another source for the material you requested, permission must be obtained 
from that source. 
 
 
Copyright © 2015 Copyright Clearance Center, Inc. All Rights Reserved. Privacy statement. 
Terms and Conditions. 
Comments? We would like to hear from you. E-mail us at customercare@copyright.com 
 
 
142 
 
 JOHN WILEY AND SONS LICENSE TERMS AND 
CONDITIONS  
Nov 04, 2014  
This is a License Agreement between Levi A Ekanger ("You") and John Wiley and Sons ("John Wiley 
and Sons") provided by Copyright Clearance Center ("CCC"). The license consists of your order 
details, the terms and conditions provided by John Wiley and Sons, and the payment terms and 
conditions.  
All payments must be made in full to CCC. For payment instructions, please see 
information listed at the bottom of this form.  
License Number  3476020392658  
License date  Sep 25, 2014  
Order Content Publisher  John Wiley and Sons  
Order Content Publication  Angewandte Chemie  
Order Content Title  Bimodal MR–PET Agent for Quantitative pH 
Imaging  
Licensed copyright line  Copyright © 2010 WILEY-VCH Verlag 
GmbH & Co. KGaA, Weinheim  
Order Content Author  Luca Frullano,Ciprian Catana,Thomas 
Benner,A. Dean Sherry,Peter Caravan  
Order Content Date  Feb 28, 2010  
Start page  2432  
End page  2434  
Type of use  Journal/Magazine  
Requestor type  University/Academic  
Is the reuse sponsored by or associated with a 
pharmaceutical or medical products company?  
no  
Format  Print and electronic  
Portion  Figure/table  
Number of figures/tables  1  
Original Wiley figure/table number(s)  Figure 3  
Will you be translating?  No  
Circulation  1  
Title of new article  Overcoming concentration-dependence in 
responsive contrast agents for MRI  
 
You are hereby granted a personal, non-exclusive, non-sub licensable (on a stand-alone basis), non-
transferable, worldwide, limited license to reproduce the Wiley Materials for the purpose specified in 
the licensing process. This license is for a one-time use only and limited to any maximum distribution 
number specified in the license. The first instance of republication or reuse granted by this licence must 
be completed within two years of the date of the grant of this licence (although copies prepared before 
the end date may be distributed thereafter). The Wiley Materials shall not be used in any other manner 
or for any other purpose, beyond what is granted in the license. Permission is granted subject to an 
appropriate acknowledgement given to the author, title of the material/book/journal and the publisher. 
You shall also duplicate the copyright notice that appears in the Wiley publication in your use of the 
Wiley Material. Permission is also granted on the understanding that nowhere in the text is a previously 
published source acknowledged for all or part of this Wiley Material. Any third party content is expressly 
excluded from this permission.  
143 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
144 
 
 JOHN WILEY AND SONS LICENSE TERMS AND 
CONDITIONS  
Nov 04, 2014  
This is a License Agreement between Levi A Ekanger ("You") and John Wiley and Sons ("John Wiley 
and Sons") provided by Copyright Clearance Center ("CCC"). The license consists of your order 
details, the terms and conditions provided by John Wiley and Sons, and the payment terms and 
conditions.  
All payments must be made in full to CCC. For payment instructions, please see 
information listed at the bottom of this form.  
License Number  3476040144668  
License date  Sep 25, 2014  
Order Content Publisher  John Wiley and Sons  
Order Content Publication  Magnetic Resonance in Medicine  
Order Content Title  Renal and systemic pH imaging by contrast-
enhanced MRI  
Licensed copyright line  Copyright © 2003 Wiley-Liss, Inc.  
Order Content Author  Natarajan Raghunand,Christine Howison,A. 
Dean Sherry,Shanrong Zhang,Robert J. Gillies  
Order Content Date  Jan 21, 2003  
Start page  249  
End page  257  
Type of use  Journal/Magazine  
Requestor type  University/Academic  
Is the reuse sponsored by or associated with a 
pharmaceutical or medical products company?  
no  
Format  Print and electronic  
Portion  Figure/table  
Number of figures/tables  2  
Original Wiley figure/table number(s)  Figure 6 Figure 7  
Will you be translating?  No  
Circulation  1  
Title of new article  Overcoming concentration-dependence in 
responsive contrast agents for MRI  
Publication the new article is in  Metallomics  
 
You are hereby granted a personal, non-exclusive, non-sub licensable (on a stand-alone basis), non-
transferable, worldwide, limited license to reproduce the Wiley Materials for the purpose specified in 
the licensing process. This license is for a one-time use only and limited to any maximum distribution 
number specified in the license. The first instance of republication or reuse granted by this licence must 
be completed within two years of the date of the grant of this licence (although copies prepared before 
the end date may be distributed thereafter). The Wiley Materials shall not be used in any other manner 
or for any other purpose, beyond what is granted in the license. Permission is granted subject to an 
appropriate acknowledgement given to the author, title of the material/book/journal and the publisher. 
You shall also duplicate the copyright notice that appears in the Wiley publication in your use of the 
Wiley Material. Permission is also granted on the understanding that nowhere in the text is a previously 
published source acknowledged for all or part of this Wiley Material. Any third party content is expressly 
excluded from this permission.  
145 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
146 
 
 JOHN WILEY AND SONS LICENSE TERMS AND 
CONDITIONS  
Nov 04, 2014  
This is a License Agreement between Levi A Ekanger ("You") and John Wiley and Sons ("John 
Wiley and Sons") provided by Copyright Clearance Center ("CCC"). The license consists of your 
order details, the terms and conditions provided by John Wiley and Sons, and the payment terms 
and conditions.  
License Number  3474851201869  
License date  Sep 23, 2014  
Order Content Publisher  John Wiley and Sons  
Order Content Publication  Magnetic Resonance in Medicine  
Order Content Title  Paramagnetic Lanthanide(III) complexes as 
pH-sensitive chemical exchange saturation 
transfer (CEST) contrast agents for MRI 
applications  
Licensed copyright line  Copyright © 2002 Wiley-Liss, Inc.  
Order Content Author  Silvio Aime,Alessandro Barge,Daniela Delli 
Castelli,Franco Fedeli,Armando 
Mortillaro,Flemming U. Nielsen,Enzo Terreno  
Order Content Date  Mar 28, 2002  
Start page  639  
End page  648  
Type of use  Journal/Magazine  
Requestor type  University/Academic  
Is the reuse sponsored by or associated with a 
pharmaceutical or medical products company?  
no  
Format  Electronic  
Portion  Figure/table  
Number of figures/tables  3  
Original Wiley figure/table number(s)  Figure 2 Figure 3 Figure 8  
Will you be translating?  No  
Circulation  1  
Title of new article  Overcoming concentration-dependence in 
responsive contrast agents for MRI  
 
You are hereby granted a personal, non-exclusive, non-sub licensable (on a stand-alone basis), non-
transferable, worldwide, limited license to reproduce the Wiley Materials for the purpose specified in 
the licensing process. This license is for a one-time use only and limited to any maximum distribution 
number specified in the license. The first instance of republication or reuse granted by this licence must 
be completed within two years of the date of the grant of this licence (although copies prepared before 
the end date may be distributed thereafter). The Wiley Materials shall not be used in any other manner 
or for any other purpose, beyond what is granted in the license. Permission is granted subject to an 
appropriate acknowledgement given to the author, title of the material/book/journal and the publisher. 
You shall also duplicate the copyright notice that appears in the Wiley publication in your use of the 
Wiley Material. Permission is also granted on the understanding that nowhere in the text is a previously 
published source acknowledged for all or part of this Wiley Material. Any third party content is expressly 
excluded from this permission.  
147 
 
 JOHN WILEY AND SONS LICENSE TERMS AND 
CONDITIONS  
Nov 04, 2014  
This is a License Agreement between Levi A Ekanger ("You") and John Wiley and Sons ("John Wiley 
and Sons") provided by Copyright Clearance Center ("CCC"). The license consists of your order 
details, the terms and conditions provided by John Wiley and Sons, and the payment terms and 
conditions.  
All payments must be made in full to CCC. For payment instructions, please see 
information listed at the bottom of this form.  
License Number  3474961163665  
License date  Sep 23, 2014  
Order Content Publisher  John Wiley and Sons  
Order Content Publication  Angewandte Chemie International Edition  
Order Content Title  YbIII-HPDO3A: A Dual pH- and 
Temperature-Responsive CEST Agent  
Licensed copyright line  Copyright © 2011 WILEY-VCH Verlag 
GmbH & Co. KGaA, Weinheim  
Order Content Author  Daniela Delli Castelli,Enzo Terreno,Silvio 
Aime  
Order Content Date  Jan 18, 2011  
Start page  1798  
End page  1800  
Type of use  Journal/Magazine  
Requestor type  University/Academic  
Is the reuse sponsored by or associated with a 
pharmaceutical or medical products company?  
no  
Format  Print  
Portion  Figure/table  
Number of figures/tables  3  
Original Wiley figure/table number(s)  Scheme 1 Figure 4 Figure 5  
Will you be translating?  No  
Circulation  1  
Title of new article  Overcoming concentration-dependence in 
responsive contrast agents for MRI  
 
You are hereby granted a personal, non-exclusive, non-sub licensable (on a stand-alone basis), non-
transferable, worldwide, limited license to reproduce the Wiley Materials for the purpose specified in 
the licensing process. This license is for a one-time use only and limited to any maximum distribution 
number specified in the license. The first instance of republication or reuse granted by this licence must 
be completed within two years of the date of the grant of this licence (although copies prepared before 
the end date may be distributed thereafter). The Wiley Materials shall not be used in any other manner 
or for any other purpose, beyond what is granted in the license. Permission is granted subject to an 
appropriate acknowledgement given to the author, title of the material/book/journal and the publisher. 
You shall also duplicate the copyright notice that appears in the Wiley publication in your use of the 
Wiley Material. Permission is also granted on the understanding that nowhere in the text is a previously 
published source acknowledged for all or part of this Wiley Material. Any third party content is expressly 
excluded from this permission.  
148 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
149 
 
 JOHN WILEY AND SONS LICENSE TERMS AND 
CONDITIONS  
Nov 04, 2014  
This is a License Agreement between Levi A Ekanger ("You") and John Wiley and Sons ("John Wiley 
and Sons") provided by Copyright Clearance Center ("CCC"). The license consists of your order 
details, the terms and conditions provided by John Wiley and Sons, and the payment terms and 
conditions.  
License Number  3475521266048  
License date  Sep 24, 2014  
Order Content Publisher  John Wiley and Sons  
Order Content Publication  Angewandte Chemie International Edition  
Order Content Title  A R2p/R1p Ratiometric Procedure to Assess 
Matrix Metalloproteinase-2 Activity by 
Magnetic Resonance Imaging  
Licensed copyright line  Copyright © 2013 WILEY-VCH Verlag 
GmbH & Co. KGaA, Weinheim  
Order Content Author  Valeria Catanzaro,Concetta V. 
Gringeri,Valeria Menchise,Sergio 
Padovan,Cinzia Boffa,Walter Dastrù,Linda 
Chaabane,Giuseppe Digilio,Silvio Aime  
Order Content Date  Feb 28, 2013  
Start page  3926  
End page  3930  
Type of use  Journal/Magazine  
Requestor type  University/Academic  
Is the reuse sponsored by or associated with a 
pharmaceutical or medical products company?  
no  
Format  Print and electronic  
Portion  Figure/table  
Number of figures/tables  2  
Original Wiley figure/table number(s)  Figure 2 Figure 4  
Will you be translating?  No  
Circulation  1  
 
You are hereby granted a personal, non-exclusive, non-sub licensable (on a stand-alone basis), non-
transferable, worldwide, limited license to reproduce the Wiley Materials for the purpose specified in 
the licensing process. This license is for a one-time use only and limited to any maximum distribution 
number specified in the license. The first instance of republication or reuse granted by this license must 
be completed within two years of the date of the grant of this license (although copies prepared before 
the end date may be distributed thereafter). The Wiley Materials shall not be used in any other manner 
or for any other purpose, beyond what is granted in the license. Permission is granted subject to an 
appropriate acknowledgement given to the author, title of the material/book/journal and the publisher. 
You shall also duplicate the copyright notice that appears in the Wiley publication in your use of the 
Wiley Material. Permission is also granted on the understanding that nowhere in the text is a previously 
published source acknowledged for all or part of this Wiley Material. Any third party content is expressly 
excluded from this permission.  
 
150 
 
 
 
You are hereby granted a personal, non-exclusive, non-sub licensable (on a stand-alone basis), non-
transferable, worldwide, limited license to reproduce the Wiley Materials for the purpose specified in 
the licensing process. This license is for a one-time use only and limited to any maximum distribution 
number specified in the license. The first instance of republication or reuse granted by this license must 
be completed within two years of the date of the grant of this license (although copies prepared before 
the end date may be distributed thereafter). The Wiley Materials shall not be used in any other manner 
or for any other purpose, beyond what is granted in the license. Permission is granted subject to an 
appropriate acknowledgement given to the author, title of the material/book/journal and the publisher. 
You shall also duplicate the copyright notice that appears in the Wiley publication in your use of the 
Wiley Material. Permission is also granted on the understanding that nowhere in the text is a previously 
published source acknowledged for all or part of this Wiley Material. Any third party content is expressly 
excluded from this permission.  
 
 
151 
 
 
 
You are hereby granted a personal, non-exclusive, non-sub licensable (on a stand-alone basis), non-
transferable, worldwide, limited license to reproduce the Wiley Materials for the purpose specified in 
the licensing process. This license is for a one-time use only and limited to any maximum distribution 
number specified in the license. The first instance of republication or reuse granted by this license must 
be completed within two years of the date of the grant of this license (although copies prepared before 
the end date may be distributed thereafter). The Wiley Materials shall not be used in any other manner 
or for any other purpose, beyond what is granted in the license. Permission is granted subject to an 
appropriate acknowledgement given to the author, title of the material/book/journal and the publisher. 
You shall also duplicate the copyright notice that appears in the Wiley publication in your use of the 
Wiley Material. Permission is also granted on the understanding that nowhere in the text is a previously 
published source acknowledged for all or part of this Wiley Material. Any third party content is expressly 
excluded from this permission.  
 
 
152 
 
REFERENCES 
(1) Lowe, M. P. Curr. Pharm. Biotechnol. 2004, 5, 519. 
(2) Zhou J.; van Zijl, P. C. M. Prog. Nucl. Magn. Reson. Spectrosc. 2006, 48, 109. 
(3) Yoo, B.; Pagel, M. D. Front. Biosci. 2008, 13, 1733. 
(4) Hyodo, F.; Soule, B. P.; Matsumoto, K.-i.; Matusmoto, S.; Cook, J. A.; Hyodo, E.; 
Sowers, A. L.; Krishna, M. C.; Mitchell, J. B. J. Pharm. Pharmacol. 2008, 60, 1049. 
(5) Pérez-Mayoral, E.; Negri, V.; Soler-Padrós, J.; Cerdán, S.; Ballesteros, P. Eur. J. Radiol. 
2008, 67, 453. 
(6) Aime, S; Castelli, D. D.; Crich, S. G.; Gianolio, E.; Terreno, E. Acc. Chem. Res. 2009, 
42, 822. 
(7) Ali, M. M.; Liu, G.; Shah, T.; Flask, C. A.; Pagel, M. D. Acc. Chem. Res. 2009, 42, 915. 
(8) De Leon-Rodriguez, L. M.; Lubag, A. J. M.; Malloy, C. R.; Martinez, G. V.; Gillies, R. 
J.; Sherry, A. D. Acc. Chem. Res. 2009, 42, 948. 
(9) Que, E. L.; Chang, C. J. Chem. Soc. Rev. 2010, 39, 51. 
(10) Hanaoka, K. Chem. Pharm. Bull. 2010, 58, 1283. 
(11) Angelovski, G.; Mamedov, I. Curr. Inorg. Chem. 2011, 1, 76. 
(12) Tu, C.; Osborne, E. A.; Louie, A. Y. Ann. Biomed. Eng. 2011, 39, 1335. 
(13) Davies, G.-L.; Kramberger, I.; Davis, J. J. Chem. Commun. 2013, 49, 9704. 
(14) Shen, C.; New, E. J. Curr. Opin. Chem. Biol. 2013, 17, 158. 
(15) Sherry, A. D.; Wu, Y. Curr. Opin. Chem. Biol. 2013, 17, 167. 
(16) Tu, C.; Louie, A. Y. NMR Biomed. 2013, 26, 781. 
(17) Soesbe, T. C.; Wu, Y.; Sherry, A. D. NMR Biomed. 2013, 26, 829. 
(18) Heffern, M. C.; Matosziuk, L. M.; Meade, T. J. Chem. Rev. 2014, 114, 4496. 
153 
 
(19) Tsitovich, P. B.; Burns, P. J.; McKay, A. M.; Morrow, J. R. J. Inorg. Biochem. 2014, 
133, 143. 
(20) Do, Q. N.; Ratnakar, J. S.; Kovács, Z.; Sherry, A. D. ChemMedChem 2014, 9, 1116. 
(21) Radecki, G.; Nargeot, R.; Jelescu, I. O.; Le Bihan, D.; Ciobanu, L. Proc. Natl. Acad. Sci. 
U.S.A. 2014, 111, 8667. 
(22) Kowalewski, J.; Nordenskiӧld, L.; Benetis, N.; Westlund, P.-O. Prog. Nucl. Magn. 
Reson. Spectrosc. 1985, 17, 14. 
(23) Lauffer, R. B. Chem. Rev. 1987, 87, 901. 
(24) Caravan, P.; Ellison, J. J.; McMurry, T. J.; Lauffer, R. B. Chem. Rev. 1999, 99, 2293. 
(25) Xu, J.; Franklin, S. J.; Whisenhunt, D. W. Jr.; Raymond, K. N. J. Am. Chem. Soc. 1995, 
117, 7245. 
(26) Werner, E. J.; Avedano, S.; Botta, M.; Hay, B. P.; Moore, E. G.; Aime, S.; Raymond, K. 
N. J. Am. Chem. Soc. 2007, 129, 1870. 
(27) Caravan, P.; Farrar, C. T.; Frullano, L.; Uppal, R. Contrast Media Mol. Imaging 2009, 4, 
89. 
(28) Zhang, J.; Fatouros, P. P.; Shu, C.; Reid, J.; Owens, L. S.; Cai, T.; Gibson, H. W.; Long, 
G. L.; Corwin, F. D.; Chen, Z.-J.; Dorn, H. C. Bioconjugate Chem. 2010, 21, 610. 
(29) Pӧselt, E.; Kloust, H.; Tromsdorf, U.; Janschel, M.; Hahn, C.; Maßlo, C.; Weller, H. ACS 
Nano 2012, 6, 1619. 
(30) Gale, E. M.; Kenton, N.; Caravan, P. Chem. Commun. 2013, 49, 8060. 
(31) Martinelli, J.; Thangavel, K.;Tei, L.; Botta, M. Chem. Eur. J. 2014, 20, 10944. 
(32) Harrison, V. S. R.; Carney, C. E.; Macrenaris, K. W.; Meade, T. J. Chem. Commun. 
2014, 50, 11469. 
154 
 
(33) Moats, R. A.; Fraser, S. E.; Meade, T. J. Angew. Chem. Int. Ed. 1997, 36, 726.  
(34) Urbanczyk-Pearson, L. M.; Femia, F. J.; Smith, J.; Parigi, G.; Duimstra, J. A.; 
Eckermann, A. L.; Luchinat, C.; Meade, T. J. Inorg. Chem. 2008, 47, 56. 
(35) Li, W.-h.; Fraser, S. E.; Meade, T. J. J. Am. Chem. Soc. 1999, 121, 1413.  
(36) Li, W.-h.; Parigi, G.; Fragai, M.; Luchinat, C.; Meade, T. J. Inorg. Chem. 2002, 41, 4018. 
(37) Zhang, S.; Wu, K.; Sherry, A. D. Angew. Chem. Int. Ed. 1999, 38, 3192. 
(38) Aime, S.; Botta, M.; Crich, S. G.; Giovenzana, G.; Palmisano, G.; Sisti, M. Chem. 
Commun. 1999, 1577. 
(39) Hovland, R.; Gløgård, C.; Aasen, A. J.; Klaveness, J. J. Chem. Soc., Perkin Trans. 2 
2001, 929. 
(40) Woods, M.; Kiefer, G. E.; Bott, S.; Castillo-Muzquiz, A.; Eshelbrenner, C.; Michaudet, 
L; McMillan, K.; Mudigunda, S. D. K.; Ogrin, D.; Tircsó, G.; Zhang, S.; Zhao, P.; Sherry, A. D. 
J. Am. Chem. Soc. 2004, 126, 9248. 
(41) Tóth, É.; Bolskar, R. D.; Borel, A.; González, G.; Helm, L.; Merbach, A. E.; Sitharaman, 
B.; Wilson, L. J. J. Am. Chem. Soc. 2005, 127, 799. 
(42) Ali, M. M.; Woods, M.; Caravan, P.; Opina, A. C. L.; Spiller, M.; Fettinger, J. C.; Sherry, 
A. D. Chem. Eur. J. 2008, 14, 7250. 
(43) Zhang, S.; Zhou, K.; Huang, G.; Takahashi, M.; Sherry, A. D.; Gao, J. Chem. Commun. 
2013, 49, 6418. 
(44) Baranyai, Z.; Rolla, G. A.; Negri, R.; Forgács, A.; Giovenzana, G. B.; Tei, L. Chem. Eur. 
J. 2014, 20, 2933. 
(45) Aime, S.; Barge, A.; Castelli, D. D.; Fedeli, F.; Mortillaro, A.; Nielsen, F. U.; Terreno, E. 
Magn. Reson. Med. 2002, 47, 639. 
155 
 
(46) Aime, S.; Castelli, D. D.; Terreno, E. Angew. Chem. 2002, 114, 4510. 
(47) Terreno, E.; Castelli, D. D.; Cravotto, G.; Milone, L.; Aime, S. Invest. Radiol. 2004, 39, 
235. 
(48) Liu, G.; Li, Y.; Sheth, V. R.; Pagel, M. D. Molecular Imaging 2012, 11, 47. 
(49) Dorazio, S. J.; Olatunde, A. O.; Spernyak, J. A.; Morrow, J. R. Chem. Commun. 2013, 
49, 10025. 
(50) Aime, S.; Fedeli, F.; Sanino, A.; Terreno, E. J. Am. Chem. Soc. 2006, 128, 11326. 
(51) Gianolio, E.; Porto, S.; Napolitano, R.; Baroni, S.; Giovenzana, G. B.; Aime, S. Inorg. 
Chem. 2012, 51, 7210. 
(52) Frullano, L.; Catana, C.; Benner, T.; Sherry, A. D.; Caravan, P. Angew. Chem. 2010, 122, 
2432. 
(53) Gianolio, E.; Maciocco, L.; Imperio, D.; Giovenzana, G. B.; Simonelli, F.; Abbas, K.; 
Bisi, G.; Aime, S. Chem. Commun. 2011, 47, 1539. 
(54) Harvey, P.; Blamire, A. M.; Wilson, J. I.; Finney, K.-L. N. A.; Funk, A. M.; Senanayake, 
P. K.; Parker, D. Chem. Sci. 2013, 4, 4251. 
(55) Gianolio, E.; Napolitano, R.; Fedeli, F.; Arena, F.; Aime, S. Chem. Commun. 2009, 6044. 
(56) Raghunand, N.; Howison, C.; Sherry, A. D.; Zhang, S.; Gillies, R. J. Magn. Reson. Med. 
2003, 49, 249. 
(57) McVicar, N.; Li, A. X.; Suchý, M.; Hudson, R. H. E.; Menon, R. S.; Bartha, R. Magn. 
Reson. Med. 2013, 70, 1016. 
(58) Castelli, D. D.; Terreno, E.; Aime, S. Angew. Chem. Int. Ed. 2011, 50, 1798. 
(59) Zhang, S.; Malloy, C. R.; Sherry, A. D. J. Am. Chem. Soc. 2005, 127, 17572.  
156 
 
(60) McDannold, N.; Fossheim, S. L.; Rasmussen, H.; Martin, H.; Vykhodtseva, N.; Hynynen, 
K. Radiology 2004, 230, 743. 
(61) Langereis, S.; Keupp, J.; van Velthoven, J. L. J.; de Roos, I. H. C.; Burdinski, D.; 
Pikkemaat, J. A.; Grüll, H. J. Am. Chem. Soc. 2009, 131, 1380. 
(62) Jeon, l.-R.; Park, J. G.; Haney, C. R.; Harris, T. D. Chem. Sci. 2014, 5, 2461. 
(63) Trokowski, R.; Ren, J.; Kálmán, F. K.; Sherry, A. D. Angew. Chem. Int. Ed. 2005, 44, 
6920. 
(64) Que, E. L.; Gianolio, E.; Baker, S. L.; Wong, A. P.; Aime, S.; Chang, C. J. J. Am. Chem. 
Soc. 2009, 131, 8527. 
(65) Weitz, E. A.; Lewandowski, C.; Smolensky, E. D.; Marjańska, M.; Pierre, V. C. ACS 
Nano 2013, 7, 5842. 
(66) Aime, S.; Botta, M.; Gianolio, E.; Terreno, E. Angew. Chem. Int. Ed. 2000, 39, 747. 
(67) Tu, C.; Osborne, E. A.; Louie, A. Y. Tetrahedron 2009, 65, 1241. 
(68) Ratnakar, S. J.; Soesbe, T. C.; Lumata, L. L.; Do, Q. N.; Viswanathan, S.; Lin, C.-Y.; 
Sherry, A. D.; Kovacs, Z. J. Am. Chem. Soc. 2013, 135, 14904. 
(69) Tsitovich, P. B.; Spernyak, J. A.; Morrow, J. R. Angew. Chem. 2013, 125, 14247. 
(70) Song, B.; Wu, Y.; Yu, M.; Zhao, P.; Zhou, C.; Kiefer, G. E.; Sherry, A. D. Dalton Trans. 
2013, 42, 8066. 
(71) Loving, G. S.; Mukherjee, S.; Caravan, P. J. Am. Chem. Soc. 2013, 135, 4620. 
(72) Liu, G.; Li, Y.; Pagel, M. D. Magn. Reson. Med. 2007, 58, 1249. 
(73) Ekanger, L. A.; Ali, M. M.; Allen, M. J. Chem. Commun. 2014, 50, 14835. 
(74) Ward, K. M.; Balaban, R. S. Magn. Reson. Med. 2000, 44, 799. 
(75) Forsén, S.; Hoffman, R. A. J. Chem. Phys. 1963, 39, 2892. 
157 
 
(76) Zaiss, M.; Bachert, P. Phys. Med. Biol. 2013, 58, R221. 
(77) Liu, G.; Moake, M.; Har-el, Y.-e.; Long, C. M.; Chan, K. W. Y.; Cardona, A.; Jamil, M.; 
Walczak, P.; Gilad, A. A.; Sgouros, G.; van Zijl, P. C. M.; Bulte, J. W. M.; McMahon, M. T. 
Magn. Reson. Med. 2012, 67, 1106. 
(78) Bleaney, B. J. Magn. Reson. 1972, 8, 91.  
(79) Chalmers, K. H.; Kenwright, A. M.; Parker, D.; Blamire, A. M. Magn. Reson. Med. 2011, 
66, 931. 
(80) Selwood, P. W. J. Am. Chem. Soc. 1933, 55, 4869. 
(81) Hammell, J.; Buttarazzi, L.; Huang, C.-H.; Morrow, J. R. Inorg. Chem. 2011, 50, 4857. 
(82) Lin, Z.; Allen, M. J. Dyes Pigments 2014, 110, 261. 
(83) Bünzli, J.-C. G.; Eliseeva, S. V. Chem. Sci. 2013, 4, 1939. 
(84) Zhang, S.; Winter, P.; Wu, K.; Sherry, A. D. J. Am. Chem. Soc. 2001, 123, 1517. 
(85) Aime, S.; Barge, A.; Botta, M.; De Sousa, A. S.; Parker, D. Angew. Chem. Int. Ed. 1998, 
37, 2673. 
(86) Longo, D. L.; Sun, P. Z.; Consolino, L.; Michelotti, F. C.; Uggeri, F.; Aime, S. J. Am. 
Chem. Soc. 2014, 136, 14333. 
(87) Aime, S.; Botta, M.; Fasano, M.; Terreno, E. Acc. Chem. Res. 1999, 32, 941. 
(88) Catanzaro, V.; Gringeri, C. V.; Menchise, V.; Padovan, S.; Boffa, C.; Dastrù, W.; 
Chaabane, L.; Digilio, G.; Aime, S. Angew. Chem. Int. Ed. 2013, 52, 3926. 
(89) Botta, M.; Tei, L. Eur. J. Inorg. Chem. 2012, 2012, 1945. 
(90) Alford, J. K.; Sorensen, A. G.; Benner, T.; Chronik, B. A.; Handler, W. B.; Scholl, T. J.; 
Madan, G.; Caravan, P. Proc. Intl. Soc. Magn. Reson. Med. 2011, 19, 452. 
(91) Smolensky, E. D.; Marjańska, M.; Pierre, V. C. Dalton Trans. 2012, 41, 8039. 
158 
 
(92) Perez, J. M.; Josephson, L.; O’Loughlin, T.; Hӧgemann, D.; Weissleder, R. Nat. Biotech. 
2002, 20, 816. 
(93) Zhao, M.; Josephson, L.; Tang, Y.; Weissleder, R. Angew. Chem. Int. Ed. 2003, 42, 1375. 
(94) Yigit, M. V.; Mazumdar, D.; Lu, Y. Bioconjugate Chem. 2008, 19, 412. 
(95) Perez, J. M.; Simeone, F. J.; Saeki, Y.; Josephson, L.; Weissleder, R. J. Am. Chem. Soc. 
2003, 125, 10192. 
(96) Rüdiger, V.; Eliseev, A.; Simova, S.; Schneider, H.-J.; Blandamer, M. J.; Cullis, P. M.; 
Meyer, A. J. J. Chem. Soc., Perkin Trans. 2 1996, 2119. 
(97) Garcia, J.; Neelavalli, J.; Haacke, E. M.; Allen, M. J. Chem. Commun. 2011, 47, 12858.  
(98) Garcia, J.; Kuda-Wedagedara, A. N. W.; Allen, M. J. Eur. J. Inorg. Chem. 2012, 2012, 
2135. 
(99) Garcia, J.; Allen, M. J. Inorg. Chim. Acta 2012, 393, 324. 
(100) Kuda-Wedagedara, A. N. W.; Allen, M. J. Analyst 2014, 139, 4401. 
(101) Gamage, N.-D. H.; Mei, Y.; Garcia, J.; Allen, M. J. Angew. Chem. Int. Ed. 2010, 49, 
8923.  
(102) Burai, L.; Tóth, É.; Seibig, S.; Scopelliti, R.; Merbach, A. E. Chem. Eur. J. 2000, 6, 3761.  
(103) Yee, E. L.; Gansow, O. A.; Weaver, M. J. J. Am. Chem. Soc. 1980, 102, 2278. 
(104) Garcia-Martin, M. L.; Martinez, G. V.; Raghunand, N.; Sherry, A. D.; Zhang, S.; Gillies, 
R. J. Magn. Reson. Med. 2006, 55, 309. 
(105) Martinez, G. V.; Zhang, X.; García-Martín, M. L.; Morse, D. L.; Woods, M.; Sherry, A. 
D.; Gillies, R. J. NMR Biomed. 2011, 24, 1380. 
(106) Averill, D. J.; Allen, M. J. Inorg. Chem. 2014, 53, 6257. 
(107) Caravan, P. Chem. Soc. Rev. 2006, 35, 512.  
159 
 
(108) Vithanarachchi, S. M.; Allen, M. J. Current Molecular Imaging 2012, 1, 12. 
(109) Facciabene, A.; Peng, X.; Hagemann, I. S.; Balint, K.; Barchetti, A.; Wang, L.; Gimotty, 
P. A.; Gilks, C. B.; Lal, P.; Zhang, L.; Coukos, G. Nature 2011, 475, 226. 
(110) Ishikawa, K.; Takenaga, K.; Akimoto, M.; Koshikawa, N.; Yamaguchi, A.; Imanishi, H.; 
Nakada, K.; Honma, Y.; Hayashi, J. Science 2008, 320, 661. 
(111) Shweiki, D.; Itin, A.; Soffer, D.; Keshet, E. Nature 1992, 359, 843. 
(112) Ushio-Fukai, M.; Nakamura, Y. Cancer Lett. 2008, 266, 37. 
(113) Weir, E. K.; López-Barneo, J.; Buckler, K. J.; Archer, S. L. N. Engl. J. Med. 2005, 353, 
2042.  
(114) Rosenbaugh, E. G.; Savalia, K. K.; Manickam, D. S.; Zimmerman, M. C. Am. J. Physiol. 
Regulatory Integrative Comp. Physiol. 2013, 304, R917. 
(115) Park, L.; Zhou, P.; Pitstick, R.; Capone, C.; Anrather, J.; Norris, E. H.; Younkin, L.; 
Younkin, S.; Carlson, G.; McEwen, B. S.; Iadecola, C. Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 
1347. 
(116) Mattson, M. P. Nature 2004, 430, 631. 
(117) Lin, M. T.; Beal, M. F. Nature 2006, 443, 787. 
(118) Nunomura, A.; Tamaoki, T.; Motohashi, N.; Nakamura, M.; McKeel, D. W.; Tabaton, 
M.; Lee, H.; Smith, M. A.; Perry, G.; Zhu, X. J. Neuropathol. Exp. Neurol. 2012, 71, 233. 
(119) Donohue, T. M.; Thomes, P. G. Redox Biol. 2014, 3, 29. 
(120) Angulo, P. N. Engl. J. Med. 2002, 346, 1221. 
(121) Ruiz, S.; Pergola, P. E.; Zager, R. A.; Vaziri, N. D. Kidney Int. 2013, 83, 1029. 
(122) Aime, S.; Cabella, C.; Colombatto, S.; Crich, S. G.; Gianolio, E.; Maggioni, F. J. Magn. 
Reson. Imaging 2002, 16, 394. 
160 
 
(123) Pierre, V. C.; Allen, M. J.; Caravan, P. J. Biol. Inorg. Chem. 2014, 19, 127. 
(124) Ekanger, L. A.; Allen, M. J. Metallomics 2015, 7, 405. 
(125) Ekanger, L. A.; Polin, L. A.; Shen, Y.; Haacke, E. M.; Martin, P. D.; Allen, M. J. Angew. 
Chem. Int. Ed. 2015, 54, 14398. 
(126) Burai, L.; Tóth, É.; Moreau, G.; Sour, A.; Scopelliti, R.; Merbach, A. E. Chem. Eur. J. 
2003, 9, 1394. 
(127) Burai, L.; Scopelliti, R.; Tóth, É. Chem. Commun. 2002, 2366. 
(128) Seibig, S.; Tóth, É.; Merbach, A. E. J. Am. Chem. Soc. 2000, 122, 5822. 
(129) Caravan, P.; Tóth, É.; Rockenbauer, A.; Merbach, A. E. J. Am. Chem. Soc. 1999, 121, 
10403. 
(130) Gansow, O. A.; Kausar, A. R.; Triplett, K. M.; Weaver, M. J.; Yee, E. L. J. Am. Chem. 
Soc. 1977, 99, 7087. 
(131) Kuda-Wedagedara, A. N. W.; Wang, C.; Martin, P. D.; Allen, M. J. J. Am. Chem. Soc. 
2015, 137, 4960. 
(132) Regueiro-Figueroa, M.; Barriada, J. L.; Pallier, A.; Esteban-Gómez, D.; de Blas, A.; 
Rodríguez-Blas, T.; Tóth, É.; Platas-Iglesias, C. Inorg. Chem. 2015, 54, 4940. 
(133) Gál, M.; Kielar, F.; Sokolová, R.; Ramešová, Š.; Kolivoška, V. Eur. J. Inorg. Chem. 
2013, 2013, 3217. 
(134) Hardee, M. E.; Dewhirst, M. W.; Agarwal, N.; Sorg, B. S. Curr. Mol. Med. 2009, 9, 435. 
(135) Leow, M. K. Adv. Physiol. Educ. 2007, 31, 198. 
(136) Carreau, A.; Hafny-Rahbi, B. E.; Matejuk, A.; Grillon, C.; Kieda, C. J. Cell. Mol. Med. 
2011, 15, 1239. 
(137) Golub, A. S.; Barker, M. C.; Pittman, R. N. Am. J. Physiol. Heart Circ. Physiol. 2007, 
293, H1097. 
161 
 
(138) Janssen, B.; Debets, J.; Leenders, P.; Smits, J. Am. J. Physiol. Regulatory Integrative 
Comp. Physiol. 2002, 282, R928. 
(139) Cartlidge, S. A.; Duncan, R.; Lloyd, J. B.; Kopečková-Rejmanová, P.; Kopeček, J. J. 
Control. Release 1987, 4, 265. 
(140) van Veluw, S. J.; Zwanenburg, J. J. M.; Engelen-Lee, J.; Spliet, W. G. M.; Hendrikse, J.; 
Luijten, P. R.; Biessels, G. J. J. Cereb. Blood Flow Metab. 2013, 33, 322. 
(141) Evelhoch, J. L.; LoRusso, P. M.; He, Z.; DelProposto, Z.; Polin, L.; Corbett, T. H.; 
Langmuir, P.; Wheeler, C.; Stone, A.; Leadbetter, J.; Ryan, A. J.; Blakey, D. C.; Waterton, J. C. 
Clin. Cancer Res. 2004, 10, 3650. 
(142) Polin, L.; White, K.; Kushner, J.; Paluch, J.; Simpson, C.; Pugh, S.; Edelstein, M. K.; 
Hazeldine, S.; Fontana, J.; LoRusso, P.; Horwitz, J. P.; Corbett, T. H. Invest. New Drug 2002, 
20, 13. 
(143) Aslakson, C. J.; Miller, F. R. Cancer Res. 1992, 52, 1399. 
(144) Venkatesan, R.; Lin, W.; Haacke, E. M. Magn. Reson. Med. 1998, 40, 592. 
(145) Lotze, M. T.; Zeh, H. J.; Rubartelli, A.; Sparvero, L. J.; Amoscato, A. A.; Washburn, N. 
R.; DeVera, M. E.; Liang, X.; Tör, M.; Billiar, T. Immunol. Rev. 2007, 220, 60. 
(146) Rubartelli, A.; Lotze, M. T. Trends Immunol. 2007, 28, 429. 
(147) Ruiz-Martínez, A.; Casanova, D.; Alvarez, S. Chem. Eur. J. 2008, 14, 1291. 
(148) Apelblat, A.; Esteso, M. A.; Bešter-Rogač, M. J. Phys. Chem. B 2013, 117, 5241. 
(149) Christoffers, J.; Starynowicz, P. Polyhedron 2008, 27, 2688. 
(150) Supkowski, R. M.; Horrocks, W. D. Inorg. Chem. 1999, 38, 5616. 
(151) Tao, K.; Fang, M.; Alroy, J.; Sahagian, G. G. BMC Cancer 2008, 8, 228. 
162 
 
(152) Degenhardt, K.; Mathew, R.; Beaudoin, B.; Bray, K.; Anderson, D.; Chen, G.; 
Mukherjee, C.; Shi, Y.; Gélinas, C.; Fan, Y.; Nelson, D. A.; Jin, S.; White, E. Cancer Cell 2006, 
10, 51. 
(153) Hermann, P.; Kotek, J.; Kubíček, V.; Lukeš, I. Dalton Trans. 2008, 3027. 
(154) Wu, Y.; Soesbe, T. C.; Kiefer, G. E.; Zhao, P.; Sherry, A. D. J. Am. Chem. Soc. 2010, 
132, 14002. 
(155) Torres, E.; Mainini, F.; Napolitano, R.; Fedeli, F.; Cavalli, R.; Aime, S.; Terreno, E. J. 
Controlled Release 2011, 154, 196. 
(156) Opina, A. C. L.; Wu, Y.; Zhao, P.; Kiefer, G.; Sherry, A. D. Contrast Media Mol. 
Imaging 2011, 6, 459. 
(157) Coman, D.; Kiefer, G. E.; Rothman, D. L.; Sherry, A. D.; Hyder, F. NMR Biomed. 2011, 
24, 1216. 
(158) Hingorani, D. V.; Randtke, E. A.; Pagel, M. D. J. Am. Chem. Soc. 2013, 135, 6396. 
(159) Liu, G.; Liang, Y.; Bar-Shir, A.; Chan, K. W. Y.; Galpoththawela, C. S.; Bernard, S. M.; 
Tse, T.; Yadav, N. N.; Walczak, P.; McMahon, M. T.; Bulte, J. W. M.; van Zijl, P. C. M.; Gilad, 
A. A. J. Am. Chem. Soc. 2011, 133, 16326. 
(160) Gløgård, C.; Stensrud, G.; Aime, S. Magn. Reson. Chem. 2003, 41, 585. 
(161) Huang, C.-H.; Hammell, J.; Ratnakar, S. J.; Sherry, A. D.; Morrow, J. R. Inorg. Chem. 
2010, 49, 5963. 
(162) Karhausen, J.; Furuta, G. T.; Tomaszewski, J. E.; Johnson, R. S.; Colgan, S. P.; Haase, V. 
H. J. Clin. Invest. 2004, 114, 1098. 
(163) Terreno, E.; Boffa, C.; Menchise, V.; Fedeli, F.; Carrera, C.; Castelli, D. D.; Digilio, G.; 
Aime, S. Chem. Commun. 2011, 47, 4667. 
163 
 
(164) Ali, M. M.; Bhuiyan, M. P. I.; Janic, B.; Varma, N. R. S.; Mikkelsen, T.; Ewing, J. R.; 
Knight, R. A.; Pagel, M. D.; Arbab, A. S. Nanomedicine 2012, 7, 1827. 
(165) Zhang, S. MATLAB Central. http://mathworks.com/matlabcentral/fileexchange/7449-
varian-mri-fdf-reader/content/fdf.m (accessed Aug 21, 2013). 
(166) NIH ImageJ. http://imagej.nih.gov/ij/ (accessed Aug 26, 2013). 
(167) Opina, A. C. L.; Ghaghada, K. B.; Zhao, P.; Kiefer, G.; Annapragada, A.; Sherry, A. D. 
PLoS One 2011, 6, e27370. 
(168) Aime, S.; Castelli, D. D.; Terreno, E. Angew. Chem. Int. Ed. 2005, 44, 5513. 
(169) Zhao, J. M.; Har-el, Y.; McMahon, M. T.; Zhou, J.; Sherry, A. D.; Sgouros, G.; Bulte, J. 
W. M.; van Zijl, P. C. M. J. Am. Chem. Soc. 2008, 130, 5178. 
(170) Duimstra, J. A.; Femia, F. J.; Meade, T. J. J. Am. Chem. Soc. 2005, 127, 12847. 
(171) Hanaoka, K.; Kikuchi, K.; Urano, Y.; Nagano, T. J. Chem. Soc. Perkin Trans. 2 2001, 
1840. 
(172) Hanaoka, K.; Kikuchi, K.; Urano, Y.; Narazaki, M.; Yokawa, T.; Sakamoto, S.; 
Yamaguchi, K.; Nagano, T. Chem. Biol. 2002, 9, 1027. 
(173) Hifumi, H.; Tanimoto, A.; Citterio, D.; Komatsu, H.; Suzuki, K. Analyst 2007, 132, 1153. 
(174) Martinelli, J.; Fekete, M.; Tei, L.; Botta, M. Chem. Commun. 2011, 47, 3144. 
(175) Shuhendler, A. J.; Staruch, R.; Oakden, W.; Gordijo, C. R.; Rauth, A. M.; Stanisz, G. J.; 
Chopra, R.; Wu, X. Y. J. Controlled Release 2012, 157, 478. 
(176) Xu, W.; Lu, Y. Chem. Commun. 2011, 47, 4998. 
(177) Aime, S.; Castelli, D. D.; Lawson, D.; Terreno, E. J. Am. Chem. Soc. 2007, 129, 2430. 
(178) Longo, D. L.; Dastrù, W.; Digilio, G.; Keupp, J.; Langereis, S.; Lanzardo, S.; Prestigio, 
S.; Steinbach, O.; Terreno, E.; Uggeri, F.; Aime, S. Magn. Reson. Med. 2011, 65, 202. 
164 
 
(179) Zheng, S.; van der Bom, I. M. J.; Zu, Z.; Lin, G.; Zhao, Y.; Gounis, M. J. Magn. Reson. 
Med. 2014, 71, 1082. 
(180) Chan, K. W. Y.; Yu, T.; Qiao, Y.; Liu, Q.; Yang, M.; Patel, H.; Liu, G.; Kinzler, K. W.; 
Vogelstein, B.; Bulte, J. W. M.; van Zijl, P. C. M.; Hanes, J.; Zhou, S.; McMahon, M. T. J. 
Controlled Release 2014, 180, 51. 
(181) Sun, P. Z.; Wang, E.; Cheung, J. S.; Zhang, X.; Benner, T.; Sorensen, A. G. Magn. 
Reson. Med. 2011, 66, 1042. 
(182) Bar-Shir, A.; Liu, G.; Liang, Y.; Yadav, N. N.; McMahon, M. T.; Walczak, P.; 
Nimmagadda, S.; Pomper, M. G.; Tallman, K. A.; Greenberg, M. M.; van Zijl, P. C. M.; Bulte, J. 
W. M.; Gilad, A. A. J. Am. Chem. Soc. 2013, 135, 1617. 
(183) Fralix, T. A.; Ceckler, T. L.; Wolff, S. D.; Simon, S. A.; Balaban, R. S. Magn. Reson. 
Med. 1991, 18, 214. 
(184) van Zijl, P. C. M.; Yadav, N. N. Magn. Reson. Med. 2011, 65, 927. 
(185) Kim, J. E.; Bogart, J. A.; Carroll, P. J.; Schelter, E. J. Inorg. Chem. 2016, 55, 775. 
(186) Bogart, J. A.; Lewis, A. J.; Medling, S. A.; Piro, N. A.; Carroll, P. J.; Booth, C. H.; 
Schelter, E. J. Inorg. Chem. 2013, 52, 11600. 
(187) MacDonald, M. R.; Bates, J. E.; Ziller, J. W.; Furche, F.; Evans, W. J. J. Am. Chem. Soc. 
2013, 135, 9857. 
(188) Fieser, M. E.; MacDonald, M. R.; Krull, B. T.; Bates, J. E.; Ziller, J. W.; Furche, F.; 
Evans, W. J. J. Am. Chem. Soc. 2015, 137, 369. 
(189) Meihaus, K. R.; Fieser, M. E.; Corbey, J. F.; Evans, W. J.; Long, J. R. J. Am. Chem. Soc. 
2015, 137, 9855. 
165 
 
(190) Kelly, R. P.; Bell, T. D. M.; Cox, R. P.; Daniels, D. P.; Deacon, G. B.; Jaroschik, F.; Junk, 
P. C.; Le Goff, X. F.; Lemercier, G.; Martinez, A.; Wang, J.; Werner, D. Organometallics 2015, 
34, 5624. 
(191) Chciuk, T. V.; Flowers, R. A., II J. Am. Chem. Soc. 2015, 137, 11526. 
(192) Allen, M. J. Synlett 2016, 27, 1310.  
(193) Mikulas, T. C.; Chen, M.; Fang, Z.; Peterson, K. A.; Andrews, L.; Dixon, D. A. J. Phys. 
Chem. A 2016, 120, 793.  
(194) Ekanger, L. A.; Polin, L. A.; Shen, Y.; Haacke, E. M.; Allen, M. J. Contrast Media Mol. 
Imaging 2016, in press.  
(195) He, J.; Bonnet, C. S.; Eliseeva, S. V.; Lacerda, S.; Chauvin, T.; Retailleau, P.; Szeremeta, 
F.; Badet, B.; Petoud, S.; Tóth, É.; Durand, P. J. Am. Chem. Soc. 2016, 138, 2913.  
(196) Ratnakar, S. J.; Viswanathan, S.; Kovacs, Z.; Jindal, A. K.; Green, K. N.; Sherry, A. D. J. 
Am. Chem. Soc. 2012, 134, 5798. 
(197) Zhang, S.; Wu, K.; Biewer, M. C.; Sherry, A. D. Inorg. Chem. 2001, 40, 4284. 
(198) Baranyai, Z.; Brücher, E.; Iványi, T.; Király, R.; Lázár, I.; Zékány, L. Helv. Chim. Acta 
2005, 88, 604.  
(199) Zhang, S.; Trokowski, R.; Sherry, A. D. J. Am. Chem. Soc. 2003, 125, 15288.  
(200) Ratnakar, S. J.; Woods, M.; Lubag, A. J. M.; Kovács, Z.; Sherry, A. D. J. Am. Chem. Soc. 
2008, 130, 6.  
(201) Harris, D. C. Quantitative Chemical Analysis, 8th ed.; W. H. Freeman and Company: New 
York, NY, 2010; pp 103.  
(202) Sherry, A. D.; Caravan, P.; Lenkinski, R. E. J. Magn. Reson. Imaging 2009, 30, 1240.  
166 
 
(203) Funk, A. M.; Jordan, V. C.; Sherry, A. D.; Ratnakar, S. J.; Kovacs, Z. Angew. Chem. Int. 
2016, 55, 5024.  
(204) Tóth, É.; Brücher, E.; Lázár, I.; Tóth, I. Inorg. Chem. 1994, 33, 4070. 
(205) Shannon, R. D. Acta Cryst. 1976, A32, 751.  
(206) Calculated by subtracting 0.197 V from the standard reduction potential of ZnII (–0.763 V 
vs normal hydrogen electrode). Bard, A. J.; Faulkner, L. R. Electrochemical Methods: 
Fundamentals and Applications, 2nd ed.; John Wiley & Sons, Inc.: Hoboken, NJ, 2001; pp 3 and 
810. 
(207) Higashiyama, N.; Takemura, K.; Kimura, K.; Adachi, G. Inorg. Chim. Acta 1992, 194, 
201. 
(208) Evbuomwan, O. M.; Lee, J.; Woods, M.; Sherry, A. D. Inorg. Chem. 2014, 53, 10012. 
(209) Evbuomwan, O. M.; Merritt, M. E.; Kiefer, G. E.; Sherry, A. D. Contrast Media Mol. 
Imaging 2012, 7, 19. 
 
 
 
 
 
 
 
 
 
167 
 
ABSTRACT 
 
EUROPIUM(II)-CONTAINING COMPLEXES FOR  
RESPONSIVE MAGNETIC RESONANCE IMAGING 
 
by 
 
LEVI ALEXANDER EKANGER 
 
August 2016 
 
 
Advisor: Dr. Matthew J. Allen 
 
Major: Inorganic Chemistry 
 
Degree: Doctor of Philosophy 
 
 The research projects described in this dissertation are focused on studying the oxidation 
of EuII-containing complexes within the context of responsive MRI. Prior to this research, EuII 
had not been explored within the context of oxidation-responsive MRI nor had the use of this ion 
been reported in vivo. The results of these studies enable predictions about the oxidation-
responsive behavior of EuII-containing complexes in vitro and in vivo.  
 The EuII-containing cryptate 1.33 was used to evaluate EuII-based positive contrast 
enhancement after intravenous, intraperitoneal, and subcutaneous injections. The transitory 
behavior of the positive contrast enhancement correlated with reported levels of oxygenation and 
rates of diffusion. Additionally, europium was observed to clear primarily through the liver and 
kidneys with no observable adverse side effects. 
 The EuII-containing cryptate 3.6 was synthesized and characterized in the solid and 
solution phases. While a chloride counterion was coordinated in the solid state, conductivity and 
17O-NMR experiments strongly suggested chloride counterions were dissociated in aqueous 
solution. EuII-based positive contrast enhancement persisted in a mammary carcinoma model for 
168 
 
at least 3 hours after intratumoral injection. Additionally, EuII-based positive contrast 
enhancement persisted specifically in necrotic regions of the tumor as evidenced by histological 
staining.  
 The EuII-containing complex 1.33 was encapsulated inside of liposomes with an average 
diameter of 110 nm. Positive contrast enhancement and CEST were observed before oxidation of 
1.33, but only CEST was observed after oxidation of 1.33 by molecular oxygen in the air. CEST 
effect was likely caused by the exchange of hydroxyl protons on cholesterol or water molecules 
associated with the outer phospholipid bilayer. This project demonstrated the feasibility of 
encapsulating air-sensitive EuII-containing complexes in liposomes and the ability to combine 
positive contrast enhancement with CEST. 
 The commercially available EuIII-containing complex 5.1 was reduced with Zn dust to 
produce its EuII-containing analogue 5.2. Changes in oxidation state were monitored using 
luminescence, EPR, UV–visible, and 1H-NMR spectroscopies. Collectively, all of the 
experiments indicated that europium remained chelated upon reduction to the 2+ oxidation state 
and oxidation back to the 3+ oxidation state. While the poly(amino glycinate) ligand caused the 
EuII/III redox couple to be approximately –0.9 V vs Ag/AgCl, the kinetic stability of the complex 
in the 2+ oxidation state was within the range of clinically approved contrast agents. Only 
positive contrast enhancement was observed when EuII was present, and only CEST was 
observed when EuIII was present. 
 The ability to essentially disable positive contrast enhancement through the oxidation of 
EuII holds great potential for responsive MRI. The balance of oxidative and kinetic stability will 
yield fundamental information regarding the EuII/III redox couple and coordination environment. 
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